論文業績一覧
1.

一元化登録（2009年4月以降）データ利用申請・WG研究

論文タイトル

論文業績

著者

雑誌名

発行
年

日本さい帯血バンクネットワーク設立10 2009
周年記念 そして明日から

刊・号・
頁

業績
番号

54-7.

U1

1

小児へのさい帯血移植.

加藤剛二.

2

Pre-transplant imatinib-based therapy
improves the outcome of allogeneic
hematopoietic stem cell transplantationfor BCR-ABL-positive acutelymphoblastic leukemia.

Mizuta S, Matsuo K, Yagasaki F, Yujiri T,
Hatta Y, Kimura Y, Ueda Y, Kanamori H,
Usui N, Akiyama H, Miyazaki Y, Ohtake S, Leukemia
Atsuta Y, Sakamaki H, Kawa K,
Morishima Y, Ohnishi K, Naoe T, Ohno R.

2011

25(1):417.

U2

3

A suggested total size for the cord bloodbanks of Japan.

Takanashi M, Tanaka H, Kohsaki M,
Bone Marrow
2011
Nakajima K, Tadokoro K, Nakabayashi M. Transplant46(7):101
4-5.

U3

4

Successful cord blood transplantation in a
Yagasaki H, Kato M, Ishige M, Shichino H,
42-day-old boy with infantile Krabbe
Int J Hematol 2011
Chin M, Mugishima H.
disease.

93(4):566
-8.

U4

5

Allogeneic hematopoietic stem cell
Ishiyama K, Takami A, Kanda Y, Nakao S,
transplantation for acute myeloid leukemia
Hidaka M, Maeda T, Naoe T, Taniguchi S,
with t(6;9)(p23;q34) dramatically improves
Leukemia
Kawa K, Nagamura T, Atsuta Y, Sakamaki
the patient prognosis: a matched-pairH.
analysis.

2012

26(3):461
-4.

U5

6

Prognostic factors for acute myeloid
Ishiyama K, Takami A, Kanda Y, Nakao S,
leukemia patients with t(6;9)(p23;q34) who Hidaka M, Maeda T, Naoe T, Taniguchi S,
Leukemia
underwent an allogeneic hematopoietic
Kawa K, Nagamura T, Tabuchi K, Atsuta
stem cell transplant.
Y, Sakamaki H.

2012

26(6):141
6-9.

U6

7

Peripheral blood as a preferable source ofFuji S, Nakamura F, Hatanaka K,
stem cells for salvage transplantation in
Taniguchi S, Sato M, Mori S, Sakamaki H, Biol Bloodpatients with graft failure after cord blood
Yabe H, Miyamoto T, Kanamori H, Ueda Marrowtransplantation: a retrospective analysis of
Y, Kawa K, Kato K, Suzuki R, Atsuta Y,
Transplant
the registry data of the Japanese Society
Tamaki T, Kanda Y.
for Hematopoietic Cell Transplantation.

2012

18(9):140
7-14.

U7

2012

119(9):21
41-8.

U8

2012

119(10):2
409-16.

U9

Kanda J, Hishizawa M, Utsunomiya A,
Taniguchi S, Eto T, Moriuchi Y, Tanosaki
R, Kawano F, Miyazaki Y, Masuda M,
Nagafuji K, Hara M, Takanashi M, Kai S,
Blood
Atsuta Y, Suzuki R, Kawase T, Matsuo K,
Nagamura-Inoue T, Kato S, Sakamaki H,
Morishima Y, Okamura J, Ichinohe T,
Uchiyama T.

8Impact of graft-versus-host disease on
outcomes after allogeneic hematopoietic
cell transplantation for adult T-cellleukemia: a retrospective cohort study.

9

Kanda J, Saji H, Fukuda T, Kobayashi T,
Related transplantation with HLA-1 Ag
Miyamura K, Eto T, Kurokawa M,
mismatch in the GVH direction and HLAKanamori H, Mori T, Hidaka M, Iwato K,
8/8 allele-matched unrelated
Yoshida T, Sakamaki H, Tanaka J, Kawa
transplantation: a nationwide retrospective
K, Morishima Y, Suzuki R, Atsuta Y,
study.
Kanda Y.

Blood

雑誌名

発行
年

刊・号・
頁

業績
番号

Hirokawa M, Fukuda T, Ohashi K, Hidaka
M, Ichinohe T, Iwato K, Kanamori H,
Biol Blood
Murata M, Sakura T, Imamura M, Adachi Marrow
S, Suzuki R, Morishima Y, Sakamaki H;
Transplant
PRCA Collaborative Study Group.

2013

19(7):102
6-32.

U10

Changes in incidence and causes of nonKurosawa S, Yakushijin K, Yamaguchi T,
relapse mortality after allogeneic
Atsuta Y, Nagamura-Inoue T, Akiyama H,
hematopoietic cell transplantation in
Taniguchi S, Miyamura K, Takahashi S,
Bone Marrow
11 patients with acute2013
Eto T, Ogawa H, Kurokawa M, Tanaka J, Transplantleukemia/myelodysplastic syndrome: an
Kawa K, Kato K, Suzuki R, Morishima Y,
analysis of the Japan Transplant Outcome
Sakamaki H, Fukuda T.
Registry.

48(4):529
-36.

U11

Recent decrease in non-relapse mortality
due to GVHD and infection after
12 allogeneic hematopoietic celltransplantation in non-remission acuteleukemia.

Kurosawa S, Yakushijin K, Yamaguchi T,
Atsuta Y, Nagamura-Inoue T, Akiyama H,
Taniguchi S, Miyamura K, Takahashi S,
Bone Marrow
2013
Eto T, Ogawa H, Kurokawa M, Tanaka J, Transplant
Kawa K, Kato K, Suzuki R, Morishima Y,
Sakamaki H, Fukuda T.

48(9):119
8-204.

U12

PBSCT is associated with poorer survival
and increased chronic GvHD than BMT in
13 Japanese paediatric patients with acuteleukaemia and an HLA-matched sibling
donor.

Shinzato A, Tabuchi K, Atsuta Y, Inoue
M, Inagaki J, Yabe H, Koh K, Kato K,
Pediatr Blood
Ohta H, Kigasawa H, Kitoh T, Ogawa A,
2013
CancerTakahashi Y, Sasahara Y, Kato S, AdachiS.

60(9):151
3-9.

U13

Allogeneic hematopoietic stem cell
14 transplantation for intermediate
cytogenetic risk AML in first CR.

Imahashi N, Suzuki R, Fukuda T,
Kakihana K, Kanamori H, Eto T, Mori T,
Kobayashi N, Iwato K, Sakura T, Ikegame Bone Marrow
2013
K, Kurokawa M, Kondo T, Iida H,
Transplant
Sakamaki H, Tanaka J, Kawa K,
Morishima Y, Atsuta Y, Miyamura K.

48(1):5662.

U14

Feasibility of reduced-intensity
conditioning followed by unrelated cord
blood transplantation for primary
15
hemophagocytic lymphohistiocytosis: anationwide retrospective analysis inJapan.

Sawada A, Ohga S, Ishii E, Inoue M,
Okada K, Inagaki J, Goto H, Suzuki N,
Koike K, Atsuta Y, Suzuki R, Yabe H,
Kawa K, Kato K, Yasutomo K.

Int J Hematol 2013

98(2):223
-30.

U15

血液事業

35(4):703-5.

U16

論文タイトル
Efficacy and long-term outcome oftreatment for pure red cell aplasia after
10
allogeneic stem cell transplantation frommajor ABO-incompatible donors.

16

著者

移植に必要なAB型の血漿・血小板製剤の永澤雅秀.
需給動向について.

2013

Association between decreasing trend in
the mortality of adult T-cellleukemia/lymphoma and allogeneic
hematopoietic stem cell transplants in
17
Japan: analysis of Japanese vitalstatistics and Japan Society for
Hematopoietic Cell Transplantation(JSHCT).

Chihara D, Ito H, Matsuda T, Katanoda K,
Blood Cancer
Shibata A, Taniguchi S, Utsunomiya A,
2013
J
Sobue T, Matsuo K.

3:e159.

U17

Granulocyte colony-stimulating factor
combined regimen in cord blood
18 transplantation for acute myeloid
leukemia: a nationwide retrospective
analysis in Japan.

Konuma T, Ooi J, Uchida N, Ogawa H,
Ohashi K, Kanamori H, Aotsuka N, Onishi
Haematologic
Y, Yamaguchi H, Kozai Y, Nagamura2014
aInoue T, Kato K, Suzuki R, Atsuta Y,
Kato S, Asano S, Takahashi S.

99(12):e2
64-8.

U18

28(9):980-9.

U19

Mycophenolate mofetil use after unrelated Iida M, Fukuda T, Uchida N, Murata M,
hematopoietic stem cell transplantation
Aotsuka N, Minagawa K, Oohashi K,
Clin
19 for prophylaxis and treatment of graftFukushima K, Kondo T, Eto T, Miyamoto
Transplantvs.-host disease in adult patients in
T, Morishima Y, Nagamura T, Atsuta Y,
Japan.
Suzuki R.

2014

発行
年

刊・号・
頁

業績
番号

Murata M, Nishida T, Taniguchi S, Ohashi
Allogeneic transplantation for primaryK, Ogawa H, Fukuda T, Mori T, Kobayashi
myelofibrosis with BM, peripheral blood orBone Marrow
20
H, Nakaseko C, Yamagata N, Morishima
2014
umbilical cord blood: an analysis of theTransplant
Y, Nagamura-Inoue T, Sakamaki H,
JSHCT.
Atsuta Y, Suzuki R, Naoe T.

49(3):355
-60.

U20

20(2):203
-14.

U21

52(4):574-9.

U22

論文タイトル

Hematopoietic stem cell transplantation
for inborn errors of metabolism: A reportfrom the Research Committee on
Transplantation for Inborn Errors of
21 Metabolism of the Japanese Ministry of
Health, Labour and Welfare and theWorking Group of the Japan Society for
Hematopoietic Cell Transplantation.

著者

雑誌名

Kato S, Yabe H, Takakura H, Mugishima
H, Ishige M, Tanaka A, Kato K, Yoshida N, Pediatr
Adachi S, Sakai N, Hashii Y, Ohashi T,
Transplant
Sasahara Y, Suzuki Y, Tabuchi K.

2016

Kurita N, Gosho M, Yokoyama Y, Kato T,
Obara N, Sakata-Yanagimoto M,
A phase I/II trial of intrabone marrow cord
Hasegawa Y, Uchida N, Takahashi S,
blood transplantation and comparison ofBone Marrow
22
Kouzai Y, Atsuta Y, Kurata M, Ichinohe T,2017
the hematological recovery with theTransplant
Chiba S.
Japanese nationwide database.

Comparison of Conditioning with
Fludarabine/Busulfan and
23 Fludarabine/Melphalan in Allogeneic
Transplantation Recipients 50 Years or
Older.

Kawamura K, Kako S, Mizuta S, Ishiyama
K, Aoki J, Yano S, Fukuda T, Uchida N, Biol Blood
Ozawa Y, Eto T, Iwato K, Kanamori H,
Marrow
Kahata K, Kondo T, Sawa M, Ichinohe T, Transplant
Atsuta Y, Kanda Y.

201723(12):20
79-87.

U23

Impact of a Low CD34+ Cell Dose on
24 Allogeneic Peripheral Blood Stem Cell
Transplantation.

Yamamoto C, Ogawa H, Fukuda T,
Biol Blood
Igarashi A, Okumura H, Uchida N, Hidaka
Marrow
M, Nakamae H, Matsuoka KI, Eto T,
Transplant
Ichinohe T, Atsuta Y, Kanda Y.

201824(4):708
-16.

U24

Impact of HIV Infection on Transplant
Yoshinaga N, Kanda J, Aisa Y, Hagiwara
Outcomes after Autologous Peripheral
S, Mori T, Fukuda T, Ishida Y, Hashimoto Biol Blood
25 Blood Stem Cell Transplantation: A
H, Iwato K, Kanda Y, Kurokawa M,
Marrow
Retrospective Study of Japanese Registry Nakazawa H, Ota S, Uchida N, Ichinohe Transplant
Data.
T, Atsuta Y, Takaori-Kondo A.

201824(8):159
6-601.

U25

Yoshizato T, Dumitriu B, Hosokawa K,
Makishima H, Yoshida K, Townsley D,
Sato-Otsubo A, Sato Y, Liu D, Suzuki H,
Wu CO, Shiraishi Y, Clemente MJ,
Kataoka K, Shiozawa Y, Okuno Y, Chiba N Engl J Med 2015
K, Tanaka H, Nagata Y, Katagiri T, Kon A,
Sanada M, Scheinberg P, Miyano S,
Maciejewski JP, Nakao S, Young NS,
Ogawa S.

373(1):35
-47.

U26

2018

24(10):21
39-44.

U27

Bone Marrow
2018
Transplant53(4):478
-82.

U28

26

Somatic Mutations and Clonal
Hematopoiesis in Aplastic Anemia.

Kako S, Fujiwara S, Sato M, Kimura SI,
Safety and Efficacy of Once-Daily
Nakasone H, Ohashi K, Kawakita T,
Biol Blood
27 Intravenous Busulfan in Allogeneic
Maeda T, Morishita T, Suzuki R, Fukuda Marrow
Transplantation: A Matched-Pair Analysis. T, Ichinohe T, Kurata M, Atsuta Y, Kanda TransplantY.
Impact of pretransplant leukemic blast% in
Ogawa H, Ikegame K, Daimon T, Uchidabone marrow and peripheral blood on
N, Fukuda T, Kakihana K, Eto T, Ozawa
transplantation outcomes of patients with
28
Y, Kanamori H, Hidaka M, Iwato Y,
acute myeloid leukemia undergoing
Ichinohe T, Takanashi M, Atsuta Y,
allogeneic stem cell transplantation in
Kanda Y.
non-CR.

雑誌名

発行
年

刊・号・
頁

業績
番号

Kawajiri-Manako C, Sakaida E, Ohwada
C, Miyamoto T, Azuma T, Taguchi J, Mori
Biol Blood
T, Hasegawa Y, Kondo T, Yujiri T,
Marrow
Yoshimitsu M, Imada K, Kurahashi S,
Transplant
Kahata K, Ichinohe T, Hirokawa M, Atsuta
Y, Nakaseko C.

201824(6):118
0-6.

U29

折原勝己, 吾郷浩厚, 奥山美樹, 落合亮
日本造血細日本骨髄バンクドナーの2回骨髄提供に関 一, 澤 正史, 田野﨑隆二, 玉井佳子, 豊
30
胞移植学会
する検討.
嶋崇徳, 中尾康夫, 日野雅之, 宮﨑泰司,
雑誌
神田善伸, 金森平和.

2017

6(2):10814.

U30

Successful preemptive donor lymphocyte
Hirai M, Yagasaki H, Fujimura J, Inoue M,
infusions from a haploidentical donor in a
Leuk
31
Shimozawa K, Okuma H, Chin M,
boy with E2A-HLF-positive ALL.
Lymphoma
Takahashi S.

201859(3):746-8.

U31Prophylaxis and treatment withmycophenolate mofetil in children withgraft-versus-host disease undergoing32
allogeneic hematopoietic stem celltransplantation: a nationwide survey inJapan.

Kawashima N, Iida M, Suzuki R, Fukuda
T, Atsuta Y, Hashii Y, Inoue M, Kobayashi
Int J Hematol 2019
M, Yabe H, Okada K, Adachi S, Yuza Y,
Kawa K, Kato K.

109(4):49
1-8.

U32

High probability of follow-up termination
33 among AYA survivors after allogeneic
hematopoietic cell transplantation.

Miyamura K, Yamashita T, Atsuta Y,
Ichinohe T, Kato K, Uchida N, Fukuda T,
Ohashi K, Ogawa H, Eto T, Inoue M,
Takahashi S, Mori T, Kanamori H, Yabe
H, Hama A, Okamoto S, Inamoto Y.

2019

3(3):397405.

U33

A consideration for efficient unrelated
34 hematopoietic stem cell source
acquisition-from an experience of Japan.

Nishiwaki S, Miyamura K, Kanda Y,
Takanashi M, Uchida N, Fukuda T,
Ikegame K, Ohashi K, Eto T, Ozawa Y,
Bone Marrow
2020
Shiratori S, Iwato K, Matsuoka KI, Hidaka TransplantM, Ichinohe T, Atsuta Y, Kodera Y,
Okamoto S.

55(3):657
-60.

U34

Retrospective analysis of children with
Hyakuna N, Hashii Y, Ishida H, Umeda K,
high-risk acute myeloid leukemia who
Takahashi Y, Nagasawa M, Yabe H,
underwent allogeneic hematopoietic stem Nakazawa Y, Koh K, Goto H, Fujisaki H, Pediatr Blood35
2019
cell transplantation following complete
Matsumoto K, Kakuda H, Yano M, Tawa Cancer
remission with initial induction
A, Tomizawa D, Taga T, Adachi S, Kato
chemotherapy in the AML-05 clinical trial. K.

66(10):e2
7875.

U35

Kudo K, Maeda M, Suzuki N, Kanegane H,
Ohga S, Ishii E, Shioda Y, Imamura T,
Nationwide retrospective review of
Imashuku S, Tsunematsu Y, Endo M,
hematopoietic stem cell transplantation in Shimada A, Koga Y, Hashii Y, Noguchi M,
36
Int J Hematol 2020children with refractory Langerhans cell
Inoue M, Tabuchi K, Morimoto A;
histiocytosis.
Histiocytosis study group of theJapanese Society of PediatricHematology/Oncology.

111(1):13
7-48.

U36

A high CD34+ cell dose is associated with
Yokoyama Y, Maie K, Fukuda T, Uchida
better disease-free survival in patients
N, Mukae J, Sawa M, Kubo K, Kurokawa
37 with low-risk diseases undergoing
M, Nakamae H, Ichinohe T, Atsuta Y,
peripheral blood stem cell transplantation
Chiba S.
from HLA-matched related donors.

55(9):172
6-35.

U37

12(2):E424.

U38

論文タイトル
Efficacy and Long-Term Outcomes ofAutologous Stem Cell Transplantation in
29
POEMS Syndrome: A Nationwide Survey
in Japan.

著者

Blood
Advances

Bone Marrow
2020
Transplant

Horio T, Morishita E, Mizuno S, Uchino K,
Donor Heme Oxygenase-1 Promoter Gene
Hanamura I, Espinoza JL, Morishima Y,
Polymorphism Predicts Survival after
38
Kodera Y, Onizuka M, Kashiwase K,
Cancers
Unrelated Bone Marrow Transplantation
Fukuda T, Doki N, Miyamura K, Mori T,
for High-Risk Patients.
Nakao S, Takami A.

2020

雑誌名

発行
年

刊・号・
頁

業績
番号

Could the minimum number of
Yabe H, Tabuchi K, Uchida N, Takahashi
haematopoietic stem cells to obtain
S, Onishi Y, Aotsuka N, Sugio Y, Ikegame Br J
39
engraftment exist in unrelated, single cord K, Ichinohe T, Takahashi M, Kato K,
Haematolblood transplantation?
Atsuta Y, Kanda Y.

2020

189(2):e5
6-60.

U39

Kaito S, Nakajima Y, Hara K, Toya T,
Heterogeneous impact of cytomegalovirus Nishida T, Uchida N, Mukae J, Fukuda T,
Blood
40 reactivation on nonrelapse mortality inOzawa Y, Tanaka M, Ikegame K,
Advances
hematopoietic stem cell transplantation. Katayama Y, Kuriyama T, Kanda J,
Atsuta Y, Ogata M, Taguchi A, Ohashi K.

2020

4(6):1051
-61.

U40

Kuwatsuka Y,Atsuta Y,
Hirakawa A,Uchida N, Inamoto Y, Najima
Y, Ikegame K,Eto T , Ozawa Y,Ichinohe T, Int J Hematol 2020
Inoue M,Kimura T, Okamoto S, Miyamura
K, Fukuda T.

112(6):84
1-50.

U41

2020

59(16):19
47-56.

U42

Yanada M, Uchida N, Ichinohe T, Fukuda
Bone Marrow
T, Kanda J, Kanda Y,Atsuta Y, Nakasone
2021
TransplantH.

56(7):172
0-22.

U43

2019

185(1):16
6-69.

U44

Adding melphalan to fludarabine and amyeloablative dose of
Shimomura Y, Hara M, Yamamoto H,
busulfan improved survival after allogeneic Uchida N, Kawakita T, Ashida T, Takada
Bone Marrow
45 hematopoietic stem cellT, Ikeda T, Morishige S, Maruyama Y,
2021
Transplanttransplantation in a propensity scoreWake A, Ichinohe T, Fukuda T, Takanashi
matched cohort ofM, Atsuta Y, Ishikawa T.
hematological malignancies.

56(7):169
1-99.

U45

Inoue T,Koyama M, Kaida K,Ikegame K,
Kathleen S Ensbey,Luke Samson,
Takahashi S, Ping Zhang, Simone A
Peritransplant glucocorticoids redistribute
Minnie, Maruyama S, Ishii S,Daimon T,
46 donor T cells to the bone marrow andFukuda T,Nakamae H, Ara T,Maruyama
prevent relapse after haploidentical SCT.
Y, Ishiyama K, Ichinohe T,Atsuta Y,
Bruce R Blazar, Scott N Furlan, Ogawa
H,Geoffrey R Hill.

2021

6(22):e15
3551.

U46

Bone Marrow
2021
Transplant56(11):27
71-78.

U47

論文タイトルUse of unapproved or off‑label drugs inJapan for the treatment of graft‑versus‑
41
host disease and post‑transplant viral
infection.

著者

Murata M, Suzuki R,Nishida T, Shirane
Allogeneic Hematopoietic Stem Cell
S,Shimazu Y,Minami Y, Mori T, Doki N,
Transplantation for Post-essential
42
Kanda Y, Uchida N, Tanaka M, Ishikawa Intern Med
Thrombocythemia and Post-polycythemia
J, Togitani K,Fukuda T, Ichinohe T,Atsuta
Vera Myelofibrosis.
Y, Nagamura -Inoue T,Kiyoi H.

Does one model fit all? Predicting non43 relapse mortality after allogeneic
hematopoietic cell transplantation.

Nakasone H,Tabuchi K,Uchida N,Ohno
Which is more important for the selection
Y,Matsuhashi Y, Takahashi S, Onishi Y,of cord blood units for haematopoietic cell
Br J
44Onizuka M, Kobayashi H, Fukuda T,transplantation: the number of CD34Haematol
Ichinohe T, Takanashi M, Kato K, Atsuta
positive cells or total nucleated cells?
Y, Yabe H, Kanda Y.

Cord blood index predicts engraftment
and early non-relapse mortality in adult47
patients with single-unit cord bloodtransplantation.

Kondo G,Ishimaru F, Konuma T,
Takahashi S, Atsuta Y,Ogawa A,
Minemoto M, Kashiwase K, Azuma F,Ito
M, Isoyama K,Kobayashi T, Ohashi
K,Nakajima F, Hiruma K, Makino S,
Mugishima H,Namba N,Tsuno H,Nagai
T,Muroi K, Nakajima K and on behalf of
the Japanese Red Cross KantoKoshinetsu Cord Blood Bank.

JCI inSIGHT

雑誌名

発行
年

刊・号・
頁

業績
番号

Essential Roles of the Transcription
Factor NR4A1 in Regulatory T Cell
48
Differentiation under the Influence of
Immunosuppressants.

Sekiya T, Kasahara H, Takemura R, Fujita
S, Kato J, Doki N, Katayama Y, Ozawa Y,
Takada S, Eto T, Fukuda T, Ichinohe T, Journal of
Takanashi M, Onizuka M, Atsuta Y,
Immunology
Okamoto S, Yoshimura A, Takaki S, Mori
T.

2022

208(9):21
22-30.

U48

Donor UNC-93 Homolog B1 genetic
polymorphism predicts survival outcomes
49
after unrelated bone marrowtransplantation.

Uchino K, Vu Quang L, Mizuno S, HorioT, Yamamoto H, Hanamura I, Kodera Y,
Luis Espinoza J, Onizuka M, Kashiwase
K, Morishima Y, Fukuda T, Doki N,
Miyamura K, Mori T, Morishita E, Nakao
S, Takami A.

Genes Immun 2021

22(1):3543.

U49

2022

28(10):67
7.e1677.e6.

U50

論文タイトル

著者

Effect of Cryopreservation in Unrelated
Kanda Y,Doki N,Kojima M,Kako S,Inoue
Bone Marrow and Peripheral Blood Stem M,Uchida N,Onishi Y7, Kamata R,Kotaki
Transplant
50 Cell Transplantation in the Era of theM, Kobayashi R,Tanaka J, Fukuda T, Fujii
Cell Ther
COVID-19 Pandemic: An Update from the N, Miyamura K,Mori S, Mori Y, Morishima
Japan Marrow Donor Program.
Y, Yabe Y, Atsuta Y, Kodera Y.

Registry data analysis of hematopoietic
stem cell transplantation on systemic
51
chronic active Epstein-Barr virus
infection patients in Japan.

Yamamoto M, Sato M, Onishi Y,
Sasahara Y, Sano H, Masuko M, Nakamae
H, Matsuoka K, Ara T, Washio K,
Am J
Onizuka M, Watanabe K, Takahashi Y,
Hematol
Hirakawa T, Nishio M, Sakashita C,
Kobayashi T, Sawada A, Ichinohe T,
Fukuda T, Hashii Y, Atsuta Y,Arai A.

2022

1;97(6):7
80-790.

U51

Comparable survival outcomes with
haploidentical stem cell
52
transplantation and unrelated bonemarrow transplantation.

Atsuta Y, Sugita J, Nakamae H,
Maruyama Y, Ishiyama K, Shiratori S,
Fukuda T, Kurata M, Shingai N,Ozawa Y, Bone Marrow
2022
Masuko M, Nagafuji K, Takada S, Kako S, Transplant
Kanda Y, Kanda J, Ichinohe T, TeshimaT.

57(12):17
81-1787.

U52

Comparable survival outcomes with53 haploidentical stem cell transplantationand cord blood transplantation.

Sugita J, Atsuta Y, Nakamae H,
Maruyama Y, Ishiyama K, Shiratori S,
Fukuda T, Kurata M, Shingai N, Ozawa Y, Bone Marrow
2022
Masuko M, Nagafuji K, Uchida N,
Transplant
Tanaka M, Onizuka M, Kanda J, Kimura
T, Ichinohe T,Teshima T.

57(11):16
81-1688.

U53

Morishima Y, Morishima S, Phil
Stevenson, Kodera Y,
Mary Horowitz, Caroline McKallor, Mari
Malkki, Stephen R. Spellman, Ted Gooley, Transplant
EffieW. Petersdorf,on-behalf-of-theCell Ther
International HistocompatibilityWorking-Group-in-Hematopoietic-CellTransplantation .

28(7):357.e1357.e6.

U54

54

Race and Survival in Unrelated
Hematopoietic Cell Transplantation.

2022

雑誌名

発行
年

刊・号・
頁

業績
番号

Peritransplantation Glucocorticoid
Haploidentical Stem Cell
Transplantation Is a Promising Strategy
55 for AML Patients With High
Leukemic Burden: Comparison With
Transplantations Using Other
Donor Types.

Kaida K, Ikegame K, Inoue T, Maruyama
S, Ishii S, Uchida N, Doki N, Eto T,
Transplant
Fukuda T, Katayama Y, Takada S,
Cell Ther
Kawakita T, Ichinohe T, Atsuta Y,
Daimon T, Ogawa H.

2023

29(4):273.e1273.e9.

U55

Graft-Versus-Host Disease Prophylaxis
Using Low-Dose Antithymocyte
56 Globulin in Peripheral Blood Stem Cell
Transplantation—A MatchedPair Analysis.

Shiratori S, Kurata M, Sugita J, Ota S,
Kasahara S, Ishikawa J, Imada K, Onishi
Transplant
Y, Ishiyama K, Ashida T, Kanda Y,
Cell Ther
Ichinohe T, Fukuda T, Atsuta Y, Teshima
T.

2021

27(12):99
5.e1995.e6.

U56

Cryopreservation of Unrelated
Hematopoietic Stem Cells from a
Blood and Marrow Donor Bank During the57
COVID-19 Pandemic:
A Nationwide Survey by the Japan
Marrow Donor Program.

Kanda Y, Inoue M, Uchida N, Onishi Y,
Kamata R, Kotaki M, Kobayashi R,
Transplant
Tanaka J, Fukuda T, Fujii N, Miyamura K,
Cell Ther
Mori S, Mori Y, Morishima Y, Yabe H,
Kodera Y.

2021

27(8):664.e1664.e6.

U57

Using a machine learning algorithm to58 predict acute graft-versus-host disease
following allogeneic transplantation.

Arai Y, Kondo T, Fuse K, Shibasaki Y,
Masuko M, Sugita J, Teshima T, UchidaN, Fukuda T, Kakihana K, Ozawa Y, Eto
T, Tanaka M, Ikegame K, Mori T, Iwato
K, Ichinohe T, Kanda Y, Atsuta Y.

20193(22):362
6-34.

U58

High-risk Combinations of Additional
Chromosomal Abnormalities in
59 Philadelphia Chromosome-positive Acute
Lymphoblastic Leukemia: JALSG Ph+ALL
TKI-SCT Study.

Nishiwaki S, Sugiura I, Fujisawa S, Hatta
Y,Atsuta Y,Doki N, Kurahashi S,Ueda
Y,Dobashi N, Maeda T,Taniguchi Y,
Tanaka M,Kako S,Ichinohe T, Fukuda
Hemasphere
T,Ohtake S, Ishikawa Y, Kiyoi H,
Matsumura I, Miyazaki Y, On behalf ofJapan Adult Leukemia Study Group.

2023

7(6):e899.

U59

Improved Long-Term Net Survival after
Allogeneic Hematopoietic Cell
60 Transplantation in Patients with
Hematologic Malignancies over Two
Decades.

Ohbiki M, Ito Y, Inamoto Y, Miyamura K,
Uchida N, Fukuda T, Fujiwara H, Nishida
T, Hayashi M, Tanaka M, Kawakita T,
Ikegame K, Katayama Y, Ara T, Ichinohe
T, Kiyoi H, Matsuo K, Atsuta Y.

2023

S26666367(23)01558.

U60

Effect of the COVID-19 pandemic on
61 allogeneic stem cell transplantation in
Japan.

Shimomura Y,Kitamura T,Nishikubo
M,Sobue T,Uchida N, Doki N, Tanaka M,
Ito A,Ishikawa J,Ara T, Ota S, Onizuka
Int J Hematol 2023
M,Sawa M,Ozawa Y,Maruyama Y,Ikegame
K,Kanda Y,Ichinohe T,Fukuda T,Okamoto
S, Teshima T,Atsuta Y.

117(4):590-597.

U61

NUDT15 polymorphism influences the
62 metabolism and therapeutic effects ofacyclovir and ganciclovir.

Rina Nishii, Takanori Mizuno, Daniel
Rehling, Colton Smith, Brandi L Clark,
Xujie Zhao, Scott A Brown, Brandon
NatureSmart, Takaya Moriyama, Yuji Yamada,Communicatio 2021
Tatsuo Ichinohe, Makoto Onizuka,ns
Yoshiko Atsuta, Lei Yang, Wenjian Yang,
Paul G Thomas, Pål Stenmark, Motohiro
Kato, Jun J Yang.

12(1):418
1

U62

Adenovirus disease after hematopoietic
63 cell transplantation:
A Japanese transplant registry analysis.

Inamoto Y, Takeda W, Hirakawa T,
Sakaguchi H, Nakano N, Uchida N, DokiN, Ikegame K, Katayama Y, Sawa M,
Am J
Kuriyama T, Hiramoto N, Ota S, Ozawa Hematol
Y, Kataoka K, Kanda Y, Hino M, Kimura T,
Atsuta Y, Fukuda T, Nagafuji K.

97(12):15
68-79.

U63

論文タイトル

著者

Blood
Advances

Transplant
Cell Ther

2022

雑誌名

発行
年

刊・号・
頁

業績
番号

Morishima Y,Watanabe-Okochi N,Kai
S,Azuma F,Kimura T,Matsumoto K,Hatasa
SelectionofCordBloodUnitbyCD34+Celland S,Araki N,Miyamoto A,Sekimoto
GM-CFUNumbersandAlleleT,Minemoto M,Ishii H,Uchida N,Takahashi Transplant64
LevelHLAMatchinginSingleCordBloodTrans S,Tanaka M,Shingai N,Miyakoshi S,Kozai Cell Ther
plantation.
Y,Onizuka M,Eto T,Ishimaru F,Kanda
J,Ichinohe T,Atsuta Y,Takanashi M,Kato
K.

2023

29(10):62
2-31.

U64

Utility of allogeneic stem cell
65 transplantation for adult Ph+ALL withcomplete molecular remission.

Nishiwaki S, Sugiura I, Fujisawa S, Hatta
Y, Atsuta Y, Doki N, Kurahashi S, Ueda
Y, Dobashi N,
Maeda T, Matsumura I, Tanaka M, Kako Am J
S,Ichinohe T, Fukuda T, Ohtake S,
Hematol
Ishikawa Y,Miyazaki Y, Kiyoi H on behalfof Japan Adult Leukemia Study
Group.

in press

U65

RhD mismatch does not affecthaematopoietic recovery, graft-versus66 host disease and survival in allogeneic
haematopoietic cell transplantation: A
Japanese registry-based study.

Konuma T, Uchida N, Takeda W, Doki N,
Yoshihara S, Nishida T, Kuriyama T,
Tanaka M, Ohigashi H, Nakamae H,
Vox Sang
Katayama Y, Ota S, Hashii Y, Ishimaru F,
Fukuda T, Ohbiki M, Atsuta Y.

in press

U66

Reduced intensity conditioning in
67 allogeneic stem cell transplantation for
AML with Down syndrome.

Muramatsu H, Sakaguchi H, Taga T,
Tabuchi K, Adachi S, Inoue M, Kitoh T,
Suminoe A, Yabe H, Azuma E, Shioda Y, Pediatr Blood
2014
Ogawa A, Kinoshita A, Kigasawa H, Osugi Cancer
Y, Koike K, Kawa K, Kato K, Atsuta Y,
Kudo K.

61(5):925 WGP-7.
1-1

Comparison of a fludarabine andmelphalan combination-based reduced
toxicity conditioning with myeloablative
68
conditioning by radiation and/or busulfan
in acute myeloid leukemia in Japanesechildren and adolescents.

Ishida H, Adachi S, Hasegawa D,
Okamoto Y, Goto H, Inagaki J, Inoue M,
Koh K, Yabe H, Kawa K, Kato K, Atsuta
Y, Kudo K.

Pediatr Blood
2015
Cancer62(5):883 WGP-9.
1-2

Biol Blood
Marrow
Transplant2015

21(12):21 WGP
41-7.
1-3

Pediatr Blood
2016
Cancer63(4):701 WGP-5.
1-4

Biol Blood
Marrow
Transplant2017

23(9):151 WGP
5-22.
1-5

Bone Marrow
2019
Transplant54(3):393 WGP
-401.
1-6

論文タイトル

著者

Comparison of Outcomes for PediatricPatients With Acute Myeloid Leukemia in
Remission and Undergoing Allogeneic
Ishida H, Kato M, Kudo K, Taga T,
Hematopoietic Cell Transplantation With Tomizawa D, Miyamura T, Goto H,
69 Myeloablative Conditioning Regimens
Inagaki J, Koh K, Terui K, Ogawa A,
Based on Either Intravenous Busulfan or Kawano Y, Inoue M, Sawada A, Kato K,
Total Body Irradiation: A Report From the Atsuta Y, Yamashita T, Adachi S.
Japanese Society for Hematopoietic Cell
Transplantation.
Role of Second Transplantation for
70 Children With Acute Myeloid Leukemia
Following Posttransplantation Relapse.

71

Allogeneic Hematopoietic Stem Cell
Transplantation for Adolescents andYoung Adults with Acute Myeloid
Leukemia.

Allogeneic hematopoietic stem celltransplantation for children and
72 adolescents with high-risk cytogenetic
AML: distinctly poor outcomes of FUSERG-positive cases.

Taga T, Murakami Y, Tabuchi K, Adachi
S, Tomizawa D, Kojima Y, Kato K, Koike
K, Koh K, Kajiwara R, Hamamoto K, Yabe
H, Kawa K, Atsuta Y, Kudo K.
Tomizawa D, Tanaka S, Kondo T, Hashii
Y, Arai Y, Kudo K, Taga T, Fukuda T,
Goto H, Inagaki J, Koh K, Ohashi K,
Ozawa Y, Inoue M, Kato K,Tanaka J,
Atsuta Y, Adachi S, Ishida H.
Tomizawa D, Yoshida M, Kondo T,
Miyamura T, Taga T, Adachi S, Koh K,
Noguchi M, Kakuda H, Watanabe K, Cho
Y, Fukuda T, Kato M, Shiba N, Goto H,
Okada K, Inoue M, Hashii Y, Atsuta Y,
Ishida H.

論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

業績
番号

Comparison of conditioning regimens forautologous stem cell transplantation in73
children with acute myeloid leukemia: A
nationwide retrospective study in Japan.

Sakaguchi H, Muramatsu H, Hasegawa D,
Kudo K, Ishida H, Yoshida N, Koh K,
Noguchi M, Shiba N, Tokimasa S, Fukuda
T, Goto H, Miyamura T, Nakazawa Y,
Pediatr Blood
2019
Hashii Y, Inoue M, Atsuta Y; PediatricCancer
AML Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

66(1):e27 WGP
459.
1-7

Hematopoietic stem-cell transplantation
74 in children with refractory acute myeloid
leukemia.

Okamoto Y, Kudo K, Tabuchi K,
Tomizawa D, Taga T, Goto H, Yabe H,
Nakazawa Y, Koh K, Ikegame K, YoshidaN, Uchida N, Watanabe K, Koga Y, Inoue
M, Kato K, Atsuta Y, Ishida H.

54(9):148 WGP
9-98.
1-8

Hematopoietic stem cell transplantation
for pediatric acute myeloid leukemia
75 patients with KMT2A rearrangement; A
nationwide retrospective analysis inJapan.

Miyamura T, Kudo K, Tabuchi K, Ishida H,
Tomizawa D, Adachi S, Goto H, Yoshida
N, Inoue M, Koh K, Sasahara Y, Fujita N, Leuk Res
Kakuda H, Noguchi M, Hiwatari M, Hashii
Y, Kato K, Atsuta Y, Okamoto Y.

Yamamoto S, Tomizawa D, Kudo K,
Hematopoietic stem cell transplantation
Hasegawa D, Taga T, Yanada M, Kondo
76 for pediatric acute promyelocytic leukemia
T, Nakazawa Y, Eto T, Inoue M, Kato K,
in Japan.
Atsuta Y, Ishida H.

Bone Marrow
2019
Transplant2019

87:10626
3.

WGP
1-9

Pediatr Blood
2020
Cancer67(5):e28 WGP
181.
1-10

Effect of extramedullary disease on
Sakaguchi H, Miyamura T, Tomizawa D,
allogeneic hematopoietic cell
Taga T, Ishida H, Okamoto Y, Koh K,
Bone Marrow
77 transplantation for pediatric acute myeloid Yokosuka T, Yoshida N, Sato M, Noguchi
2021
Transplantleukemia: a nationwide retrospective
M, Okada K, Hori T, Takeuchi M, Kosaka
study.
Y, Inoue M, Hashii Y, Atsuta Y.

56(8):185 WGP
9-65.
1-11

Haematopoietic cell transplantation for
78 children with acute megakaryoblastic
leukaemia without Down syndrome.

Hama A, Taga T, Tomizawa D,
Muramatsu H, Hasegawa D, Adachi S,
Yoshida N, Noguchi M, Sato M, Okada K, Br J
Koh K, Mitsui T, Takahashi Y, Miyamura Haematol
T, Hashii Y, Kato K, Atsuta Y, Okamoto
Y.

Optimizing transplantation procedures
through identification of prognostic
79 factors in second remission for children
with acute myeloid leukemia with no priorhistory of transplant.
Donor lymphocyte infusion for thetreatment of relapsed acute myeloid
leukemia after allogeneic hematopoietic
stem cell transplantation: a retrospective
80
analysis by the Adult Acute Myeloid
Leukemia Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.
Outcome of allogeneic hematopoietic
stem cell transplantation for acute81
myeloid leukemia patients with central
nervous system involvement.

Efficiency of high-dose cytarabine added
82 to CY/TBI in cord blood transplantation
for myeloid malignancy.

2023

201(4):74 WGP
7-56.
1-12

Ishida H, Tsujimoto SI, Hasegawa D,
Sakaguchi H, Yamamoto S, Yanagimachi
M, Koh K, Watanabe A, Hama A, Cho Y,
Watanabe K, Noguchi M, Takeuchi M,
Takita J, Washio K, Kato K, Koike T,
Hashii Y, Tabuchi K, Hino M, Atsuta Y,
Okamoto Y.

Haematologic2024a109(1):31 WGP
2-7.
1-13

Takami A, Yano S, Yokoyama H,
Kuwatsuka Y, Yamaguchi T, Kanda Y,
Morishima Y, Fukuda T, Miyazaki Y,
Nakamae H, Tanaka J, Atsuta Y,
Kanamori H.

Biol Blood
Marrow
Transplant2014

20(11):17 WGP
85-90.
2-1

2014

20(12):20 WGP
29-33.
2-2

2015

126(3):41 WGP
5-22.
2-3

Aoki J, Ishiyama K, Taniguchi S, Fukuda
Biol Blood
T, Ohashi K, Ogawa H, Kanamori H, Eto
Marrow
T, Iwato K, Sakamaki H, Morishima Y,
Transplant
Nagamura T, Atsuta Y, Takami A.
Arai Y, Takeda J, Aoki K, Kondo T,
Takahashi S, Onishi Y, Ozawa Y, Aotsuka
N, Kouzai Y, Nakamae H, Ota S,
Nakaseko C, Yamaguchi H, Kato K,
Blood
Atsuta Y, Takami A ; AML and MDSWorking Group of the Japan Society for
Hematopoietic Cell Transplantation.

雑誌名

発行
年

刊・号・
頁

業績
番号

Clinical significance of high-dose
cytarabine added tocyclophosphamide/total-body irradiation
83
in bone marrow or peripheral blood stem
cell transplantation for myeloid
malignancy.

Arai Y, Aoki K, Takeda J, Kondo T, Eto T,
Ota S, Hashimoto H, Fukuda T, Ozawa Y,
Kanda Y, Kato C, Kurokawa M, Iwato K,
J Hematol
Onizuka M, Ichinohe T, Atsuta Y, Takami
Oncol
A ; AML and MDS Working Group ofJapan Society for Hematopoietic Cell
Transplantation.

2015

8:102.

WGP
2-4

Impact of age on outcomes of allogeneic
hematopoietic stem cell transplantation
84 with reduced intensity conditioning inelderly patients with acute myeloid
leukemia.

Aoki J, Kanamori H, Tanaka M, Yamasaki
S, Fukuda T, Ogawa H, Iwato K, Ohashi
Am JK, Okumura H, Onizuka M, Maesako Y,
Hematol
Teshima T, Kobayashi N, Morishima Y,
Hirokawa M, Atsuta Y, Yano S, Takami A.

2016

91(3):302 WGP-7.
2-5

Impact of low-dose TBI on outcomes of
reduced intensity conditioning allogeneic
85
hematopoietic stem cell transplantation
for AML.

2016

51(4):604 WGP
-6.
2-6

86

2016

51(5):645 WGP
-53.
2-7

2016

95(2):295 WGP
-300.
2-8

2016

47:47-53.

2017

96(2):289 WGP
-97.
2-10

2017

52(6):818 WGP
-24.
2-11

2016

22(12):22 WGP
08-13.
2-12

Konuma T, Kondo T, Yamashita T, UchidaN, Fukuda T, Ozawa Y, Ohashi K, Ogawa
Outcome of allogeneic hematopoietic
H, Kato C, Takahashi S, Kanamori H, Eto
stem cell transplantation in adult patients T, Nakaseko C, Kohno A, Ichinohe T,
92
Ann Hematol 2017with acute myeloid leukemia harboring
Atsuta Y, Takami A, Yano S; Adult Acutetrisomy 8.
Myeloid Leukemia Working Group of theJapan Society for Hematopoietic Cell
Transplantation (JSHCT).

96(3):469 WGP
-78.
2-13

論文タイトル

87

88

89

90

著者

Aoki J, Seo S, Kanamori H, Tanaka M,
Fukuda T, Onizuka M, Kobayashi N,
Bone Marrow
Kondo T, Sawa M, Uchida N, Iwato K,
Transplant
Icihnohe T, Atsuta Y, Yano S, Takami A.
Mizutani M, Hara M, Fujita H, Aoki J,
Comparable outcomes between
Kanamori H, Ohashi K, Usuki K, Fukuda Bone Marrowautologous and allogeneic transplant for
T, Chou T, Tanaka J, Atsuta Y, Takami Transplant
adult acute myeloid leukemia in first CR.
A.
Mori J, Ishiyama K, Yamaguchi T, Tanaka
Outcomes of allogeneic hematopoietic cell J, Uchida N, Kobayashi T, Fukuda T,transplantation in patients withKanamori H, Miyamura K, Takahashi S,
Ann Hematolbiphenotypic acute leukemia.
Eto T, Hirokawa M, Mori S, Nagamura T,
Atsuta Y, Takami A.
Ishiyama K, Yamaguchi T, Eto T, Ohashi
Acute megakaryoblastic leukemia, unlike
K, Uchida N, Kanamori H, Fukuda T,
acute erythroid leukemia, predicts an
Miyamura K, Inoue Y, Taguchi J, Mori T, Leuk Res
unfavorable outcome after allogeneic
Iwato K, Morishima Y, Nagamura-Inoue T,
HSCT.
Atsuta Y, Sakamaki H, Takami A.
Yamasaki S, Hirakawa A, Aoki J, Uchida
Role of reduced-intensity conditioning
N, Fukuda T, Ogawa H, Ohashi K, Kondo
allogeneic hematopoietic cellT, Eto T, Kanamori H, Okumura H, Iwato
Ann Hematoltransplantation in older patients with deK, Ichinohe T, Kanda J, Onizuka M,
novo acute myeloid leukemia.
Kuwatsuka Y, Yanada M, Atsuta Y,
Takami A, Yano S.
Yanada M, Kurosawa S, Kobayashi T,
Reduced-intensity conditioning allogeneic
Ozawa Y, Kanamori H, Kobayashi N,
hematopoietic cell transplantation forBone Marrow
Sawa M, Nakamae H, Uchida N,
younger patients with acute myeloid
Transplant
Hashimoto H, Fukuda T, Hirokawa M,
leukemia: a registry-based study.
Atsuta Y, Yano S.

Allogeneic Hematopoietic Cell
Transplantation for Leukemic
Transformation Preceded by Philadelphia
Chromosome-Negative Myeloproliferative91
Neoplasms: A Nationwide Survey by the
Adult Acute Myeloid Leukemia Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

Autologous hematopoietic celltransplantation for acute promyelocytic
93 leukemia in second complete remission:outcomes before and after the
introduction of arsenic trioxide.

Takagi S, Masuoka K, Uchida N,
Biol Blood
Kurokawa M, Nakamae H, Imada K, Iwato
Marrow
K, Ichinohe T, Atsuta Y, Takami A, Yano
Transplant
S.

Yanada M, Yano S, Kanamori H, Gotoh M,
Emi N, Watakabe K, Kurokawa M,
Nishikawa A, Mori T, Tomita N, Murata M, Leuk
Hashimoto H, Henzan H, Kanda Y, Sawa Lymphoma
M, Kohno A, Atsuta Y, Ichinohe T,
Takami A.

2017

WGP
2-9

58(5):106 WGP
1-7.
2-14

論文タイトル
Outcomes of Allogeneic Hematopoietic
Cell Transplantation in Acute Myeloid
Leukemia Patients with Abnormalities of
the Short Arm of Chromosome 17.
Effect of cytogenetic risk status on
outcomes for patients with acute myeloid
leukemia undergoing various types of95
allogeneic hematopoietic celltransplantation: an analysis of 7812
patients.
94

Outcomes after allogeneic hematopoietic
stem cell transplantation in patients with
96
acute myeloid leukemia harboringt(7;11)(p15;p15).

Comparison of Autologous and Unrelated
97 Transplants for Cytogenetically Normal
Acute Myelogenous Leukemia.
Allogeneic haematopoietic celltransplantation for adult acute myeloid
leukaemia in second remission: a
98 retrospective study of the Adult Acute
Myeloid Leukaemia Working Group of theJapan Society for Haematopoietic Cell
Transplantation (JSHCT).
Allogeneic hematopoietic celltransplantation in adult acute myeloid
leukemia with 11q23 abnormality: aretrospective study of the Adult Acute99
Myeloid Leukemia Working Group of theJapan Society for Hematopoietic Cell
Transplantation (JSHCT).

Patients with acute myeloid leukemia
undergoing allogeneic hematopoietic cell100transplantation: trends in survival during
the past two decades.
Prognostic impact of melphalan dose andtotal body irradiation use in patients with
101 acute myeloid leukemia undergoing
allogeneic stem cell transplantation with
reduced-intensity conditioning.

Hematopoietic Cell Transplantation for
102 Acute Panmyelosis with Myelofibrosis: A
Retrospective Study in Japan.

雑誌名

発行
年

刊・号・
頁

Biol Blood
Marrow
Transplant2017

23(8):139 WGP
8-404.
2-15

Yanada M, Mori J, Aoki J, Harada K,
Mizuno S, Uchida N, Kurosawa S, Toya T,
Leuk
Kanamori H, Ozawa Y, Ogawa H, Henzan
Lymphoma
H, Iwato K, Sakura T, Ota S, Fukuda T,
Ichinohe T, Atsuta Y, Yano S.

201859(3):601 WGP
-9.
2-16

著者
Mori J, Yanada M, Uchida N, Fukuda T,
Sakura T, Hidaka M, Watakabe-Inamoto
K, Kanamori H, Ogawa H, Ichinohe T,
Tanaka J, Atsuta Y, Yano S.

Harada K, Doki N, Aoki J, Mori J,
Machida S, Masuko M, Uchida N, Najima
Y, Fukuda T, Kanamori H, Ogawa H, Ota Haematologic
2018
S, Ogawa K, Takahashi S, Kasai M,
aMaeda A, Nagafuji K, Kawakita T,
Ichinohe T, Atsuta Y.
Mizutani M, Takami A, Hara M, Mizuno S,
Yanada M, Chou T, Uchiyama H, Ohashi
Biol Blood
K, Miyamoto T, Ozawa Y, Imataki O,
Marrow
2017
Kobayashi N, Uchida N, Kanamori H,
Transplant
Kamimura T, Eto T, Onizuka M, Tanaka J,
Atsuta Y, Yano S.
Konuma T, Yanada M, Yamasaki S,
Kuwatsuka Y, Fukuda T, Kobayashi T,
Ozawa Y, Uchida N, Ota S, Hoshino T,
Br J
Takahashi S, Kanda Y, Ueda Y, Takanashi Haematol
M, Kanda J, Ichinohe T, Atsuta Y, Yano
S.

業績
番号

103(2):e6 WGP
9-72.
2-17

23(9):144 WGP
7-54.
2-18

2018

182(2):24 WGP
5-50.
2-19

Konuma T, Mizuno S, Kondo T,
Yamaguchi H, Fukuda T, Uchida N,
Najima Y, Kanamori H, Ota S, Nakamae
H, Nakamae M, Mizuno I, Sugita J, Onishi
Y, Yokota A, Takahashi S, Kanda Y,
Ann Hematol 2018
Ichinohe T, Atsuta Y, Yano S; Adult
Acute Myeloid Leukemia Working Groupof the Japan Society for Hematopoietic
Cell Transplantation (JSHCT).

97(11):21 WGP
73-83.
2-20

Yanada m,Masuko M,Mori J,Aoki
J,Mizuno S,Fukuda T,Kakihana K,Ozawa
Y,ota S,Kannamori H,Mori T,Nakamae
Bone Marrow
2019
H,Eto T,Shiratori S,Maeda T,Iwato
Transplant
K,Ichinohe T,Kanda Y,Tanaka J,Atsuta
Y,Yano S.
Harada K, Yanada M, Machida S,
Kanamori H, Onizuka M, Ozawa Y,
Leuk
Kobayashi H, Sawa M, Katayama Y,
2019
Lymphoma
Ohashi K, Kanda J, Ichinohe T, Atsuta Y,
Yano S.
Konuma T, Kondo T, Kawata T, Iwato K3,
Sato Y, Mori T, Ohashi K, Nakazawa H,
Sugahara H, Ago H, Eto T, Imamura Y,
Biol Blood
Fukuda T, Kanda Y, Atsuta Y, Yano S;
Marrow
2019
Adult Acute Myeloid Leukemia Working TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.

Konuma T, Harada K, Yamasaki S,
Mizuno S, Uchida N, Takahashi S,
Upfront allogeneic hematopoietic cell
Onizuka M, Nakamae H, Hidaka M,
transplantation (HCT) versus remission
Fukuda T, Ohashi K, Kohno A, Matsushita
induction chemotherapy followed by
Am J
103
A, Kanamori H, Ashida T, Kanda J,
allogeneic HCT for acute myeloid leukemia
Hematol
Atsuta Y, Yano S; Adult Acute Myeloidwith multilineage dysplasia: A propensity
Leukemia Working Group of the Japanscore matched analysis.
Society for Hematopoietic Cell
Transplantation.

2019

54(4):578 WGP
-86
2-21

60(6):149 WGP
3-502
2-22

25(1):23- WGP
7.
2-23

94(1):103 WGP
-10.
2-24

論文タイトル

Effect of allogeneic stem cell
104 transplantation in patients with minimallydifferentiated acute myeloid leukemia.

雑誌名

発行
年

刊・号・
頁

業績
番号

Yamasaki Satoshi, Aoki Jun,Mori Junichi,
Harada Kaito, Sawa Masashi, Uchida
Maoyuki, Ohashi Kazuki, Fukuda
日本造血細Takahiro, Koh Shiro, Kanamori Heiwa,
胞移植学会
Ogawa Hiroyasu, Okumura Hirokazu,
雑誌
Ichinohe Tatsuo, Kanda Yoshinobu,
Tanaka Junji, Atsuta Yoshiko, Yanada
Masamitsu, Yano Shingo.

2019

8(2):509.

WGP
2-25

著者

Yanada M, Konuma T, Kuwatsuka Y,
Unit selection for umbilical cord blood
Kondo T, Kawata T, Takahashi S, Uchidatransplantation for adults with acute
Bone Marrow
105
N, Miyakoshi S, Tanaka M, Ozawa Y,
2019myeloid leukemia in complete remission: aTransplant
Sawa M, Nakamae H, Aotsuka N, Kanda ,Japanese experience.
Takanashi M, Kanda Y, Atsuta Y, Yano S.

54(11):17 WGP
89-98.
2-26

Risk stratification and prognosticators of
acute myeloid leukemia withmyelodysplasia-related changes patients
undergoing allogeneic stem cell106
transplantation: a retrospective study of
the Adult Acute Myeloid Leukemia
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

2019

25(9):173 WGP
0-43.
2-27

Role of alternative donor allogeneic
Yano S, Yokoyama H, Yanada M, Mori J,
hematopoietic stem cell transplantation in Aoki J, Ohashi K, Kanomori H, Ozawa Y,
Bone Marrow
107 patients with intermediate- or poor-risk Sawa M, Nakamae H, Eto T, Ohta S,
2019
Transplant
acute myeloid leukemia in first complete Tanaka J, Ichinohe T, Atsuta Y, Takami
remission.
A.

54(12):20 WGP
04-12.
2-28

Yamasaki S, Aoki J, Mori J, Mizuno S,
Uchida N, Ohashi K, Fukuda T, Ikegame
K, Eto T, Ogawa Y, Tanaka M, Hidaka M,
Iwato K, Sawa M, Ichinohe T, Kanda Y,
Bone Marrow
2020
Atsuta Y, Yanada M, Yano S; Adult Acute Transplant
Myeloid Leukemia Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

55(1):249 WGP
-52.
2-29

Better disease control before allogeneic
stem cell transplantation is crucial to
108 improve the outcomes of transplantation
for acute myeloid leukemia patients withextramedullary disease.

Harada K, Konuma T, Machida S, Mori J,
Aoki J, Uchida N, Ohashi K, Fukuda T,
Biol Blood
Tanaka M, Ikegame K, Ozawa Y, Iwato K, Marrow
Eto T, Onizuka M, Ichinohe T, Atsuta Y, Transplant
Yano S.

Yanada M , Konuma T , Yamasaki S ,Time-Varying Effects of Graft Type on
Kuwatsuka Y , Masuko M , Tanaka M ,Biol Blood
Outcomes for Patients with Acute Myeloid Ozawa Y , Toya T , Fukuda T , Ota S ,109
Marrow
2020
Leukemia Undergoing Allogeneic
Sawa M , Uchida N , Nakamae H , Eto T ,Transplant
Hematopoietic Cell Transplantation.
Kanda J , Takanashi M , Kanda Y , Atsuta
Y , Yano S.
Yanada M, Mori J, Aoki J, Masuko M,
Allogeneic hematopoietic cell
Harada K, Uchida N, Doki N, Fukuda T,transplantation for patients with a history
110
Sakura T, Kanamori H, Sawa M, Kondo T, Ann Hematol 2019of multiple relapses of acute myeloid
Katayama Y, Kanda J, Ichinohe T, Atsuta
leukemia.
Y, Yano S.
Yanada M, Takami A, Mizuno S, Mori J,
Autologous hematopoietic cell
Chou T, Usuki K, Uchiyama H, Amano I,
111 transplantation for acute myeloid leukemia Fujii S, Miyamoto T, Saito T, Kamimura Int J Hematol 2020
in adults: 25 years of experience in Japan. T, Ichinohe T, Fukuda T, Okamoto S,
Atsuta Y, Yano S.

26(2):307 WGP
-15.
2-30

98(9):217 WGP
9-86.
2-31

111(1):93 WGP
-102.
2-32

Conditioning Intensity for Allogeneic
Hematopoietic Cell Transplantation in
112 Acute Myeloid Leukemia Patients with
Poor-Prognosis Cytogenetics in First
Complete Remission.

Konuma T, Kondo T, Mizuno S, Doki N,
Aoki J, Fukuda T, Tanaka M, Sawa M,
Katayama Y, Uchida N, Ozawa Y,
Biol Blood
Morishige S, Matsuoka KI, Ichinohe T,
Marrow
Onizuka M, Kanda J, Atsuta Y, Yanada M;
Transplant
Adult Acute Myeloid Leukemia Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

2020

26(3):463 WGP
-71.
2-33

Long-term results of reduced-intensity
conditioning allogeneic hematopoietic cell
113 transplantation for older patients withacute myeloid leukemia: a retrospective
analysis of 10-year follow-up data.

Yanada M, Fukuda T, Tanaka M, Ota S,
Toya T, Mori T, Uchida N, Ozawa Y,
Bone Marrow
2020
Nakamae H, Kanda Y, Ichinohe T, Atsuta Transplant
Y, Yano S.

55(10):20 WGP
08-16.
2-34

発行
年

刊・号・
頁

2020

99(6):135 WGP
1-60.
2-35

2021

56(1):232 WGP
-42.
2-36

2021

56(2):387 WGP
-94.
2-37

2020

99(12):29 WGP
27-37.
2-38

2021

56(5):112 WGP
6-33.
2-39

2021

27(2):185 WGP.e1-6.
2-40

2021

27(4):334 WGP.e1-11.
2-41

2021

27(4):314 WGP.e1-10.
2-42Isobe M, Konuma T, Masuko M, Uchida N,
Miyakoshi S, Sugio Y, Yoshida S, Tanaka
M, Matsuhashi Y, Hattori N, Onizuka M,
Aotsuka N, Kouzai Y, Wake A, Kimura T,
Ann Hematol 2021
Ichinohe T, Atsuta Y, Yanada M; Adult
Acute Myeloid Leukemia Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.

100(7):18 WGP
49-61.
2-43

Reduced-intensity stem cellYamashita T, Takami A, Uchida N,
transplantation for acute myeloid leukemia Fukuda T, Eto T, Shiratori S, Ota S,
Bone Marrow
123
2020
with fludarabine-based conditioning with Akasaka T, Miyakoshi S, Kondo T, Hidaka Transplant
intravenous busulfan versus melphalan.
M, Kanda J, Atsuta Y, Yano S.

55(10):19 WGP
55-65.
2-44

Hirabayashi S, Uozumi R, Kondo T, Arai
Personalized prediction of overall survival Y, Kawata T, Uchida N, Marumo A,
124 in patients with AML in non-complete
Ikegame K, Fukuda T, Eto T, Tanaka M, Cancer Med
remission undergoing allo-HCT.
Wake A, Kanda J, Kimura T, Tabuchi K,
Ichinohe T, Atsuta Y, Yanada M, Yano S.

10(13):42 WGP
50-68.
2-45

論文タイトル著者

雑誌名

Yanada M, Takami A, Yamasaki S, Arai Y,
Konuma T, Uchida N, Najima Y, Fukuda T,
Tanaka M, Ozawa Y, Ikegame K,
Ann Hematol
Takanashi M, Ichinohe T, Okamoto S,
Atsuta Y, Yano S.
Mizuno S, Yanada M, Kawamura K,
Allogeneic hematopoietic cell
Masuko M, Uchida N, Ozawa Y, Iwato K,
transplantation efficacy in patients with
Bone Marrow
115
Ohashi K, Ikegame K, Kim SW, Tanaka M,
Philadelphia chromosome-positive acuteTransplant
Eto T, Kanda Y, Fukuda T, Atsuta Y,
myeloid leukemia in complete remission.
Yano S, Takami A.
Yanada M, Konuma T, Mizuno S, Saburi
Predicting non-relapse mortality following M, Shinohara A, Tanaka M, Marumo A,
allogeneic hematopoietic cell
Sawa M, Uchida N, Ozawa Y, Onizuka M, Bone Marrow
116
transplantation during first remission of
Yoshioka S, Nakamae H, Kondo T, Kimura Transplant
acute myeloid leukemia.
T, Kanda J, Fukuda T, Atsuta Y,
Nakasone H, Yano S.
Yamasaki S, Mori J, Kanda J, Imahashi N,
Effect of allogeneic HCT from unrelated
Uchida N, Doki N, Tanaka M, Katayama Y,
donors in AML patients with intermediate117
Eto T, Ozawa Y, Takada S, Onizuka M,
Ann Hematolor poor-risk cytogenetics: a retrospective
Hino M, Kanda Y, Fukuda T, Atsuta Y,
study from the Japanese Society for HCT.
Yanada M.
Yanada M, Konuma T, Yamasaki S, Kondo
Relapse of acute myeloid leukemia after
T, Fukuda T, Shingai N, Sawa M, Ozawa
allogeneic hematopoietic cell
Bone Marrow
118
Y, Tanaka M, Uchida N, Nakamae H,
transplantation: clinical features andTransplant
Katayama Y, Matsuoka KI, Kimura T,
outcomes.
Kanda Y, Ichinohe T, Atsuta Y, Yano S.
Prognostic Impact of the Fractionation of Ueda N, Konuma T, Aoki J, Takahashi S,
Total Body Irradiation for Patients with
Ozawa Y, Mori T, Ota S, Eto T, Takada
Transplant
119 Acute Myeloid Leukemia Undergoing
S, Yoshioka S, Shiratori S, Kako S,
Cell Ther
Myeloablative Allogeneic Hematopoietic
Onizuka M, Fukuda T, Kanda Y, Atsuta Y,
Cell Transplantation.
Yanada M.
Konuma T, Kanda J, Yamasaki S, Harada
K, Shimomura Y, Terakura S, Mizuno S,
Single Cord Blood Transplantation Versus
Uchida N, Tanaka M, Doki N, Ozawa Y,
Unmanipulated Haploidentical
Transplant
120
Nakamae H, Sawa M, Matsuoka KI,
Transplantation for Adults with Acute
Cell Ther
Morishige S, Maruyama Y, Ikegame K,
Myeloid Leukemia in Complete Remission.
Kimura T, Kanda Y, Ichinohe T, Atsuta Y,
Yanada M.
Allogeneic hematopoietic celltransplantation for adults with acute114
myeloid leukemia conducted in Japan
during the past quarter century.

Mizuno S, Takami A, Kawamura K, Arai Y,
Allogeneic Hematopoietic Cell
Kondo T, Kawata T, Uchida N, Marumo A,
Transplantation for Adolescent and Young Fukuda T, Tanaka M, Ozawa Y, Yoshida Transplant
121
Adult Patients with Acute Myeloid
S, Ota S, Takada S, Sawa M, Onizuka M, Cell Ther
Leukemia.
Kanda Y, Ichinohe T, Atsuta Y, Yanada
M.

Single cord blood transplantation for
acute myeloid leukemia patients aged 60
122years or older: a retrospective study inJapan.

2021

業績
番号

雑誌名

発行
年

刊・号・
頁

Yanada M, Mizuno S, Yamasaki S, Harada
K, Konuma T, Tamaki H, Shingai N,
Uchida N, Ozawa Y, Tanaka M, Onizuka
LeukM, Sawa M, Nakamae H, Shiratori S,
LymphomaMatsuoka KI, Eto T, Kawakita T,
Maruyama Y, Ichinohe T, Kanda Y, Atsuta
Y, Aoki J, Yano S.

2021

62(14):34 WGP
11-9.
2-46

Ann Hematol 2021

100(12):3 WGP
017-27.
2-47

Kurosawa S, Mizuno S, Arai Y, Masuko
M, Kanda J, Kohno K, Onai D, Fukuda T,
Ozawa Y, Katayama Y, Tanaka M,
Blood Cancer
2021
Ikegame K, Uchida N, Eto T, Ota S,
JTanaka J, Ichinohe T, Atsuta Y, YanadaM.

11(9):159 WGP.
2-48

Yanada M, Konuma T, Yamasaki S,
Harada K, Iwasaki M, Kobayashi A,
Nishijima A, Tanaka M, Uchida N,
Transplant
Nakamae H, Fukuda T, Onizuka M, Ozawa
Cell Ther
Y, Sawa M, Katayama Y, Yoshioka S,
Kimura T, Ichinohe T, Atsuta Y, Kanda J,
Yano S.

2021

27(12):10 WGP
05.e1-8. 2-49

Autologous hematopoietic celltransplantation during second or
129 subsequent complete remission of acutepromyelocytic leukemia: a prognostic
factor analysis.

Yanada M, Ota S, Mukae J, Nara M, Kako
S, Nishikawa A, Uchida N, Sawa M,
Bone Marrow
2022
Nakano N, Onizuka M, Kanda Y, Ichinohe Transplant
T, Atsuta Y, Yano S.

57(1):78- WGP
82.
2-50

Donor lymphocyte infusion after
haploidentical hematopoietic stem cell
130transplantation for acute myeloid
leukemia.

Harada K, Mizuno S, Yano S, Takami A,
Ishii H, Ikegame K, Najima Y, Kako S,
Ashida T, Shiratori S, Ota S, Onizuka M, Ann Hematol 2022
Fukushima K, Fukuda T, Ichinohe T,
Atsuta Y, Yanada M.

101(3):64 WGP
3-53.
2-51

Prognostic value of measurable residual
disease at allogeneic transplantation for
adults with core binding factor acute
myeloid leukemia in complete remission.

Konuma T, Kondo T, Masuko M, Shimizu
H, Shiratori S, Fukuda T, Kato J, Sawa
M, Ozawa Y, Ota S, Uchida N, Kanda Y,
Kako S, Fujisawa S, Fukushima K,
Bone Marrow
2021
Ichinohe T, Atsuta Y, Yanada M; Adult
Transplant
Acute Myeloid Leukemia Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.

56(11):27 WGP
79-87.
2-52

Comparison of fludarabine, amyeloablative dose of busulfan, andmelphalan vs conventional myeloablative132
conditioning regimen in patients withrelapse and refractory acute myeloid
leukemia in non-remission status.

Shimomura Y, Hara M, Hirabayashi S,
Kondo T, Mizuno S, Uchida N, Mukae J,
Kawakita T, Fukuda T, Kanda Y, Ota S,
Bone Marrow
2021
Ozawa Y, Eto T, Maruyama Y, Tanaka M, Transplant
Nakano N, Kimura T, Ichinohe T, Atsuta
Y, Yanada M.

56(9):230 WGP
2-4.
2-53

論文タイトルDifference in outcomes following
allogeneic hematopoietic cell
125 transplantation for patients with acute
myeloid leukemia and myelodysplastic
syndromes.

著者

Yanada M, Konuma T, Yamasaki S,
The differential effect of disease status at Mizuno S, Hirabayashi S, Nishiwaki S,
allogeneic hematopoietic cell
Uchida N, Doki N, Tanaka M, Ozawa Y,
126transplantation on outcomes in acute
Sawa M, Eto T, Kawakita T, Ota S,
myeloid and lymphoblastic leukemia.
Fukuda T, Onizuka M, Kimura T, Atsuta
Y, Kako S, Yano S.
Syngeneic hematopoietic stem celltransplantation for acute myeloid
127
leukemia: a propensity score-matchedanalysis.

128

131

Allogeneic Hematopoietic Cell
Transplantation from Alternative Donors
in Acute Myelogenous Leukemia: A
Comparative Analysis.

業績
番号Shimomura Y, Sobue T, Hirabayashi S,
Kondo T, Mizuno S, Kanda J, Fujino T,
Comparing cord blood transplantation and Kataoka K, Uchida N, Eto T, Miyakoshi S,
133 matched related donor transplantation in Tanaka M, Kawakita T, Yokoyama H, Doki Leukemia
non-remission acute myeloid leukemia.
N, Harada K, Wake A, Ota S, Takada S,
Takahashi S, Kimura T, Onizuka M,
Fukuda T, Atsuta Y, Yanada M.

2022

36(4):113 WGP
2-8
2-54

Mizuno S, Takami A, Kawamura K,
Shimomura Y, Arai Y, Konuma T, Ozawa
Y, Sawa M, Ota S, Takahashi S, Anzai N, Transplant
Hiramoto N, Onizuka M, Nakamae H,
Cell Ther
Tanaka M, Murata M, Kimura T, Kanda J,
Fukuda T, Atsuta Y, Yanada M.

2022

28(11):77 WGP
5.e1-9.
2-55

Favorable Outcome with Conditioning
Regimen of Flu/Bu4/Mel in Acute134 Myelogenous Leukemia Patients in
Remission Undergoing Cord Blood
Transplantation.

論文タイトル

著者

Yanada M, Matsuda K, Ishii H, Fukuda T,
Allogeneic Hematopoietic Cell
Ozeki K, Ota S, Tashiro H, Uchida N,
135 Transplantation for Patients with
Kako S, Doki N, Kawakita T, Onishi Y,
Relapsed Acute Promyelocytic Leukemia. Takada S, Kondo Y, Tanaka J, Kanda Y,
Atsuta Y, Yano S.
Yanada M, Yamasaki S, Konuma T,
Mizuno S, Uchida N, Onai D, Fukuda T,
Age and allogeneic hematopoietic cell
Tanaka M, Ozawa Y, Eto T, Ikegame K,
136 transplantation outcomes in acute myeloid
Sawa M, Katayama Y, Kawakita T,
leukemia.
Onizuka M, Kanda Y, Ichinohe T, Atsuta
Y, Yano S.
Mizumaki H, Ishiyama K, Aoki J, Mori J,
Outcomes after allogeneic hematopoietic Mizuno S, Doki N, Fukuda T, Uchida N,
137 stem cell transplantation in acute myeloid Onizuka M, Tanaka M, Katayama Y,
leukemia patients with der(1;7)(q10;p10). Ozawa Y,Ikegame K, Takada S, Kawakita
T, Aotsuka N, Atsuta Y, Yanada M.

Improved trends in survival andengraftment after single cord blood
138
transplantation for adult acute myeloid
leukemia.

雑誌名

発行
年

刊・号・
頁

Transplant
Cell Ther

2022

28(12):84 WGP
7.e1-8.
2-56

Int J Hematol 2023

117(3):39 WGP
8-408.
2-57

eJHaem4(1):251- WGP
7.
2-58

2022

Konuma T, Mizuno S, Kondo T, Arai Y,
Uchida N, Takahashi S, Tanaka M,
Kuriyama T, Miyakoshi S, Onizuka M, Ota
S, Sugio Y, Kouzai Y, Kawakita T,
Blood Cancer
Kobayashi H, Ozawa Y, Kimura T,
2022
J
Ichinohe T, Atsuta Y, Yanada M; Adult
Acute Myeloid Leukemia Working Groupof the Japanese Society forTransplantation and Cellular Therapy.

Konuma T, Mizuno S, Harada K, Uchida
Reducing Mortality of Single-Unit
Unrelated Cord Blood Transplantation for N, Takahashi S, Eto T, Ota S, Kobayashi
Relapsed Acute Myeloid Leukemia after a H, Katayama Y, Mori Y, Maruyama Y,
Transplant
139
2022
Onizuka M, Yonezawa A, Kawakita T,
Previous Allogeneic Transplantation: A
Cell Ther
Real-World Retrospective Study Over the Kimura T, Kanda Y, Fukuda T, Atsuta Y,
Yanada M; Adult Acute Myeloid Leukemia
Past 19 Years in Japan.
Working Group of the Japanese Society
for Transplantation and Cellular Therapy.
Konuma T, Harada K, Kondo T, Masuko
M, Uchida N, Yano S, Kawakita T,
Salvage single-unit unrelated cord blood
Onizuka M, Ota S, Sakaida E, Miyakoshi
transplantation for graft failure following
S, Ozawa Y, Imamura Y, Kimura T, Kanda Bone Marrow
140 initial allogeneic transplantation in adult
2022
Y, Fukuda T, Atsuta Y, Yanada M; Adult Transplant
acute myeloid leukemia: trends in
Acute Myeloid Leukemia Working Groupoutcomes over the past 20 years.
of the Japanese Society forTransplantation and Cellular Therapy.
Matsuda K, Konuma T, Fuse K, Masuko
Comparison of transplant outcomes
M, Kawamura K, Hirayama M, Uchida N,
between haploidentical transplantation and Ikegame K, Wake A, Eto T, Doki N,
Br J
141 single cord blood transplantation in non- Miyakoshi S, Tanaka M, Takahashi S,
Haematolremission acute myeloid leukaemia: A
Onizuka M, Kato K, Kimura T, Ichinohe T,
nationwide retrospective study.
Takayama N, Kobayashi H, Nakamae H,
Atsuta Y, Kanda J, Yanada M.

12(5):81.

業績
番号

WGP
2-59

28(11):77 WGP
7.e1-11. 2-60

57(12):18 WGP
48-50.
2-61

2023

201(1):10 WGP
6-13.
2-62

Yamasaki S, Mizuno S, Iwasaki M, Seo S,
Efficacy and safety of allogeneic
Uchida N, Shigesaburo M, Nakano N,
hematopoietic cell transplantation in acute Ishiwata K, Uehara Y, Eto T, Takase K,
142
Ann Hematol 2023
myeloid leukemia patients aged > 65 years Kawakita T, Tanaka M, Sawa M,
with unfavorable cytogenetics.
Katayama Y, Nawa Y, Makoto O, Ichinohe
T, Atsuta Y, Kanda J, Yanada M.

102(6):15 WGP
49-59.
2-63

Jo T, Arai Y, Oshima S, Kondo T, Harada
K, Uchida N, Doki N, Fukuda T, Tanaka
Prognostic impact of complex and/or
M, Ozawa Y, Kuriyama T, Ikegame K,
monosomal karyotypes in post-transplant
Br J
143
Katayama Y, Ota S, Ara T, Kawakita T,
poor cytogenetic acute myeloid leukaemia:
HaematolOnizuka M, Ichinohe T, Atsuta Y, Yanada
A quantitative approach.
M; Japanese Society for Transplantation
and Cellular Therapy (JSTCT).

202(2):35 WGP
6-68.
2-64

2023

論文タイトル

著者

Yanada M, Shimomura Y, Mizuno S,
Matsuda K, Kondo T, Doki N, Tanaka M,
External validation and extended
Fukuda T, Ara T, Uchida N, Onizuka M,
144 application of the transplant conditioning
Sawa M, Ozawa Y, Hiramoto N, Ota S,
intensity score in acute myeloid leukemia.
Kanda J, Kanda Y, Ichinohe T, Okamoto
S, Atsuta Y, Konuma T.

雑誌名

発行
年

Bone Marrow
2023
Transplant

Effect of Graft-versus-Host Disease on Konuma T, Matsuda K, Shimomura Y,
Post-Transplantation Outcomes following Tanoue S, Sugita J, Inamoto Y, Hirayama
Single Cord Blood Transplantation
M, Ara T, Nakamae H, Ota S, Maruyama
Transplant
145 Compared with Haploidentical
Y, Eto T, Uchida N, Tanaka M, Ishiwata K,
Cell Ther
Transplantation with Post-Transplantation Koi S, Takahashi S, Ozawa Y, Onizuka M,
Cyclophosphamide for Adult Acute
Kanda Y, Kimura T, Ichinohe T, Atsuta Y,
Myeloid Leukemia.
Kanda J, Yanada M.

刊・号・
頁

業績
番号

58(10):10 WGP
96-103.
2-65

2023

29(6):365 WGP.e1-11.
2-66

Araie H, Arai Y, Kida M, Aoki J, Uchida N,
Doki N, Fukuda T, Tanaka M, Ozawa Y,
Poor outcome of allogeneic
Sawa M, Katayama Y, Matsuo Y, Onizuka
transplantation for therapy-related acute M, Kanda Y, Kawakita T, Kanda J, Atsuta
146
Ann Hematol 2023
myeloid leukemia induced by prior
Y, Yanada M; Adult Acute Myeloid
chemoradiotherapy.
Leukemia Working Group of theJapanese Society for Transplantation
and Cellular Therapy.

102(10):2 WGP
879-93.
2-67

Advantages of Higher Busulfan DoseIntensity in Fludarabine-Combined
147 Conditioning for Patients with Acute
Myeloid Leukemia Undergoing Cord Blood
Transplantation.

Allogeneic hematopoietic cell
148 transplantation for patients with acute
myeloid leukemia not in remission.

Shibata S, Arai Y, Kondo T, Mizuno S,
Harada K, Miyakoshi S, Uchida N,
Maruyama Y, Eto T, Katsuoka Y, Matsue Transplant
K, Nishiwaki K, Takada S, Doki N, Itoh M, Cell Ther
Nagafuji K, Kawakita T, Tanaka J, Fukuda
T, Atsuta Y, Yanada M.
Yanada M, Yamasaki S, Kondo T, Kawata
T, Harada K, Uchida N, Doki N, Yoshihara
S, Katayama Y, Eto T, Tanaka M, Takada
Leukemia
S, Kawakita T, Nishida T, Ota S,
Serizawa K, Onizuka M, Kanda Y, Fukuda
T, Atsuta Y, Konuma T.

Konuma T, Yamasaki S, Ishiyama K,
Comparison of Allogeneic Transplant
Mizuno S, Hayashi H, Uchida N,
Outcomes Between Matched Sibling
Shimabukuro M, Tanaka M, Kuriyama T,
Donors and Alternative Donors in Patients Onizuka M, Ishiwata K, Sawa M, Tanaka
Over 50 Years of Age with Acute Myeloid T, Ohigashi H, Fujiwara SI, Matsuoka KI,
149 Leukemia: 8/8 Allele-Matched Unrelated Ota S, Nishida T, Kanda Y, Fukuda T,
Donors and Unrelated Cord Blood Provide Atsuta Y, Nakasone H, Yanada M; Adult
Better Leukemia-Free Survival Compared Acute Myeloid Leukemia andwith Matched Sibling Donors During
Donor/source Working Groups of theNonremission Status.
Japanese Society for Transplantation
and Cellular Therapy.
Yanada M, Yano S, Kuwatsuka Y,
The effect of center experience on
Kawamura K, Fukuda T, Ichinohe T,
allogeneic hematopoietic cell
Hashii Y, Goto H, Kato K, Ishimaru F,
150
transplantation outcomes in acute myeloid Sato A, Onizuka M, Matsuo K, Ito Y,
leukemia.
Yanagisawa A, Ohbiki M, Tabuchi K,
Atsuta Y, Kanda J, Konuma T.
Kato M, Horikoshi Y, Okamoto Y,
Takahashi Y, Hasegawa D, Koh K, Takita
Second allogeneic hematopoietic SCT for
151
J, Inoue M, Kigasawa H, Ogawa A,
relapsed ALL in children.
Sasahara Y, Kawa K, Yabe H, Sakamaki
H, Suzuki R, Kato K.
Comparison of intravenous with oral
Kato M, Takahashi Y, Tomizawa D,
busulfan in allogeneic hematopoietic stem Okamoto Y, Inagaki J, Koh K, Ogawa A,
152 cell transplantation with myeloablative
Okada K, Cho Y, Takita J, Goto H,
conditioning regimens for pediatric acute Sakamaki H, Yabe H, Kawa K, Suzuki R,
leukemia.
Kudo K, Kato K.
Comparison of transplantation with
Kato K, Kato M, Hasegawa D, Kawasaki
reduced and myeloablative conditioning
H, Ishida H, Okamoto Y, Koh K, Inoue M,
153
for children with acute lymphoblastic
Inagaki J, Kato K, Sakamaki H, Yabe H,
leukemia.
Kawa K, Suzuki R, Atsuta Y.

Transplant
Cell Ther

2023

29(5):332 WGP.e1-11.
2-68

in press

2024

WGP
2-69

30(2):215 WGP.e1-18.
2-70

Bone Marrow
Transplantin press

WGP
2-71

Bone Marrow
2012
Transplant

47(10):13 WGP
07-11.
3-1

Biol Blood
Marrow
Transplant2013

19(12):16 WGP
90-4.
3-2

Blood

2015

125(8):13 WGP
52-4.
3-3

論文タイトル
Hematopoietic stem cell transplantation
154 for patients with acute lymphoblastic
leukemia and Down syndrome.

著者

雑誌名

発行
年

Goto H, Kaneko T, Shioda Y, Kajiwara M,
Sakashita K, Kitoh T, Hayakawa A, Miki
Pediatr Blood
M, Kato K, Ogawa A, Hashii Y, Inukai T,
2015
Cancer
Kato C, Sakamaki H, Yabe H, Suzuki R,
Kato K.

刊・号・
頁

業績
番号

62(1):148 WGP
-52.
3-4

Allogeneic haematopoietic stem celltransplantation for infant acutelymphoblastic leukaemia with KMT2A
Kato M, Hasegawa D, Koh K, Kato K,(MLL) rearrangements: a retrospective
Takita J, Inagaki J, Yabe H, Goto H,
155
study from the paediatric acute
Adachi S, Hayakawa A, Takeshita Y,
lymphoblastic leukaemia working group of Sawada A, Atsuta Y, Kato K.
the Japan Society for Haematopoietic Cell
Transplantation.

Br J
Haematol

2015

168(4):56 WGP
4-70.
3-5

Comparison of chemotherapeutic agentsas a myeloablative conditioning with total
body irradiation for pediatric acute156 lymphoblastic leukemia: A study from thepediatric ALL working group of the Japan
Society for Hematopoietic Cell
Transplantation.

Pediatr Blood
2015
Cancer62(10):18 WGP
44-50.
3-6

Kato M, Ishida H, Koh K, Inagaki J, Kato
K, Goto H, Kaneko T, Cho Y, Hashii Y,
Kurosawa H, Takita J, Hamamoto K,
Inoue M, Sawada A, Suzuki R, Kato K.

Kato M, Kurata M, Kanda J, Kato K,
Tomizawa D, Kudo K, Yoshida N,
Impact of graft-versus-host disease on
Watanabe K, Shimada H, Inagaki J, Koh Bone Marrow
157 relapse and survival after allogeneic stem
2019
K, Goto H, Kato K, Cho Y, Yuza Y, Ogawa Transplant
cell transplantation for pediatric leukemia.
A, Okada K, Inoue M, Hashii Y, TeshimaT, Murata M, Atsuta Y.
Hangai M, Urayama KY, Tanaka J, Kato
Allogeneic Stem Cell Transplantation for
Biol BloodK, Nishiwaki S, Koh K, Noguchi M, Kato
158 Acute Lymphoblastic Leukemia in
Marrow
2019
K, Yoshida N, Sato M, Goto H, Yuza Y,
Adolescents and Young Adults.
Transplant
Hashii Y, Atsuta Y, Mizuta S, Kato M.
Kawahara Y, Morimoto A, Inagaki J, KohUnrelated cord blood transplantation with
K, Noguchi M, Goto H, Yoshida N, Cho Y,
myeloablative conditioning for pediatricBone Marrow
159
Hori T, Hiwatari M, Kato K, Ogawa A,
2021
acute lymphoblastic leukemia in remission:
Transplant
Hashii Y, Inoue M, Kato K, Atsuta Y,
prognostic factors.
Kimura F, Kato M.
Ishida H, Kato M, Kawahara Y, Ishimaru
Prognostic factors of children and
S, Najima Y, Kako S, Sato M, Hiwatari M,
adolescents with T-cell acute
Noguchi M, Kato K, Koh K, Okada K,
Hematological160
2022
lymphoblastic leukemia after allogeneic
Iwasaki F, Kobayashi R, Igarashi S, Saito Oncology
transplantation.
S, Takahashi Y, Sato A, Tanaka J, Hashii
Y, Atsuta Y, Sakaguchi H, Imamura T.
Kawahara Y, Ishimaru S, Tanaka J, Kako
Impact of KIR-ligand mismatch on
S, Hirayama M, Kanaya M, Ishida H, Satopediatric T-cell acute lymphoblastic
Transplant161
M, Kobayashi R, Kato M, Goi K, Saito S,
2022
leukemia in unrelated cord blood
Cell Ther
Koga Y, Hashii Y, Kato K, Sato A, Atsuta
transplantation.
Y, Sakaguchi H.
Hematopoietic stem cell transplantation in Okamoto Y, Nakazawa Y, Inoue M,
children and adolescents with
Watanabe K, Goto H, Yoshida N, Noguchi Pediatr Blood
162
2020
nonremission acute lymphoblastic
M, Kikuta A, Kato K, Hashii Y, Atsuta Y, Cancer
leukemia.
Kato M.

54(1):68- WGP75.
3-725(8):159 WGP
7-602.
3-8

56(2):357 WGP
-67.
3-9

40(3):457 WGP
-68.
3-10

28(9):598 WGP.e1-8.
3-11

67(12):e2 WGP
8732.
3-12

Ishida H, Arakawa Y, Hasegawa D, Usami
Reduced-intensity allogenic
I, Hashii Y, Arai Y, Nishiwaki S, Keino D,
transplantation for children and
Kato K, Sato M, Yoshida N, Ozawa Y,
163 adolescents with Philadelphia
Ann Hematol
Okada K, Hidaka M, Yuza Y, Tanaka M,
chromosome-positive acute lymphoblastic
Watanabe K, Takita J, Kosaka Y, Fujita N,
leukemia.
Tanaka J, Sato A, Atsuta Y, Imamura T.

in press

Reduced-intensity allogeneic stem cell
Kanamori H, Mizuta S, Kako S, Kato H,
transplantation for patients aged 50 years Nishiwaki S, Imai K, Shigematsu A,or older with B-cell ALL in remission: aNakamae H, Tanaka M, Ikegame K, Yujiri
164
retrospective study by the Adult ALL
T, Fukuda T, Minagawa K, Eto T,
Working Group of the Japan Society for
Nagamura-Inoue T, Morishima Y, Suzuki
Hematopoietic Cell Transplantation.
R, Sakamaki H, Tanaka J.

48(12):15 WGP
13-8.
4-1

Bone Marrow
2013
Transplant

WGP
3-13

雑誌名

発行
年

刊・号・
頁

Nishiwaki S, Miyamura K, Ohashi K,
Impact of a donor source on adult
Kurokawa M, Taniguchi S, Fukuda T,
Philadelphia chromosome-negative acute
Ikegame K, Takahashi S, Mori T, Imai K,
lymphoblastic leukemia: a retrospective
Iida H, Hidaka M, Sakamaki H, Morishima
165 analysis from the Adult AcuteAnn Oncol
Y, Kato K, Suzuki R, Tanaka J; Adult
Lymphoblastic Leukemia Working Group of
Acute Lymphoblastic Leukemia Working
the Japan Society for Hematopoietic Cell
Group of the Japan Society forTransplantation.
Hematopoietic Cell Transplantation.

2013

24(6):159 WGP
4-602.
4-2

Reduced-intensity vs myeloablative
conditioning allogeneic hematopoietic SCT Tanaka J, Kanamori H, Nishiwaki S,
for patients aged over 45 years with ALL Ohashi K, Taniguchi S, Eto T, Nakamae
Bone Marrow
166 in remission: a study from the Adult ALL H, Minagawa K, Miyamura K, Sakamaki H,
2013
Transplant
Working Group of the Japan Society for
Morishima Y, Kato K, Suzuki R,
Hematopoietic Cell Transplantation
Nishimoto N, Oba K, Masauzi N.
(JSHCT).

48(11):13 WGP
89-94.
4-3

Kato H, Kawase T, Kako S, Mizuta S,
Kurokawa M, Mori T, Ohashi K, Iwato K,
Analysis of outcomes following autologous
Miyamura K, Hidaka M, Sakamaki H,
stem-cell transplantation in adult patientsSuzuki R, Morishima Y, Tanaka J; Adult
167 with Philadelphia chromosome-negative
Acute Lymphoblastic Leukemia Working
acute lymphoblastic leukemia during theGroup of Japan Society forfirst complete remission.
Hematopoietic Cell Transplantation(JSHCT).

99(11):e2 WGP
28-30.
4-4

論文タイトル

著者

Haematologic
2014aMizuta S, Matsuo K, Nishiwaki S, Imai K,
Pretransplant administration of imatinib
Kanamori H, Ohashi K, Fukuda T, Onishi
168 for allo-HSCT in patients with BCR-ABL- Y, Miyamura K, Takahashi S, Onizuka M, Blood
2014
positive acute lymphoblastic leukemia.
Atsuta Y, Suzuki R, Morishima Y, Kato K,
Sakamaki H, Tanaka J.
Nishiwaki S, Imai K, Mizuta S, Kanamori
Impact of MRD and TKI on allogeneic
H, Ohashi K, Fukuda T, Onishi Y,
hematopoietic cell transplantation forBone Marrow
169
Takahashi S, Uchida N, Eto T, Nakamae
2016
Ph+ALL: a study from the adult ALL WG
Transplant
H, Yujiri T, Mori S, Nagamura-Inoue T,of the JSHCT.
Suzuki R, Atsuta Y, Tanaka J.
Mitsuhashi K, Kako S, Shigematsu A,
Comparison of Cyclophosphamide
Atsuta Y, Doki N, Fukuda T, Kanamori H,
Combined with Total Body Irradiation, Oral Onizuka M, Takahashi S, Ozawa Y,
Biol Blood
Busulfan, or Intravenous Busulfan for
Kurokawa M, Inoue Y, Nagamura-Inoue T,
170
Marrow
Allogeneic Hematopoietic Cell
Morishima Y, Mizuta S, Tanaka J; Adult
Transplant
Transplantation in Adults with Acute
Acute Lymphoblastic Leukemia Working
Lymphoblastic Leukemia.
Group of the Japan Society for
Hematopoietic Cell Transplantation.

業績
番号123(15):2 WGP
325-32.
4-551(1):43- WGP
50.
4-6

2016

22(12):21 WGP
94-200.
4-7Bone Marrow
2016
Transplant51(12):16 WGP
36-9.
4-8

Br J
Haematol

2017

178(1):10 WGP
6-11.
4-9

Allogeneic stem cell transplantation for
adult patients with acute lymphoblastic
leukemia who had central nervous system
173
involvement: a study from the Adult ALL
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

Shigematsu A, Kako S, Mitsuhashi K,
Iwato K, Uchida N, Kanda Y, Fukuda T,
Sawa M, Senoo Y, Ogawa H, Miyamura K,
Int J Hematol 2017
Takada S, Nagamura-Inoue T, Morishima
Y, Ichinohe T, Atsuta Y, Mizuta S,
Tanaka J.

105(6):80 WGP
5-11.
4-10

Improved prognosis with additional
medium-dose VP16 to CY/TBI in174
allogeneic transplantation for high risk
ALL in adults.

Arai Y, Kondo T, Shigematsu A, Tanaka
J, Ohashi K, Fukuda T, Hidaka M,
Am J
Kobayashi N, Iwato K, Sakura T, Onizuka
HematolM, Ozawa Y, Eto T, Kurokawa M, Kahata
K, Uchida N, Atsuta Y, Mizuta S, Kako S.

93(1):47- WGP
57.
4-11

High-dose cytarabine added to CY/TBI
improves the prognosis of cord blood
171 transplantation for acute lymphoblastic
leukemia in adults: a retrospective cohort
study.
Increased non-relapse mortality due tohigh-dose cytarabine plus CY/TBI in
172
BMT/PBSCT for acute lymphoblastic
leukaemia in adults.

Arai Y, Kondo T, Shigematsu A, Tanaka
J, Takahashi S, Kobayashi T, Uchida N,
Onishi Y, Ishikawa J, Kanamori H, Sawa
M, Yokota A, Kouzai Y, Takanashi M,
Ichinohe T, Atsuta Y, Mizuta S.
Arai Y, Kondo T, Shigematsu A, Tanaka
J, Ohashi K, Fukuda T, Kawakita T, MoriT, Hoshino T, Onizuka M, Ozawa Y,
Yoshida S, Ueda Y, Mizuno I, Atsuta Y,
Mizuta S; Japan Society for
Haematopoietic Cell Transplantation.

2018

発行
年

刊・号・
頁

2018

24(10):20 WGP
09-16.
4-12

2019

110(10):3 WGP
255-66.
4-13

Nishiwaki S, Mizuta S, Ohashi K, Fukuda
T, Uchida N, Tachibana T, Onizuka M,
Different impact of BCR-ABL transcripts
Ozawa Y, Onishi Y, Takahashi S, Eto T,
on allogeneic hematopoietic cell
Nakamae H, Tanaka J, Ichinohe T, Atsuta Am J
177 transplantation from different graft
Y, Kako S; Adult Acute Lymphoblastic
Hematolsources for Ph + ALL with minimal residual
Leukemia Working Group of the Japandisease.
Society for Hematopoietic Cell
Transplantation.

2019

94(11):E3 WGP
01-5.
4-14

The effect of melphalan dose and total
body irradiation as reduced-intensity
178 conditioning for acute lymphoblastic
leukemia patients undergoing allogeneic
stem cell transplantation.

Harada K, Tachibana T, Ohashi K, Ozawa
Y, Sawa M, Kondo T, Ishikawa J, Onizuka Leuk
M, Imada K, Fujisaki T, Tanaka J, Fukuda Lymphoma
T, Atsuta Y, Kako S.

201960(14):35 WGP
21-8.
4-15

Allogeneic hematopoietic stem celltransplantation for adult patients with B179 cell acute lymphoblastic leukemia
harboring t(1;19)(q23;p13.3); comparison
with normal karyotype.

Kaito S, Najima Y, Harada K, Fukuda T,
Noguchi Y, Ikegame K, Tanaka M, Ozawa
Y, Yoshida S, Sawa M, Ota S, Inoue Y,
Bone Marrow
Tanaka J, Ichinohe T, Atsuta Y, Kako S;
2020
Transplant
Adult Acute Lymphoblastic Leukemia
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

55(7):133 WGP
7-46.
4-16

論文タイトル著者

雑誌名

Akahoshi Y, Mizuta S, Shimizu H, UchidaN, Fukuda T, Kanamori H, Onizuka M,
Ozawa Y, Ohashi K, Ohta S, Eto T,
Biol Blood
Tanaka J, Atsuta Y, Kako S; Adult Acute Marrow
Lymphoblastic Leukemia Working Group Transplantof the Japan Society for Hematopoietic
Cell Transplantation.
Akahoshi Y, Nishiwaki S, Mizuta S,
Tyrosine kinase inhibitor prophylaxis after Ohashi K, Uchida N, Tanaka M, Fukuda T,
176 transplant for Philadelphia chromosome- Ozawa Y, Takahashi S, Onizuka M,
Cancer Sci
positive acute lymphoblastic leukemia.
Shiratori S, Nakamae H, Kanda Y,
Ichinohe T, Atsuta Y, Kako S.
Additional Cytogenetic Abnormalities with
Philadelphia Chromosome-Positive Acute
175 Lymphoblastic Leukemia on Allogeneic
Stem Cell Transplantation in the Tyrosine
Kinase Inhibitor Era.

Akahoshi Y, Igarashi A, Fukuda T, Uchida
Impact of graft-versus-host disease andN, Tanaka M, Ozawa Y, Kanda Y, Onizuka
graft-versus-leukemia effect based on
M, Ichinohe T, Tanaka J, Atsuta Y, Kako Br J
180 minimal residual disease in Philadelphia
S; Adult Acute Lymphoblastic Leukemia Haematol
chromosome-positive acute lymphoblastic
Working Group of the Japan Society forleukemia.
Hematopoietic Cell Transplantation.

業績
番号

2020

190(1):84 WGP
-92.
4-17

Akahoshi Y, Nishiwaki S, Arai Y, Harada
K, Najima Y, Kanda Y, Shono K, Ota S,
Bone Marrow
2020
Fukuda T, Uchida N, Shiratori S, Tanaka Transplant
M, Tanaka J, Atsuta Y, Kako S.

55(7):131 WGP
7-25.
4-18

Tachibana T, Najima Y, Akahoshi Y,
Hirabayashi S, Harada K, Doki N, Uchida
The impacts of BCR-ABL1 mutations in
N, Fukuda T, Sawa M, Ogata M, Takada
patients with Philadelphia chromosomeS, Tanaka M, Matsuhashi Y, Tanaka J,
182 positive acute lymphoblastic leukemia who
Ann Hematol 2020
Onizuka M, Ichinohe T, Atsuta Y, Kako S;
underwent allogeneic hematopoietic cell
Adult ALL Working Group of the Japantransplantation.
Society for Hematopoietic Cell
Transplantation.

99(10):23 WGP
93-404.
4-19

Reduced-intensity Conditioning Is a
Reasonable Alternative for Philadelphia
Chromosome-Positive Acute
Lymphoblastic Leukemia Among Elderly
181
Patients Who Have Achieved Negative
Minimal Residual Disease: A Report From
the Adult Acute Lymphoblastic Leukemia
Working Group of the JSHCT.

Measurable residual disease affects
allogeneic hematopoietic cell183
transplantation in Ph+ ALL during both
CR1 and CR2.

Nishiwaki S, Akahoshi Y, Mizuta S,
Shinohara A, Hirabayashi S, Noguchi Y,
Fukuda T, Uchida N, Tanaka M, Onizuka BloodM, Ozawa Y, Ota S, Shiratori S, Onishi Y, Advances
Kanda Y, Sawa M, Tanaka J, Atsuta Y,
Kako S.

Minimal residual disease (MRD) positivity
at allogeneic hematopoietic cell
Akahoshi Y, Arai Y, Nishiwaki S, Mizuta
transplantation, not the quantity of MRD, S, Marumo A, Uchida N, Kanda Y, Sakai
184
is a risk factor for relapse of Philadelphia H, Takada S, Fukuda T, Fujisawa S,
chromosome-positive acute lymphoblastic Ashida T, Tanaka J, Atsuta Y, Kako S.
leukemia.

2021

5(2):584- WGP
92.
4-20

Int J Hematol 2021

113(6):83 WGP
2-9.
4-21

雑誌名

発行
年

刊・号・
頁

Kurosawa S, Kaito S, Uchida N, Fukuda
T, Doki N, Mori T, Hasegawa Y, Takada S, Leuk
Sakaida E, Tanaka M, Ikegame K, Kanda Lymphoma
J, Atsuta Y, Kako S.

2021

62(10):25 WGP
14-20.
4-22

Nakamura M, Arai Y, Hirabayashi S,
Kondo T, Doki N, Uchida N, Fukuda T,
Ozawa Y, Tanaka M, Sawa M, Katayama
Y, Kanda Y, Shiratori S, Nakamae H,
Yoshioka S, Onizuka M, Ichinohe T,
Atsuta Y, Kako S.

Br J
Haematol

2021

194(2):40 WGP
3-13.
4-23

Akahoshi Y, Arai Y, Nishiwaki S,
Tachibana T, Shinohara A, Doki N,
Uchida N, Tanaka M, Kanda Y, Shiratori
S, Ozawa Y, Shono K, Katayama Y,
Tanaka J, Fukuda T, Atsuta Y, Kako S.

Bone Marrow
2021
Transplant56(11):28 WGP
42-8.
4-24

Kako S, Hayakawa F, Imai K, Tanaka J,
Mizuta S, Nishiwaki S, Kanamori H,
Optimal treatment for PhiladelphiaMukae J, Ozawa Y, Kondo T, Fukuda T,
negative acute lymphoblastic leukemia in
188
Ichinohe T, Ota S, Tanaka Y, Murayama Int J Hematol 2021
first remission in the era of high-intensity
T, Kurahashi S, Sakura T, Usui N, Ohtake
chemotherapy.
S, Kiyoi H, Matsumura I, Miyazaki Y,
Atsuta Y.

114(5):60 WGP
8-19.
4-25

Decision Analysis for Unrelated Bone
Marrow Transplantation or Immediate
Cord Blood Transplantation for Patients
189with Philadelphia Chromosome-Negative
Acute Lymphoblastic Leukemia in First
Complete Remission.

Kako S, Hayakawa F, Miyamura K,
Tanaka J, Imai K, Kanda J, Morishima S,
Uchida N, Doki N, Ikegame K, Ozawa Y,
Takada S, Usui N, Ohtake S, Kiyoi H,
Matsumura I, Miyazaki Y, Ichinohe T,
Fukuda T, Atsuta Y, Kanda Y.

Transplant
Cell Ther

2022

28(3):161 WGP.e1-10.
4-26

Allogeneic Hematopoietic Stem Cell
Transplantation for Adult Philadelphia
190 Chromosome-Negative B-Cell Acute
Lymphoblastic Leukemia in Second
Complete Remission.

Kaito S, Kurosawa S, Najima Y, Sakaida
E, Shingai N, Fukuda T, Tachibana T,
Uchida N, Ozawa Y, Sawa M, Nakazawa
H, Ota S, Kato J, Nakamae H, Katayama
Transplant
Y, Eto T, Tanaka J, Kanda Y, Atsuta Y,
Cell Ther
Arai Y, Kako S; Adult Acute
Lymphoblastic Leukemia Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.

2022

28(6):326 WGP.e1-10.
4-27

論文タイトル
Allogeneic hematopoietic stem celltransplantation for adult patients with B185 cell acute lymphoblastic leukemia withhigh hyperdiploidy: a retrospective
nationwide study.
Residual disease is a strong prognostic
marker in patients with acutelymphoblastic leukaemia with186
chemotherapy-refractory or relapsed
disease prior to allogeneic stem celltransplantation.
Newly proposed threshold and validationof white blood cell count at diagnosis for
Philadelphia chromosome-positive acutelymphoblastic leukemia: risk assessment
187 of relapse in patients with negative
minimal residual disease attransplantation-a report from the Adult
Acute Lymphoblastic Leukemia Working
Group of the JSTCT.

著者

Propensity score matching/reweighting
Mizuta S, Ugai T, Kato H, Doki N, Ota S,
analysis comparing autologous and
Kawakita T, Katayama Y, Kurokawa M,
191
Int J Hematol 2022
allogeneic stem cell transplantation for B- Nakamae H, Yano S, Nawa Y, Kanda Y,
lineage acute lymphoblastic leukemia.
Fukuda T, Atsuta Y, Kako S.
Nishiwaki S, Akahoshi Y, Morita-Fujita M,
Shimizu H, Uchida N, Ozawa Y, Fukuda T,
Improvements in allogeneic hematopoietic
Tanaka M, Ikegame K, Ota S, Katayama Blood
192 cell transplantation outcomes for adults
2022
Y, Takahashi S, Kawakita T, Ara T,
Advanceswith ALL over the past 3 decades.
Onizuka M, Kimura T, Tanaka J, Atsuta
Y, Arai Y.
Akahoshi Y, Nakasone H, Takenaka K,
Yamasaki S, Nakamura M, Doki N, Tanaka
CMV reactivation after allogeneic HCT is
M, Ozawa Y, Uchida N, Ara T, Nakamae Blood
193 associated with a reduced risk of relapse
2023
H, Ota S, Onizuka M, Yano S, Tanaka J, Advancesin acute lymphoblastic leukemia.
Fukuda T, Kanda Y, Atsuta Y, Kako S,
Yanada M, Arai Y.
Morita-Fujita M, Arai Y, Kondo T, Harada
Adult patients with Ph+ ALL benefit from K, Uchida N, Toya T, Ozawa Y, Fukuda T,
Hematological
194 conditioning regimen of medium-dose
Ota S, Onizuka M, Kanda Y, Maruyama Y,
2022
Oncology
VP16 plus CY/TBI.
Takada S, Kawakita T, Ara T, Ichinohe T,
Kimura T, Atsuta Y, Kako S.

業績
番号116(3):39 WGP
3-400.
4-28

6(15):455 WGP
8-69.
4-29

7(12):269 WGP
9-708.
4-30

40(5):104 WGP
1-55
4-31

雑誌名

発行
年

刊・号・
頁

Overcoming minimal residual disease using
intensified conditioning with medium-dose Harada K, Morita-Fujita M, Fukuda T,
etoposide, cyclophosphamide and total
Ozawa Y, Doki N, Toyosaki M, Maruyama
195 body irradiation in allogeneic stem cellY, Kanda Y, Ashida T, Eto T, Takada S, Cytotherapytransplantation for Philadelphia
Uchida N, Ichinohe T, Kanda J, Onizuka
chromosome-positive acute lymphoblastic M, Atsuta Y, Kako S, Arai Y.
leukemia in adults.

2022

24(9):954 WGP
-61
4-32

論文タイトル

著者

業績
番号

Impact of MRD on clinical outcomes of
unrelated hematopoietic stem cell196
transplantation in patients with Ph+ ALL:A retrospective nationwide study.

Hirabayashi S, Kondo T, Nishiwaki S,
Mizuta S, Doki N, Fukuda T, Uchida N,
Ozawa Y, Kanda Y, Imanaka R, Takahashi Am J
S, Ishikawa J, Yano S, Nakamae H, Eto T, Hematol
Kimura T, Tanaka J, Ichinohe T, Atsuta
Y, Kako S.

2023

98(10):16 WGP
06-18.
4-33

Prognostic Factors for Outcomes of
Allogeneic HSCT for Children and197
Adolescents/Young Adults With CML in
the TKI Era.

Shimada H, Tanizawa A, Kondo T,
Nagamura-Inoue T, Yasui M, Tojo A,
Muramatsu H, Eto T, Doki N, Tanaka M,
Sato M, Noguchi M, Uchida N, Takahashi
Transplant
Y, Sakata N, Ichinohe T, Hashii Y, Kato K,
Cell Ther
Atsuta Y, Ohashi K; Pediatric and Adult
CML/MPN Working Groups of theJapanese Society for Transplantation
and Cellular Therapy.

2022

28(7):376 WGP
-89.
5-1

Allogeneic stem cell transplantation forchildren and adolescents/young adults
198 with de novo blastic phase chronic
myeloid leukemia in the tyrosine kinase
inhibitor era.

Ishida H, Shimada H, Tanizawa A,
Shimazu Y, Tachibana T, Doki N, Ara T,
Matsuo Y, Nara M, Toubai T, Ino K,
Am J
Nakamae H, Kato K, Kato K, Sato A, Hino HematolM, Matsumoto K, Atsuta Y, Yasui M,
Nagamura-Inoue T.

2023

98(8):E20 WGP
0-3.
5-2

Effect of graft sources on allogeneic
hematopoietic stem cell transplantation
outcome in adults with chronic myeloid
199 leukemia in the era of tyrosine kinase
inhibitors: a Japanese Society of
Hematopoietic Cell Transplantation
retrospective analysis.

Ohashi K, Nagamura-Inoue T, Nagamura
F, Tojo A, Miyamura K, Mori T, Kurokawa
Int J Hematol 2014
M, Taniguchi S, Ishikawa J, Morishima Y,
Atsuta Y, Sakamaki H.

100(3):29 WGP
6-306.
6-1

Kondo T, Nagamura-Inoue T, Tojo A,
Clinical impact of pretransplant use of
Nagamura F, Uchida N, Nakamae H,
multiple tyrosine kinase inhibitors on the
Fukuda T, Mori T, Yano S, Kurokawa M, Am J
200 outcome of allogeneic hematopoietic stem
Ueno H, Kanamori H, Hashimoto H,
Hematolcell transplantation for chronic
Onizuka M, Takanashi M, Ichinohe T,
myelogenous leukemia.
Atsuta Y, Ohashi K.
Allogeneic hematopoietic stem celltransplantation for the treatment of BCR- Itonaga H, Ota S, Ikeda T, Taji H, Amano
ABL1-negative atypical chronic myeloid
I, Hasegawa Y, Ichinohe T, Fukuda T,
201
Leuk Res
leukemia and chronic neutrophil leukemia: Atsuta Y, Tanizawa A, Kondo T, Miyazaki
A retrospective nationwide study inY.
Japan.
Murata M, Takenaka K, Uchida N, Ozawa
Comparison of Outcomes of Allogeneic
Y, Ohashi K, Kim SW, Ikegame K, Kanda Biol Blood
Transplantation for Primary Myelofibrosis
202
Y, Kobayashi H, Ishikawa J, Ago H,
Marrowamong Hematopoietic Stem Cell Source
Hirokawa M, Fukuda T, Atsuta Y, Kondo TransplantGroups.
T.

2017

92(9):902 WGP
-8.
6-2

2018

75:50-7.

2019

25(8):153 WGP
6-43.
6-4

Shimazu Y, Murata M, Kondo T, Minami
Y, Tachibana T, Doki N, Uchida N, Ozawa
The new generation tyrosine kinase
Y, Yano S, Fukuda T, Kato J, Ara T, Eto
inhibitor improves the survival of chronic
Hematological203
T, Ishikawa J, Nakamae H, Tanaka J,
2022
myeloid leukemia patients after allogeneic
Oncology
Ichinohe T, Atsuta Y, Nagamura-Inoue T;
stem cell transplantation.
working group of the Japan Society forTransplantation and Cellular Therapy.

40(3):442 WGP
-56.
6-5

WGP
6-3

論文タイトル

Prognostic impact of complex karyotype
204 on post-transplant outcomes of
myelofibrosis.

The Clinical Significance of BCR-ABL1
Mutations in Patients With Philadelphia
205 Chromosome-Positive Chronic Myeloid
Leukemia Who Underwent Allogeneic
Hematopoietic Cell Transplantation.
Salvage allogeneic stem celltransplantation in patients with pediatric206
myelodysplastic syndrome andmyeloproliferative neoplasms.

著者

雑誌名

発行
年

Okada Y, Takenaka K, Murata M,
Shimazu Y, Tachibana T, Ozawa Y,
Uchida N, Wakayama T, Doki N, Sugio Y,
Hematological
Tanaka M, Masuko M, Kobayashi H, Ino K
2022
Oncology, Ishikawa J, Nakamae H, Matsuoka K,
Kanda Y, Fukuda T, Atsuta Y,
Nagamura-Inoue T.
Tachibana T, Kondo T, Uchida N, Doki N,
Takada S, Takahashi S, Yano S, Mori T,
Kohno A, Kimura T, Fukuda T, Atsuta Y,
Transplant
Nagamura-Inoue T; Adult-CMLMPN2022
Cell Ther
working-group-of-the-JapaneseSociety-for-Transplantation-andCellular-Therapy.
Kato M, Yoshida N, Inagaki J, Maeba H,
Kudo K, Cho Y, Kurosawa H, Okimoto Y, Pediatr Blood
2014
Tauchi H, Yabe H, Sawada A, Kato K,
CancerAtsuta Y, Watanabe K.

Yoshida N, Sakaguchi H, Yabe M,
Hasegawa D, Hama A, Hasegawa D, Kato
Clinical Outcomes after Allogeneic
M, Noguchi M, Terui K, Takahashi Y, Cho
Hematopoietic Stem Cell Transplantation
Y, Sato M, Koh K, Kakuda H, Shimada H, Biol Bloodin Children with Juvenile Myelomonocytic
207
Hashii Y, Sato A, Kato K, Atsuta Y,
Marrow
Leukemia: A Report from the Japan
Watanabe K; Pediatric Myelodysplastic
TransplantSociety for Hematopoietic Cell
Syndrome Working Group of the Japan
Transplantation.
Society for Hematopoietic Cell
Transplantation.
Prognostic value of the revised
Yamamoto S, Kato M, Watanabe K,
International Prognostic Scoring System Ishimaru S, Hasegawa D, Noguchi M,
five-group cytogenetic abnormality
Hama A, Sato M, Koike T, Iwasaki F,
208classification for the outcome prediction Yagasaki H, Takahashi Y, Kosaka Y,of hematopoietic stem cell transplantation Hashii Y, Morimoto A, Atsuta Y,
in pediatric myelodysplastic syndrome.
Hasegawa D, Yoshida N.

刊・号・
頁

業績
番号

40(5):107 WGP
6-85.
6-6

28(6):321 WGP.e1-8.
6-7

61(10):18 WGP
60-6.
7-1

2020

26(5):902 WGP
-10.
7-2

Bone Marrow
2021
Transplant56(12):30 WGP
16-23.
7-3

Aoki K , Ishikawa T, Ishiyama K, Aoki J,
Itonaga H, Fukuda T, Kakihana K, UchidaN, Ueda Y, Eto T, Mori T, Kondo T, Iwato
K, Morishima Y, Tanaka J, Atsuta Y,
Br J
Miyazaki Y; Adult Myelodysplastic
Haematol
Syndromes Working Group of the Japan
Society for Hematopoietic Cell
Transplantation (JSHCT).

2015

168(3):46 WGP
3-6.
8-1

Konuma T, Takahashi S, Uchida N,
Kuwatsuka Y, Yamasaki S, Aoki J, Onishi
Effect of Granulocyte Colony-Stimulating Y, Aotsuka N, Ohashi K, Mori T, Masuko
Factor-Combined Conditioning in Cord
M, Nakamae H, Miyamura K, Kato K,
Biol Blood
Blood Transplantation for Myelodysplastic Atsuta Y, Kato S, Asano S, Takami A,
210
Marrow
Syndrome and Secondary Acute Myeloid Miyazaki Y; Adult Myelodysplastic
TransplantLeukemia: A Retrospective Study in
Syndrome and Adult Acute Myeloid
Japan.
Leukemia Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

201521(9):163 WGP
2-40.
8-2

Impacts of graft-versus-host disease on
outcomes after allogeneic hematopoietic
211 stem cell transplantation for chronic
myelomonocytic leukemia: A nationwide
retrospective study.

Itonaga H, Iwanaga M, Aoki K, Aoki J,
Ishiyama K, Ishikawa T, Sakura T, Fukuda
T, Najima Y, Yujiri T, Mori T, Kurokawa
M, Nawa Y, Uchida N, Morishita Y,
Leuk Res
Hashimoto H, Eto T, Hirokawa M,
Morishima Y, Nagamura-Inoue T, Atsuta
Y, Miyazaki Y.

2016

41:48-55.

Outcomes of Allogeneic Hematopoietic
Stem Cell Transplantation in Adult
212
Patients with Myelodysplastic Syndrome
Harboring Trisomy 8.

Konuma T, Miyazaki Y, Uchida N, Ohashi
K, Kondo T, Nakamae H, Takahashi S,
Mori T, Ozawa Y, Kato C, Iwato K,
Biol Blood
Fukuda T, Ichinohe T, Atsuta Y, Ishiyama Marrow
K; Adult Myelodysplastic Syndrome
Transplant
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

2017

23(1):75- WGP
80.
8-4

Allogeneic haematopoietic celltransplantation with reduced-intensity
209 conditioning for elderly patients withadvanced myelodysplastic syndromes: anationwide study.

WGP
8-3

論文タイトル

著者

雑誌名

発行
年

Prognostic Impact of Donor Source on
Itonaga H, Aoki K, Aoki J, Ishikawa T,
Allogeneic Hematopoietic Stem Cell
Ishiyama K, Uchida N, Sakura T, Ohashi
Biol Blood
Transplantation Outcomes in Adults with K, Kurokawa M, Ozawa Y, Matsuoka KI,
213
Marrow
2018
Chronic Myelomonocytic Leukemia: A
Nakamura Y, Kimura F, Iwato K, Nawa Y,
Transplant
Nationwide Retrospective Analysis in
Hirokawa M, Kato K, Ichinohe T, Atsuta
Japan.
Y, Miyazaki Y.
Clinical impact of the loss of chromosome Itonaga H, Ishiyama K, Aoki K, Aoki J,
7q on outcomes of patients with
Ishikawa T, Ohashi K, Fukuda T, Ozawa
Bone Marrow
214 myelodysplastic syndromes treated with Y, Ota S, Uchida N, Eto T, Iwato K, Ohno
2019
Transplant
allogeneic hematopoietic stem cellY, Takanashi M, Ichinohe T, Atsuta Y,
transplantation.
Miyazaki Y.
Shimomura Y, Hara M, Tachibana T,
Outcomes of second allogeneic
Ohashi K, Sakura T, Fukuda T, Nakazawa
haematopoietic stem cell transplantation
Br J
215
H, Iwato K, Kanda Y, Ikeda T, Eto T,2019
in patients with relapse of myelodysplastic
HaematolKanda J, Ichinohe T, Atsuta Y, Ishikawa
syndrome.
T1, Ishiyama K.
Increased opportunity for prolonged
Itonaga H, Ishiyama K, Aoki K, Aoki J,
survival after allogeneic hematopoietic
Ishikawa T, Uchida N, Ohashi K, Ueda Y,
216 stem cell transplantation in patients aged Fukuda T, Sakura T, Ohno Y, Iwato K,
Ann Hematol 201960-69 years with myelodysplastic
Okumura H, Kondo T, Ichinohe T,
syndrome.
Takanashi M, Atsuta Y, Miyazaki Y.
Graft-versus-MDS effect after unrelated Ishiyama K, Aoki J, Itonaga H, Uchida N,
cord blood transplantation: a retrospective Takahashi S, Ohno Y, Matsuhashi Y,
Blood Cancer
217 analysis of 752 patients registered at the Sakura T, Onizuka M, Miyakoshi S,
2019JJapanese Data Center for Hematopoietic Takanashi M, Fukuda T, Atsuta Y, Nakao
Cell Transplantation.
S, Miyazaki Y.
Induction chemotherapy followed byallogeneic HCT versus upfront allogeneic
218 HCT for advanced myelodysplastic
syndrome: A propensity score matchedanalysis.

Konuma T, Shimomura Y, Ozawa Y, Ueda
Y, Uchida N, Onizuka M, Akiyama M, Mori
T, Nakamae H, Ohno Y, Shiratori S,
Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Hematological
2019
Ishiyama K; Adult Myelodysplastic
Oncology
Syndrome Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

刊・号・
頁

業績
番号

24(4):840 WGP-8.
8-554(9):147 WGP
1-81.
8-6

138(1):86 WGP
-90.
8-7

98(6):136 WGP
7-81.
8-8

9(3):31.

WGP
8-937(1):85- WGP
95.
8-10

Outcome of Allogeneic Hematopoietic
Stem Cell Transplantation in Patients with Kurosawa S, Shimomura Y, Tachibana T,
Myelodysplastic/Myeloproliferative
Ishiyama K, Ota S, Kobayashi T, Uchida Biol Blood
219 Neoplasms-Unclassifiable: A
N, Fukushima K, Ashida T, Matsuoka KI, Marrow
Retrospective Nationwide Study of the
Kanda J, Ichinohe T, Atsuta Y, Murata M, Transplant
Japan Society for Hematopoietic Cell
Aoki J.
Transplantation.

2020

26(9):160 WGP
7-11.
8-11

Konuma T, Ishiyama K, Igarashi A, UchidaN, Ozawa Y, Fukuda T, Ueda Y, Matsuoka
Effects of Acute and Chronic GraftKI, Mori T, Katayama Y, Onizuka M,
versus-myelodysplastic Syndrome on
Clin Cancer
220
Ichinohe T, Atsuta Y; Adult
Long-term Outcomes Following Allogeneic
Res
Myelodysplastic Syndrome Working
Hematopoietic Cell Transplantation.
Group of the Japan Society for
Hematopoietic Cell Transplantation.

2020

26(24):64 WGP
83-93.
8-12

2020

26(8):154 WGP
3-51.
8-13

Bone Marrow
2021
Transplant56(12):30 WGP
08-15.
8-14

Transplant
Cell Ther

27(8):671 WGP
-8.
8-15

Outcome and Risk Factors for TherapyRelated Myeloid Neoplasms Treated with
221
Allogeneic Stem Cell Transplantation in
Japan.
Fludarabine/busulfan versus
busulfan/cyclophosphamide as
222 myeloablative conditioning for
myelodysplastic syndrome: a propensity
score-matched analysis.

223

Pretransplantation Red Blood Cell andPlatelet Transfusion Burden in De Novo
Myelodysplastic Syndrome Undergoing
Allogeneic Transplantation.

Kida M, Usuki K, Uchida N, Fukuda T,
Katayama Y, Kondo T, Eto T, Matsuoka
KI, Matsuhashi Y, Ota S, Sawa M,
Miyamoto T, Ichinohe T, Kimura T,
Atsuta Y, Takami A, Miyazaki Y, Yano S,
Ishiyama K, Yanada M, Aoki J.
Kurosawa S, Shimomura Y, Itonaga H,
Najima Y, Kobayashi T, Ozawa Y, Kanda
Y, Kako S, Kawakita T, Matsuoka KI,
Maruyama Y, Ota S, Nakazawa H, Imada
K, Kanda J, Fukuda T, Atsuta Y, Aoki J.
Konuma T, Aoki J, Ozawa Y, Uchida N,
Kobayashi T, Onizuka M, Katayama Y,
Ohta T, Nakano N, Ota S, Onishi Y,
Kobayashi H, Fukuda T, Kanda Y, Atsuta
Y; Adult Myelodysplastic Syndrome
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

Biol Blood
Marrow
Transplant2021

論文タイトル
Allogeneic hematopoietic stem celltransplantation for myelodysplastic
224
syndrome in adolescent and young adultpatients.

著者

雑誌名

発行
年

Shimomura Y, Hara M, Konuma T, Itonaga
H, Doki N, Ozawa Y, Eto T, Uchida N,
Aoki J, Kato J, Onishi Y, Takahashi S,
Bone Marrow
2021
Fukushima K, Nakamae H, Kawakita T,
Transplant
Tanaka J, Fukuda T, Atsuta Y, Ishikawa
T, Ishiyama K.

Outcome of therapy-related
Itonaga H, Kida M, Hamamura A, Uchida
myelodysplastic syndrome and oligoblastic N, Ozawa Y, Fukuda T, Ueda Y, Kataoka
225 acute myeloid leukemia after allogeneic
K, Katayama Y, Ota S, Matsuoka KI,
hematopoietic stem cell transplantation: A Kondo T, Eto T, Kanda J, Ichinohe T,
propensity score matched analysis.
Atsuta Y, Miyazaki Y, Ishiyama K.

刊・号・
頁

業績
番号

56(10):25 WGP
10-7.
8-16

Hematological2022
Oncology

40(4):752 WGP
-62.
8-17

Transplant
Cell Ther

2022

28(6):323 WGP.e1-9.
8-18

Haploidentical transplantation with posttransplant cyclophosphamide versus single
Konuma T, Shimomura Y, Ishiyama K, Ara
cord blood transplantation for
T, Nakamae H, Hiramoto N, Eto T,
myelodysplastic syndrome: A
Maruyama Y, Nagafuji K, Ishikawa J,
Am J
227 retrospective study from the Adult
Uchida N, Tanaka M, Onizuka M, Ueda Y, Hematol
Myelodysplastic Syndrome Working Group
Anzai N, Kimura T, Kanda Y, Fukuda T,of the Japanese Society for
Atsuta Y.
Transplantation and Cellular Therapy(JSTCT).

2022

97(12):E4 WGP
47-50.
8-19

Progress in survival following three
decades of allogeneic hematopoietic cell
228 transplantation for myelodysplastic
syndrome: A real-world registry study inJapan.

Konuma T, Itonaga H, Ishiyama K,
Hamamura A, Uchida N, Ozawa Y,
Am J
Katayama Y, Sakurai M, Ueda Y,
HematolMatsuoka KI, Kawakita T, Eto T, Ara T,
Kanda J, Onizuka M, Fukuda T, Atsuta Y.

2023

98(4):E68 WGP
-71.
8-20

Should a matched sibling donor still beconsidered the primary option for
229 allogeneic hematopoietic celltransplantation in patients over 50 yearsof age with myelodysplastic syndrome?

Konuma T, Itonaga H, Ishiyama K, Doki N,
Uchida N, Sawa M, Katayama Y, Tanaka
Bone Marrow
M, Ueda Y, Onizuka M, Miyakoshi S,
2023
TransplantOzawa Y, Fukuda T, Matsuoka KI, TanakaJ, Kimura T, Ichinohe T, Atsuta Y.

58(8):893 WGP
-906.
8-21

The prognosis and risk factors forpatients with complex karyotype
230 myelodysplastic syndrome undergoing
allogeneic haematopoietic stem celltransplantation.

Shimomura Y, Komukai S, Kitamura T,
Tachibana T, Kurosawa S, Itonaga H,
Tsukamoto S, Doki N, Katayama Y, Ito A,
Br J
Sawa M, Ueda Y, Nakamae H, Nawa Y,
Haematol
Tanaka M, Arai Y, Ota S, Kataoka K,
Nishida T, Kanda J, Fukuda T, Atsuta Y,
Ishiyama K.

2024

204(2):61 WGP
2-22.
8-22

2024

99(2):E42 WGP
-5.
8-23

Myeloablative Versus Reduced-Intensity
Conditioning With Fludarabine/Busulfan
226
for Myelodysplastic Syndrome: A
Propensity Score-Matched Analysis.

Kurosawa S, Shimomura Y, Itonaga H,
Najima Y, Kobayashi T, Ozawa Y, Kanda
Y, Kako S, Kawakita T, Matsuoka KI,
Maruyama Y, Ota S, Nakazawa H, ImadaK, Kimura T, Kanda J, Fukuda T, Atsuta
Y, Ishiyama K.

Hematopoietic stem cell transplantation
Shimomura Y, Kitamura T, Konuma T,
from haploidentical offspring donors using
Nakaya Y, Doki N, Sawa M, Nakamae H,
post-transplant cyclophosphamide versus
Am J
231
Eto T, Nishida T, Ohigashi H, Ota S,
human leukocyte antigen-matched siblings
Hematol
Onizuka M, Hiramoto N, Kawakita T,
in older patients with myelodysplastic
Kanda J, Ichinohe T, Atsuta Y, Itonaga H.
syndrome.
HLA-Haploidentical Peripheral Blood
Nakaya Y, Koh H, Konuma T, Shimomura
Stem Cell Transplantation with PostY, Ishiyama K, Itonaga H, Hino M, Doki N,
Transplantation Cyclophosphamide versus Nishida T, Ohigashi H, Matsuoka KI,
Transplant
232
HLA-Matched Unrelated Donor
Kanda Y, Maruyama Y, Sawa M, Eto T,
Cell Ther
Transplantation for Myelodysplastic
Hiramoto N, Fukuda T, Atsuta Y,
Syndrome.
Nakamae H.
Single-unit unrelated cord blood
Konuma T, Itonaga H, Shimomura Y,
transplantation versus HLA-matchedFujioka M, Aoki K, Uchida N, Onizuka M,
sibling transplantation in adults with
Jinguji A, Tanaka M, Ueda Y, Katayama
233 advanced myelodysplastic syndrome: A
Y, Sawa M, Tanaka H, Nakamae H,
registry-based study from the adult MDS Kawakita T, Maruyama Y, Takahashi S,
working group of the Japanese society for Ishimaru F, Kanda J, Ichinohe T, Atsuta
transplantation and cellular therapy.
Y.

Hematological2024
Oncology

in pressWGP
8-24

42(1):e32 WGP
17.
8-25

論文タイトル

著者

雑誌名

発行
年

Allogeneic transplantation of bone marrow
versus peripheral blood stem cells from
Itonaga H, Miyazaki Y, Aoki K, Shingai N,
HLA-identical relatives in patients with
Ozawa Y, Fukuda T, Kataoka K, Kawakita
234 myelodysplastic syndromes andT, Ueda Y, Ara T, Tanaka M, Katayama Y, Ann Hematol 2023
oligoblastic acute myeloid leukemia: a
Sawa M, Eto T, Kanda J, Atsuta Y,
propensity score analysis of a nationwide Ishiyama K.
database.
Kobayashi R, Fujita N, Mitsui T, Iwasaki
Stem cell transplantation for paediatricF, Suzumiya J, Kuroda H, Nishimura R,
Br J
235 patients with non-anaplastic peripheral T- Sasahara Y, Takeshita Y, Kato K,
2012
Haematolcell lymphoma in Japan.
Okumura H, Sakamaki H, Yabe H, Kawa
K, Kato K, Suzuki R.
Fukano R, Mori T, Kobayashi R, Mitsui T,
Haematopoietic stem cell transplantation
Fujita N, Iwasaki F, Suzumiya J, Chin M,
for relapsed or refractory anaplastic large
Br J
236
Goto H, Takahashi Y, Hara J, Park YD,
cell lymphoma: a study of children and
HaematolInoue M, Koga Y, Inagaki J, Sakamaki H,
adolescents in Japan.
Adachi S, Kawa K, Kato K, Suzuki R.

2015

Kobayashi R, Mitsui T, Fujita N, Osumi T,
Outcome differences between children
Aoki T, Aoki K, Suzuki R, Fukuda T,
and adolescents and young adults with
Miyamoto T, Kato K, Nakamae H, Goto H,
237
Int J Hematol 2017
non-Hodgkin lymphoma following stem cell Eto T, Inoue M, Mori T, Terui K, Onizuka
transplantation.
M, Koh K, Koga Y, Ichinohe T, Sawada A,
Atsuta Y, Suzumiya J.
Fujita N, Kobayashi R, Atsuta Y, Iwasaki
Hematopoietic stem cell transplantation in
F, Suzumiya J, Sasahara Y, Inoue M, Koh
238 children and adolescents with relapsed or
Int J Hematol 2019
K, Hori T, Goto H, Ichinohe T, Hashii Y,
refractory B-cell non-Hodgkin lymphoma.
Kato K, Suzuki R, Mitsui T.
The effect of graft-versus-host disease Mitsui T, Fujita N, Koga Y, Fukano R,
on outcomes after allogeneic stem cell
Osumi T, Hama A, Koh K, Kakuda H,
Pediatr Blood
239 transplantation for refractory
Inoue M, Fukuda T, Yabe H, Takita J,
2020
Cancerlymphoblastic lymphoma in children andShimada A, Hashii Y, Sato A, Atsuta Y,
young adults.
Kanda Y, Suzumiya J, Kobayashi R.
The effectiveness of busulfan-based
Hori D, Kobayashi R, Fujita N, Suzumiya
conditioning regimens for stem cellJ, Suzuki R, Kato K, Kawata T, Fukuda T,
Pediatr Blood
240 transplantation against lymphomas inInoue M, Goto H, Hama A, Iwato K,
2019
Cancerchildren, adolescents, and young adults in Okumura H, Eto T, Hashii Y, Atsuta Y,
Japan.
Mitsui T.
Successful outcome with reducedFukano R, Mori T, Fujita N, Kobayashi R,
intensity condition regimen followed by
Mitsui T, Kato K, Suzuki R, Suzumiya J,
241 allogeneic hematopoietic stem cell
Fukuda T, Shindo M, Maseki , Shimoyama Int J Hematol 2019transplantation for relapsed or refractory T, Okada K, Inoue M, Inagaki J, Hashii Y,
anaplastic large-cell lymphoma.
Sato A, Tabuchi K.
High-dose chemotherapy with autologous Chihara D, Izutsu K, Kondo E, Sakai R,
stem cell transplantation for elderly
Mizuta S, Yokoyama K, Kaneko H, Kato Biol Blood
242 patients with relapsed/refractory diffuse K, Hasegawa Y, Chou T, Sugahara H,
Marrow
2014
large B cell lymphoma: a nationwide
Henzan H, Sakamaki H, Suzuki R,
Transplant
retrospective study.
Suzumiya J.
Kako S, Izutsu K, Kato K, Kim SW, MoriT, Fukuda T, Kobayashi N, Taji H,
The role of hematopoietic stem cell
Hashimoto H, Kondo T, Sakamaki H,
Am J
243 transplantation for relapsed and refractory Morishima Y, Kato K, Suzuki R, Suzumiya
2015
Hematol
Hodgkin lymphoma.
J; Adult Lymphoma Working Group of theJapanese Society for Hematopoietic Cell
Transplantation.
Long-term survival following autologous
Aoki T, Suzuki R, Kuwatsuka Y, Kako S,
and allogeneic stem cell transplantation
Fujimoto K, Taguchi J, Kondo T, Ohata K,
244
Blood
2015
for blastic plasmacytoid dendritic cell
Ito T, Kamoda Y, Fukuda T, Ichinohe T,
neoplasm.
Takeuchi K, Izutsu K, Suzumiya J.
Yamasaki S, Suzuki R, Hatano K,
Fukushima K, Iida H, Morishima S,
Therapy-related acute myeloid leukemia
Suehiro Y, Fukuda T, Uchida N,
and myelodysplastic syndrome after
Bone Marrow
245
Uchiyama H, Ikeda H, Yokota A,
2017
hematopoietic cell transplantation forTransplant
Tsukasaki K, Yamaguchi H, Kuroda J,
lymphoma.
Nakamae H, Adachi Y, Matsuoka KI,
Nakamura Y, Atsuta Y, Suzumiya J.

刊・号・
頁

業績
番号

102(5):12 WGP
15-27.
8-26

159(1):88 WGP
-93.
9-1

168(4):55 WGP
7-63.
9-2

105(3):36 WGP
9-76.
9-3

109(4):48 WGP
3-90.
9-4

67(4):e28 WGP
129.
9-5

66(10):e2 WGP
7918.
9-6

110(6):72 WGP
3-8.
9-7

20(5):684 WGP
-9.
10-1

90(2):132 WGP
-8.
10-2

125(23):3 WGP
559-62.
10-352(7):969 WGP
-76.
10-4

論文タイトル

著者

雑誌名

発行
年

Yamasaki S, Chihara D, Yoshida I, Kohda
K, Sawa M, Ago H, Togitani K, Ohno Y,
Ann Hematol 2019
Tanaka J, Fukuda T, Atsuta Y, SuzumiyaJ, Suzuki R.
Yamasaki S, Chihara D, Kim SW, Kawata
Risk factors and timing of autologous
T, Mizuta S, Ago H, Chou T, Yamane T,
247 stem cell transplantation for patients with Uchiyama H, Oyake T, Miura K, Saito B, Int J Hematol 2019
peripheral T-cell lymphoma.
Taji H, Nakamae H, Miyamoto T, Fukuda
T, Kanda J, Atsuta Y, Suzuki R.
Yamasaki S, Chihara D, Kim SW, Izutsu
Impact of hematopoietic stem cellK, Iwato K, Fukuda T, Uchida N, Amano I,
248 transplantation in patients with relapsed Nakazawa H, Kuroda J, Hashimoto H,
Ann Hematol 2018or refractory mantle cell lymphoma.
Ichinohe T, Kanda Y, Atsuta Y, SuzumiyaJ, Suzuki R.
Kondo E, Ikeda T, Izutsu K, Chihara D,
High-Dose Chemotherapy with Autologous
Shimizu-Koresawa R, Fujii N, Sakai T,
Stem Cell Transplantation in Primary
Kondo T, Kubo K, Kato Y, Akasaka T,
Biol BloodCentral Nervous System Lymphoma: Data
249
Fukuda T, Ichinohe T, Atsuta Y,
Marrow
2019
From the Japan Society for
Suzumiya J, Suzuki R; Adult Lymphoma Transplant
Hematopoietic Cell Transplantation
Working Group of the Japan Society for
Registry.
Hematopoietic Cell Transplantation.
Impact of hematopoietic stem cell
246 transplantation in patients with relapsed
or refractory marginal zone lymphoma.

Effect of allogeneic hematopoietic celltransplantation for patients with Tprolymphocytic leukemia: a retrospective
250
study from the Adult Lymphoma Working
Group of the Japan Society forhematopoietic cell transplantation.

Yamasaki S, Nitta H, Kondo E, Uchida N,
Miyazaki T, Ishiyama K, Kiyota M,
Ann Hematol 2019
Matsuoka H, Ichinohe T, Fukuda T,
Atsuta Y, Suzumiya J, Suzuki R.

Clinical outcomes of hepatitis B or C virus
infections in patients with malignant
Kato H, Kato K, Kim SW, Fukuda T, Morilymphoma receiving autologous stem cellT, Sawa M, Ohno Y, Yoshioka S, Iwato Y, Br J
251 transplantation: on behalf of the Adult
Taji H, Onizuka M, Kurahashi S, Ichinohe Haematol
Lymphoma Working Group of the JapanT, Suzumiya J, Suzuki R.
Society for Haematopoietic Cell
Transplantation (JSHCT).

刊・号・
頁

業績
番号

98(6):152 WGP
1-3.
10-5

109(2):17 WGP
5-86.
10-6

97(8):144 WGP
5-52.
10-7

25(5):899 WGP
-905.
10-8

98(9):221 WGP
3-20.
10-9

2019

186(6):e1 WGP
70-5.
10-10

Outcome of patients receiving
consolidative autologous peripheral blood
stem cell transplantation in the frontline
252 treatment of intravascular large B-cell
lymphoma: Adult Lymphoma Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

Kato K, Mori T, Kim SW, Sawa M, Sakai
T, Hashimoto H, Taguchi J, Oyake T,
Bone Marrow
Kurahashi S, Imada K, Ohno H, Tanaka J,
2019
Transplant
Ichinohe T, Atsuta Y, Suzuki R, SuzumiyaJ.

54(9):151 WGP
5-7.
10-11

Allogeneic haematopoietic stem celltransplantation for primary mediastinal
large B-cell lymphoma patients relapsing
after high dose chemotherapy with
253
autologous stem cell transplantation: datafrom the Japan Society for
Haematopoietic Cell Transplantation
registry.

Kondo E, Shimizu-Koresawa R, Chihara
D, Mizuta S, Izutsu K, Ikegame K, UchidaBr JN, Fukuda T, Ichinohe T, Atsuta Y,
HaematolSuzuki R; Adult Lymphoma Working
Group of the JSHCT.

2019

186(6):e2 WGP
19-23.
10-12

Bone Marrow
2021
Transplant56(2):347 WGP
-56.
10-13

Hematological2020
Oncology

38(3):266 WGP
-71.
10-14

Hematological2021
Oncology

39(1):66- WGP
74.
10-15

Ann Hematol 2020

99(7):163 WGP
5-42.
10-16

Fujimoto A, Ishida F, Izutsu K, Yamasaki
Allogeneic stem cell transplantation for
S, Chihara D, Suzumiya J, Mitsui T, Dokipatients with aggressive NK-cell leukemia. N, Sakai H, Kobayashi H, Kanda J,
Fukuda T, Atsuta Y, Suzuki R.
Mori T, Shiratori S, Suzumiya J,
Outcome of allogeneic hematopoietic
Kurokawa M, Shindo M, Naoyuki U,
255 stem cell transplantation for mycosis
Katsuto T, Miyamoto T, Morishige S,
fungoides and Sézary syndrome.
Hirokawa M, Fukuda T, Atsuta Y, Suzuki
R.
Takahashi T, Suzuki R, Yamamoto G,
Hematopoietic stem cell transplantation
Nakazawa H, Kurosawa M, Kobayashi T,
256 for diffuse large B-cell lymphoma having
Okada M, Akasaka T, Kim SW, Fukuda T,
8q24/MYC rearrangement in Japan.
Ichinohe T, Atsuta Y, Suzumiya J.
Outcome of stem cell transplantation for
Sakurai M, Mori T, Uchiyama H, Ago H,
Waldenström's macroglobulinemia: analysis
Iwato K, Eto T, Iwasaki H, Kawata T,
257 of the Japan Society for Hematopoietic
Takamatsu H, Yamasaki S, Takanashi M,
Cell Transplantation (JSHCT) Lymphoma
Ichinohe T, Atsuta Y, Suzuki R.
Working Group.
254

論文タイトル
Outcome of allogeneic hematopoietic
stem cell transplantation for follicularlymphoma relapsing after autologous
258transplantation: analysis of the Japan
Society for Hematopoietic Cell
Transplantation.

著者

雑誌名

Sakurai M, Mori T, Kato K, Kanaya M,
Mizuno S, Shiratori S, Wakayama T,
Uchida N, Kobayashi H, Kubo K, Amano I,
Ohta T, Miyazaki Y, Kanda J, Fukuda T, Bone Marrow
2021
Atsuta Y, Kondo E; Adult Lymphoma
Transplant
Working Group of the Japan Society for
Hematopoietic Cell Transplantation(JSHCT).

Fujimoto A, Anzai T, Fukuda T, Uchida N,
Ohta T, Mori T, Sawa M, Yoshioka S,
Impact of event-free survival status after
Miyamoto T, Uchiyama H, Katayama Y,
Blood
259 stem cell transplantation on subsequent
Matsuoka KI, Shiratori S, Nakazawa H,
Advances
survival of patients with lymphoma.
Kanda J, Ichinohe T, Atsuta Y, Fujita N,
Kondo E, Suzuki R.
Kameda K, Kako S, Kim SW, Usui Y, Kato
K, Fukuda T, Uchida N, Kobayashi H,
Autologous or allogeneic hematopoietic
Wakayama T, Sakaida E, Yano S, Imada
260 cell transplantation for relapsed or
Leukemia
K, Nara M, Ikeda T, Fuchida SI, Ishikawa
refractory PTCL-NOS or AITL.
J, Sugahara H, Kanda J, Kimura T,
Ichinohe T, Atsuta Y, Kondo E.
Improved survival after single-unit cord
blood transplantation using fludarabineand melphalan-based reduced-intensity
261 conditioning for malignant lymphoma:
impact of melphalan dose and graftversus-host disease prophylaxis withmycophenolate mofetil.
Fludarabine plus reduced-intensity
busulfan versus fludarabine plus
myeloablative busulfan in patients with
262
non-Hodgkin lymphoma undergoing
allogeneic hematopoietic celltransplantation.
Outcomes of allogeneic hematopoietic
263 stem cell transplantation for relapsed or
refractory diffuse large B-cell lymphoma.
Comparison of MEAM, MCEC and LEED
high-dose chemotherapy followed byautologous stem cell transplantation in
264 relapsed/refractory diffuse large B-cell
lymphoma: data from the Japan Societyfor Hematopoietic and Cellular Therapy
Registry.

発行
年

刊・号・
頁

業績
番号

56(6):146 WGP
2-6.
10-17

2021

5(5):1412 WGP
-24.
10-18

2022

36(5):136 WGP
1-70.
10-19

Sakatoku K, Kim SW, Okamura H, Kanaya
M, Kato K, Yamasaki S, Uchida N,
Kobayashi H, Fukuda T, Takayama N,
Ann Hematol 2022
Ishikawa J, Nakazawa H, Sakurai M, Ikeda
T, Kondo T, Yoshioka S, Miyamoto T,
Kimura T, Ichinohe T, Atsuta Y, Kondo E.

101(12):2 WGP
743-57. 10-20

Kamijo K, Shimomura Y, Shinohara A,
Mizuno S, Kanaya M, Usui Y, Kim SW,
Ara T, Mizuno I, Kuriyama T, Nakazawa
Ann Hematol 2023
H, Matsuoka KI, Kusumoto S, Maseki N,
Yamaguchi M, Ashida T, Onizuka M,
Fukuda T, Atsuta Y, Kondo E.
Kato K, Sugio T, Ikeda T, Yoshitsugu K,
Miyazaki K, Suzumiya J, Yamamoto G,
Kim SW, Ikegame K, Uehara Y, Mori Y,
Bone Marrow
Ishikawa J, Hiramoto N, Eto T, Nakazawa Transplant
H, Kobayashi H, Serizawa K, Onizuka M,
Fukuda T, Atsuta Y, Suzuki R.
Koresawa-Shimizu R, Suzuki R, Uehara
Y, Hiramoto N, Sawa M, Fukuda T,
Bone Marrow
Kataoka K, Kanda Y, Oyake T, Kubota Y,
2024
Transplant
Uchida N, Yano S, Kobayashi H, Tanaka
J, Atsuta Y, Kondo E.

102(3):65 WGP
1-61.
10-21

in press

WGP
10-22

59(1):125 WGP
-7.
10-23

Watanabe M, Kanda J, Fukuda T, UchidaN, Ikegame K, Kataoka K, Kobayashi H,
Impact of GVHD on lymphoma
Ara T, Ishikawa J, Matsuoka KI, Sugio Y,
progression: Nationwide study fromBr J
265
Nakazawa H, Ikeda T, Atsuta Y, Kondo E,
Japanese Society for Transplantation and
HaematolSuzuki R; Japanese Society for
Cellular Therapy.
Transplantation and Cellular Therapy,
Adult Lymphoma Working Group.

2023

203(3):44 WGP
6-59.
10-24

Watanabe M, Kanda J, Volt F, Ruggeri A,
Suzuki R, Rafii-Elayoubi H, Kimura F,
Cappelli B, Kondo E, Scigliuolo GM,
Takahashi S, Kenzey C, Rivera Franco
Cord blood transplantation for adult
Blood
266
MM, Okamoto S, Rocha V, Chevallier P,
lymphoid neoplasms in Europe and Japan.
Advances
Sanz J, Furst S, Cornelissen JJ, Milpied
NJ, Uchida N, Sugio Y, Kimura T,
Ichinohe T, Fukuda T, Mohty M, Peffault
de Latour R, Atsuta Y, Gluckman E.

2024

8(3):640- WGP
52.
10-25

Long-term outcome of childhood aplastic Kikuchi A, Yabe H, Kato K, Koh K, Inagaki
anemia patients who underwent allogeneic J, Sasahara Y, Suzuki R, Yoshida N,
Bone Marrow
267
2013
hematopoietic SCT from an HLA-matched Kudo K, Kobayashi R, Tabuchi K, Kawa K, Transplant
sibling donor in Japan.
Kojima S.

48(5):657 WGP
-60.
11-1

発行
年

刊・号・
頁

2014

99(12):17 WGP
84-91.
11-2

2014

20(8):114 WGP
5-9.
11-3

2015

50(10):13 WGP
12-5.
11-4

2017

52(12):16 WGP
59-61.
11-5

Yoshida N, Takahashi Y, Yabe H,
Kobayashi R, Watanabe K, Kudo K, Yabe
Conditioning Regimen for Allogeneic BoneM, Miyamura T, Koh K, Kawaguchi H,
Marrow Transplantation in Children With
Goto H, Fujita N, Okada K, Okamoto Y, Bone Marrow
272 Acquired Bone Marrow Failure:
2020
Kato K, Inoue M, Suzuki R, Atsuta Y,
Transplant
Fludarabine/Melphalan vs.
Kojima S; Pediatric Aplastic Anemia
Fludarabine/Cyclophosphamide.
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

55(7):127 WGP
2-81.
11-6

Impact of cyclophosphamide dose of
conditioning on the outcome of allogeneic
273 hematopoietic stem cell transplantation
for aplastic anemia from human leukocyte
antigen-identical sibling.

103(4):46 WGP
1-8.
12-1

論文タイトル著者

雑誌名

Yoshida N, Kobayashi R, Yabe H, Kosaka
First-line treatment for severe aplastic
Y, Yagasaki H, Watanabe K, Kudo K,
anemia in children: bone marrow
Haematologic
268
Morimoto A, Ohga S, Muramatsu H,
transplantation from a matched familyaTakahashi Y, Kato K, Suzuki R, Ohara A,
donor versus immunosuppressive therapy.
Kojima S.
Kobayashi R, Yabe H, Kikuchi A, Kudo K,
Bloodstream infection after stem cell
Yoshida N, Watanabe K, Muramatsu H,
Biol Blood
269 transplantation in children with idiopathic Takahashi Y, Inoue M, Koh K, Inagaki J, Marrowaplastic anemia.
Okamoto Y, Sakamaki H, Kawa K, Kato K, Transplant
Suzuki R, Kojima S.
Kudo K, Muramatsu H, Yoshida N,
Second allogeneic hematopoietic stem cell Kobayashi R, Yabe H, Tabuchi K, Kato K,
Bone Marrow
270 transplantation in children with severe
Koh K, Takahashi Y, Hashii Y, Kawano Y,
Transplant
aplastic anemia.
Inoue M, Cho Y, Sakamaki H, Kawa K,
Kato K, Suzuki R, Kojima S.
Kudo K, Muramatsu H, Narita A, Yoshida
Unrelated cord blood transplantation in
N, Kobayashi R, Yabe H, Endo M, Inoue
Bone Marrow
271 aplastic anemia: is antithymocyte globulin M, Hara J, Kounami S, Inagaki J, Hashii
Transplant
indispensable for conditioning?
Y, Kato K, Tabuchi K, Kojima S.

Mori T, Koh H, Onishi Y, Kako S, Onizuka
M, Kanamori H, Ozawa Y, Kato C, Iida H,
Int J Hematol 2016
Suzuki R, Ichinohe T, Kanda Y, Maeda T,
Nakao S, Yamazaki H.

Onishi Y, Mori T, Kako S, Koh H, Uchida
N, Kondo T, Kobayashi T, Yabe H,
Outcome of Second Transplantation Using
Miyamoto T, Kato K, Suzuki R, Nakao S,
Umbilical Cord Blood for Graft Failure
274
Yamazaki H; Adult Aplastic Anemia
after Allogeneic Hematopoietic Stem Cell
Working Group of the Japan Society forTransplantation for Aplastic Anemia.
Hematopoietic Cell Transplantation.

Biol Blood
Marrow
Transplant

2017

Mori T, Onishi Y, Ozawa Y, Kato C, Kai T,
Outcome of allogeneic hematopoietic
Kanda Y, Kurokawa M, Tanaka M, Ashida
275 stem cell transplantation in adult patients
Int J Hematol 2019
T, Sawayama Y, Fukuda T, Ichinohe T,with hepatitis-associated aplastic anemia.
Atsuta Y, Yamazaki H.
Kako S, Yamazaki H, Ohashi K, Ozawa Y,
Ota S, Kanda Y, Maeda T, Kato J,
Mixed Chimerism and Secondary Graft
Ishiyama K, Matsuoka KI, Miyamoto T,
Biol Blood
276 Failure in Allogeneic Hematopoietic Stem Iida H, Ikegame K, Fukuda T, Ichinohe T, Marrow
2020
Cell Transplantation for Aplastic Anemia. Atsuta Y, Mori T; Adult Aplastic Anemia Transplant
Working Group of the Japanese Societyfor Hematopoietic Cell Transplantation.
Onishi Y, Mori T, Yamazaki H, Takenaka
K, Yamaguchi H, Shingai N, Ozawa Y, Iida
H, Ota S, Uchida N, Miyamoto T,
Katayama Y, Kato J, Yoshioka S, Onizuka
Ann Hematol 2021
M, Ichinohe T, Atsuta Y; Adult Aplastic
Anemia Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.
Nakamura Y, Takenaka K, Yamazaki H,
Outcome of allogeneic hematopoietic
Onishi Y, Ozawa Y, Ikegame K, Matsuoka
278 stem cell transplantation in adult patients
Int J Hematol 2021
KI, Toubai T, Ueda Y, Kanda Y, Ichinohewith paroxysmal nocturnal hemoglobinuria.
T, Atsuta Y, Mori T.
Cyclosporine/methotrexate versus
tacrolimus/methotrexate with or without
277 anti-thymocyte globulin as GVHD
prophylaxis in adult patients with aplastic
anemia.

業績番号23(12):21 WGP
37-42.
12-2

109(6):71 WGP
1-7.
12-3

26(3):445 WGP
-50.
12-4

100(1):21 WGP
7-28.
12-5

113(1):12 WGP
2-7.
12-6

論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

業績
番号

Hiramoto N, Yamazaki H, Nakamura Y,
Uchida N, Murata M, Kondo T, Yoshioka
S, Eto T, Nishikawa A, Kimura T, Ichinohe
T, Atsuta Y, Onishi Y, Suzuki R, Mori T; Ann Hematol 2022
Adult Aplastic Anemia Working Group of
the Japanese Society for Hematopoietic
Cell Transplantation.

101(1):16 WGP
5-75.
12-7

Outcome of peripheral blood stem cell
Nakamura Y, Mori T, Kako S, Yamazaki H,
transplantation from HLA-identical sibling
280
Kanda Y, Uchida N, Tanaka M, Nawa Y,
Int J Hematol 2023
donors for adult patients with aplastic
Fukuda T, Ichinohe T, Atsuta Y, Onishi Y.
anemia.

117(3):35 WGP
6-65.
12-8

Onishi Y, Mori T, Yamazaki H, Hiramoto
N, Zaimoku Y, Kanaya M, Matsue K,
Comparison of Haploidentical Stem Cell
Onizuka M, Aotsuka N, Uchida N,
Transplantation with Post-Transplantation Onodera K, Kanda J, Nakamae H,
Transplant
281 Cyclophosphamide versus Umbilical Cord Yamamoto R, Kuriyama T, Kimura T,
Cell Ther
Blood Transplantation in Adult Patients
Ichinohe T, Atsuta Y; Adult Aplastic
with Aplastic Anemia.
Anemia Working Group of the JapaneseSociety for Transplantation and Cellular
Therapy.

2023

29(12):76 WGP
6.e1-e8. 12-92012

120(8):17 WGP
34-41.
13-1

2014

20(12):19 WGP
68-74.
13-3

Total body irradiation-containing
conditioning regimens without
279 antithymocyte globulin in adults withaplastic anemia undergoing umbilical cord
blood transplantation.

Allogeneic hematopoietic stem celltransplantation for adult T-cell leukemia282 lymphoma with special emphasis on
preconditioning regimen: a nationwide
retrospective study.
Treatment of patients with adult T cellleukemia/lymphoma with cord blood283
transplantation: a Japanese nationwide
retrospective survey.

Ishida T, Hishizawa M, Kato K, Tanosaki
R, Fukuda T, Taniguchi S, Eto T,
Takatsuka Y, Miyazaki Y, Moriuchi Y,
Blood
Hidaka M, Akashi K, Uike N, Sakamaki H,
Morishima Y, Kato K, Suzuki R,
Nishiyama T, Utsunomiya A.
Kato K, Choi I, Wake A, Uike N, Taniguchi
S, Moriuchi Y, Miyazaki Y, Nakamae H,
Biol Blood
Oku E, Murata M, Eto T, Akashi K,
Marrow
Sakamaki H, Kato K, Suzuki R, Yamanaka Transplant
T, Utsunomiya A.

Impact of graft-versus-host disease on
allogeneic hematopoietic cell
284 transplantation for adult T cell leukemialymphoma focusing on preconditioning
regimens: nationwide retrospective study.

Ishida T, Hishizawa M, Kato K, Tanosaki
R, Fukuda T, Takatsuka Y, Eto T,
Miyazaki Y, Hidaka M, Uike N, Miyamoto
T, Tsudo M, Sakamaki H, Morishima Y,
Suzuki R, Utsunomiya A.

2013

19(12):17 WGP
31-9.
13-2

Early application of related SCT might
285 improve clinical outcome in adult T-cellleukemia/lymphoma.

Fuji S, Fujiwara H, Nakano N, Wake A,
Inoue Y, Fukuda T, Hidaka M, Moriuchi Y,
Miyamoto T, Uike N, Taguchi J, Eto T,
Bone Marrow
Tomoyose T, Kondo T, Yamanoha A,
2016
Transplant
Ichinohe T, Atsuta Y, Utsunomiya A; ATL
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

51(2):205 WGP
-11.
13-4

Dismal outcome of allogeneic
hematopoietic stem cell transplantation
286 for relapsed adult T-cellleukemia/lymphoma, a Japanese nationwide study.

Fujiwara H, Fuji S, Wake A, Kato K,
Takatsuka Y, Fukuda T, Taguchi J,
Uchida N, Miyamoto T, Hidaka M,
Miyazaki Y, Tomoyose T, Onizuka M,
Bone Marrow
2017
Takanashi M, Ichinohe T, Atsuta Y,
Transplant
Utsunomiya A; ATL Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

52(3):484 WGP
-8.
13-5

Yoshimitsu M, Tanosaki R, Kato K, Ishida
T, Choi I, Takatsuka Y, Fukuda T, Eto T,
Hidaka M, Uchida N, Miyamoto T,
Biol Blood
Nakashima Y, Moriuchi Y, Nagafuji K,
Marrow
Miyazaki Y, Ichinohe T, Takanashi M,
Transplant
Atsuta Y, Utsunomiya A; ATL Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

24(4):832 WGP
-9.
13-6

Risk Assessment in Adult T Cell
Leukemia/Lymphoma Treated with
287 Allogeneic Hematopoietic Stem Cell
Transplantation.

Biol Blood
Marrow
Transplant

2018論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

業績
番号

Kato K, Uike N, Wake A, Yoshimitsu M,
Tobai T, Sawayama Y, Takatsuka Y,
Fukuda T, Uchida N, Eto T, Nakashima Y,
Kondo T, Taguchi J, Miyamoto T,
Hematological
2019
Nakamae H, Ichinohe T, Kato K, Suzuki Oncology
R, Utsunomiya A; ATL Working Group of
the Japan Society for Hematopoietic
Cell Transplantation.

37(1):54- WGP
61.
13-7

Yoshimitsu M, Utsunomiya A, Fuji S,
A retrospective analysis of haplo-identical Fujiwara H, Fukuda T, Ogawa H,
HLA-mismatch hematopoietic
Takatsuka Y, Ishitsuka K, Yokota A,
transplantation without
Okumura H, Ishii K, Nishikawa A, Eto T, Bone Marrow289
2019
posttransplantation cyclophosphamide for Yonezawa A, Miyashita K, Tsukada J,
Transplant
GVHD prophylaxis in patients with adult
Tanaka J, Atsuta Y, Kato K; ATL Working
T-cell leukemia-lymphoma.
Group of the Japan Society for
Hematopoietic Cell Transplantation.

54(8):126 WGP
6-74.
13-8

The outcome and characteristics ofpatients with relapsed adult T cell288
leukemia/lymphoma after allogeneic
hematopoietic stem cell transplantation.

Cytomegalovirus reactivation isassociated with increased mortality more
290 than 100 days after allogeneic
hematopoietic stem cell transplantation
for adult T-cell leukemia/lymphoma.

Sawayama Y, Itonaga H, Fukushima T,
Nakano N, Fujiwara H, Utsunomiya A,
Fukuda T, Miyamoto T, Eto T, Miyashita
Am J
K, Nakamae H, Ogata M, Yamanoha A,
HematolMiyazaki Y, Kanda J, Atsuta Y, Kato K;
ATL Working Group of the Japan Societyfor Hematopoietic Cell Transplantation.

2019

94(5):E14 WGP
3-6.
13-9

Outcomes of Allogeneic Hematopoietic
291 Stem Cell Transplantation for ATL with
HTLV-1 Antibody-Positive Donors.

Yoshimitsu M, Fuji S, Utsunomiya A,
Nakano N, Ito A, Ito Y, Miyamoto T,
Suehiro Y, Kawakita T, Moriuchi Y,
Biol Blood
Nakamae H, Kanda Y, Ichinohe T, Fukuda Marrow
T, Atsuta Y, Kato K; ATL Working Group Transplantof the Japan Society for Hematopoietic
Cell Transplantation.

2020

26(4):718 WGP
-22.
13-10

Fuji S, Kurosawa S, Inamoto Y, Nakano
N, Miyazaki Y, Miyashita K, Hidaka M, Eto
Does an increased probability of graft‐vs‐
T, Uchida N, Ito A, Sawayama Y,
host disease improve the survival of
Miyamoto T, Suzumiya J, Utsunomiya A, Adv Cell
292 patients with adult T‐cell leukemia‐
Kanda J, Atsuta Y, Fukuda T, Kato K, on Gene Therlymphoma? A simulation analysis using abehalf of Adult T‐cell Leukemia‐Working
Markov model.
Group of Japan Society of
Hematopoietic Cell Transplantation.

2019

2:e56.

Muranushi H, Shindo T, Hishizawa M,
Tokunaga M, Wake A, Nakano N, Eto T,
GVHD-free, relapse-free survival provides Hidaka M, Choi I, Miyamoto T, Uchida N,
novel clues for optimizing allogeneicMoriuchi Y, Miyazaki Y, Fukuda T,
Bone Marrow
293
2021
HSCT for adult T-cell
Ichinohe T, Atsuta Y; ATL Working Group Transplantleukemia/lymphoma.
of the Japanese Society for
Hematopoietic Cell Transplantation, KatoK.
Chromosomal defects and survival inpatients with adult T-cell294
leukemia/lymphoma after allogeneic
HSCT.

Nakano N, Utsunomiya A, Matsuo K,
Yoshida N, Seto M, Ohshima K, Fujiwara
H, Fuji S, Takatsuka Y, Ito A, Miyamoto Blood
T, Suehiro Y, Nakamae H, Sawayama Y, Advances
Yuasa M, Miyazaki Y, Ota S, Imada K,
Fukuda T, Ichinohe T, Atsuta Y, Kato K.

2021

Inoue Y, Nakano N, Fuji S, Eto T,
Kawakita T, Suehiro Y, Miyamoto T,
Impact of conditioning intensity andSawayama Y, Uchida N, Kondo T, Kanda
regimen on transplant outcomes in
Bone Marrow
295
J, Atsuta Y, Fukuda T, Yoshimitsu M,
2021
patients with adult T-cell leukemiaTransplant
Kato K; ATL Working Group of the Japanlymphoma.
Society for Hematopoietic Cell
Transplantation.
Utsunomiya A, Tokunaga M, Nakano N,
Fujiwara H, Miyamoto T, Ogata M,
Long-term follow-up of patients with ATL
Bone Marrow
296
Miyazaki Y, Ishitsuka K, Sakaida E, Taji H,
2022
after autologous stem cell transplantation.
Transplant
Wakayama T, Ichinohe T, Fukuda T,
Atsuta Y, Kato K, Yoshimitsu M.

WGP
13-11

56(1):155 WGP
-66.
13-12

5(2):475- WGP
86.
13-13

56(12):29 WGP
64-74.
13-14

57(2):323 WGP
-5.
13-15

論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

業績
番号

Cord blood is a suitable donor source of
allogeneic hematopoietic cell
297 transplantation for adult T-cell leukemialymphoma: a nationwide retrospective
study.

Tokunaga M, Nakano N, Fuji S, Wake A,
Utsunomiya A, Ito A, Eto T, Kawakita T,
Mori Y, Moriuchi Y, Suehiro Y, Miyazaki Bone Marrow
2023
Y, Uchida N, Sawayama Y, Ishitsuka K,
Transplant
Kanda J, Kimura T, Ichinohe T, Atsuta Y,
Fukuda T, Yoshimitsu M, Kato K.

58(4):462 WGP
-4.
13-16

Impact of HLA-mismatched unrelated
298 transplantation in patients with adult Tcell leukemia/lymphoma.

Inoue Y, Morishima S, Kato K, Ito A,
Nakano N, Kuriyama T, Kawakita T, MoriY, Suehiro Y, Itonaga H, Miyazaki Y,
Bone Marrow
Imada K, Tomori S, Kanda J, Ichinohe T,
2023
Transplant
Atsuta Y, Fukuda T, Yoshimitsu M; ATL
Working Group of the Japanese Society
for Transplantation and Cellular Therapy.

58(9):980 WGP
-90.
13-17

Fuji S, Inoue Y, Makiyama J, Nakano N,
Ito A, Kawakita T, Eto T, Suehiro Y,
Itonaga H, Sawayama Y, Mori Y, Uchida
N, Morishima S, Onizuka M, Ishitsuka K,
Fukuda T, Atsuta Y, Yoshimitsu M.

Bone Marrow
2023
Transplant58(6):729 WGP
-31.
13-18

Takamatsu H, Honda S, Miyamoto T,
Yokoyama K, Hagiwara S, Ito T, Tomita
N, Iida S, Iwasaki T, Sakamaki H, Suzuki
R, Sunami K.

Cancer Sci

2015

106(2):17 WGP
9-85.
14-1

2015

21(7):129 WGP
1-8.
14-2

2016

57(9):207 WGP
7-83.
14-3

2018

139(1):35 WGP
-44.
14-4

2019

25(3):474 WGP
-9.
14-5

Bone Marrow
2019
Transplant54(10):15 WGP
95-604.
14-6

Hematological2019
Oncology

37(5):586 WGP
-94.
14-7

The clinical benefit of acute GVHD
depends on the age at transplantation inpatients with adult T-cell leukemia299
lymphoma on behalf of the ATL Working
Group of the Japan Society forTransplantation and Cellular Therapy.
Changing trends in prognostic factors forpatients with multiple myeloma after
300 autologous stem cell transplantation
during the immunomodulator
drug/proteasome inhibitor era.

Kawamura K, Takamatsu H, Ikeda T,
Komatsu T, Aotsuka N, Amano I,
Biol Blood
Yamamoto G, Watanabe K, Ohno Y,
Marrow
Matsue K, Kouzai Y, Tsukada N, Ishiyama
Transplant
K, Anzai N, Kato K, Suzuki R, Sunami K,
Kanda Y.
Kawamura K, Ikeda T, Hagiwara S, Mori
Tandem autologous versus
T, Shinagawa A, Nishiwaki K, Ohashi K,
autologous/allogeneic transplantation for
Leuk
302
Kubonishi S, Fukuda T, Ito T, Tomita N,
multiple myeloma: propensity score
LymphomaIchinohe T, Kato K, Morishima Y, Atsuta
analysis.
Y, Sunami K, Kanda Y.
Significance of Salvage Autologous Stem Muta T, Miyamoto T, Kamimura T, Kanda
Cell Transplantation for Relapsed Multiple Y, Nohgawa M, Ueda Y, Iwato K, Sasaki Acta
303
Myeloma: A Nationwide Retrospective
O, Mori T, Uchida N, Iida S, Fukuda T,
HaematolStudy in Japan.
Atsuta Y, Sunami K.
Cord Blood Transplantation for Multiple
Myeloma:A Study from the Multiple
301 Myeloma Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

Takamatsu H, Yamashita T, Kurahashi S,
Clinical Implications of t(11;14) in Patients Saitoh T, Kondo T, Maeda T, Nakazawa Biol Blood
304 with Multiple Myeloma Undergoing
H, Murata M, Narita T, Kuroda J,
Marrow
Autologous Stem Cell Transplantation.
Hashimoto H, Kawamura K, Miyamoto T, Transplant
Honda S, Ichinohe T, Atsuta Y, Sunami K.
Mizuno S, Kawamura K, Hanamura I,
Efficacy and safety of autologous stem
Sunami K, Mori T, Nakamura F, Iida S,
cell transplantation in patients aged ≥ 65
305
Nakazawa H, Makita M, Kako S, Sawa M,
years with multiple myeloma in the era of
Ueda Y, Takahashi H, Kanda Y, Ichinohe
novel agents.
T, Atsuta Y, Takamatsu H, Takami A.
Ikeda T, Mori K, Kawamura K, Mori T,
Comparison between autologous andHagiwara S, Ueda Y, Kahata K, Uchida N,
allogeneic stem cell transplantation as
Tsukada N, Murakami S, Yamamoto M,
306 salvage therapy for multiple myeloma
Takahashi T, Ichinohe T, Onizuka M,
relapsing/progressing after autologous
Atsuta Y, Kanda Y, Okamoto S, Sunami
stem cell transplantation.
K, Takamatsu H.

Improved survival of multiple myeloma
patients treated with autologous
307transplantation in the modern era of new
medicine.

Shimazu Y, Mizuno S, Fuchida SI, Suzuki
K, Tsukada N, Hanagaishi A, Itagaki M,
Kataoka K, Kako S, Sakaida E, Yoshioka
S, Iida S, Doki N, Oyake T, Ichinohe T,
Cancer Sci
Kanda Y, Astuta Y, Takamatsu H; working
group of the Japan Society forTransplantation, Cellular Therapy.

2021

112(12):5 WGP
034-45.
14-8

雑誌名

発行
年

刊・号・
頁

Retrospective Analysis of Autologous
Stem Cell Transplantation for AL
Amyloidosis: A Study from the Multiple
308
Myeloma Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

Fuchida SI, Kawamura K, Sunami K,
Tsukada N, Fujii S, Ohkawara H, Usuki K,
Transplant
Wake A, Endo S, Ishiyama K, Ueda Y,
Cell Ther
Nakamura Y, Miyamoto T, Fukuda T,
Ichinohe T, Atsuta Y, Takamatsu H.

2022

28(2):76- WGP
82.
14-9

Autologous hematopoietic celltransplantation for myeloma patients with309
hepatitis B virus or hepatitis C virus in
the era of novel agents.

Mizuno S, Takami A, Takamatsu H,
Hanamura I, Shimazu Y, Hangaishi A,
Tsukada N, Kako S, Kikuchi T, Ota S,
Bone Marrow
2022
Shimizu H, Iida S, Yoshioka S, Sawa M, Transplant
Fukuda T, Kanda Y, Atsuta Y, KawamuraK.

57(5):846 WGP
-8.
14-10

Takamatsu H, Matsuda T, Mizuno S,
Takahashi T, Fuchida SI, Hanamura I,
Changing trends in the risk factors for
Kataoka K, Tsukada N, Matsumoto M,
second primary malignancies after
Hangaishi A, Doki N, Uchida N, Sawa M,
autologous stem cell transplantation for
Maruyama Y, Kurahashi S, Nagafuji K,
Haematologic
3102023
multiple myeloma before and after the
Harazaki Y, Kako S, Iida S, Ichinohe T,aintroduction of proteasome inhibitors and Kanda Y, Atsuta Y, Sunami K; Multiple
immunomodulatory drugs.
Myeloma Working Group in the JapaneseSociety for Transplantation and Cellular
Therapy.

108(12):3 WGP
399-408. 14-11

論文タイトル

著者

業績
番号Suzuki K, Mizuno S, Shimazu Y, Fuchida
SI, Hagiwara S, Itagaki M, Nishiwaki K,
Hangaishi A, Karasuno T, Kikuchi T,
Shimizu M, Nishikawa A, Kobayashi T,
Eur J
Sunami K, Hiramoto N, Uchiyama H,
HaematolMaruyama Y, Kanda Y, Ichinohe T, Atsuta
Y, Yano S, Kawamura K; Working Groupof the Japan Society; for Transplantation
and Cellular Therapy.

2023

110(4):44 WGP
4-54.
14-12

Suzuki K, Shimazu Y, Minakata D, Ikeda
T, Takahashi H, Tsukada N, Kanda Y,
Efficacy of Autologous Stem Cell
Doki N, Nishiwaki K, Miwa A, Sawa M,
Transplantation for Myeloma Patients withTransplant
312
Kataoka K, Hiramoto N, Ota S, Itagaki M,
Suboptimal Response: A Multicenter
Cell Ther
Ichinohe T, Atsuta Y, Yano S, Kawamura
Retrospective Analysis.
K; working group of the Japan Society
for Transplantation and Cellular Therapy.

2023

29(11):68 WGP
8.e1-13. 14-13

Tandem autologous stem celltransplantation in elderly patients with311
myeloma: A multicenter retrospective
analysis.

Efficacy of high-dose chemotherapy with 山本将平，渡邊健一郎，井上雅美，橋井 日本小児血313 stem cell transplantation
佳子，菊田 敦，金子 隆，加藤剛二，原 液・がん学会 2017for hepatoblastoma in Japan.
純一，田渕 健，高橋義行.
雑誌
Autologous Stem Cell Transplantation for
Kobayashi R, Inoue M, Takahashi Y,Children With Renal Tumors, and Adults
J Pediatr
Kikuta A, Ogawa A, Koga Y, Koh K, Hashii
314 With Wilms Tumor: Retrospective Analysis
Hematol
2020
Y, Hara J, Kato K, Tabuchi K, Matsumotoof the Japanese Transplant Registry
Oncol
K.
Unified Management Program.
Effect of high-dose chemotherapy plus
Saito Y, Urashima M, Takahashi Y,
stem cell rescue on the survival of
Ogawa A, Kiyotani C, Yuza Y, Koh K,
patients with neuroblastoma modified byBone Marrow
315
Watanabe K, Kosaka Y, Goto H, Kikuta A,
2021
MYCN gene gain/amplification andTransplant
Okada K, Koga Y, Fujimura J, Inoue M,
remission status: a nationwide registration
Sato A, Atsuta Y, Matsumoto K.
study in Japan.
Umeda K, Adachi S, Tanaka S, Miki M,
Comparison of second transplantation and Okada K, Hashii Y, Inoue M, Cho Y, Kohdonor lymphocyte infusion for donor
K, Goto H, Kajiwara R, Hyakuna N, Kato Pediatr Blood
316
2016
mixed chimerism after allogeneic stem cell K, Morio T, Yabe H; Inherited Disease
Cancertransplantation for nonmalignant diseases. Working Group of the Japan Society for
Hematopoietic Cell Transplantation.
Allogeneic Hematopoietic Stem Cell
Horikoshi Y, Umeda K, Imai K, Yabe H,
J Pediatr
Transplantation for Leukocyte Adhesion Sasahara Y, Watanabe K, Ozawa Y,
317
Hematol
2018
Deficiency.
Hashii Y, Kurosawa H, Nonoyama S,
Oncol
Morio T.

54(2):126 WGP
-32.
15-1

42(4):251 WGP
-5.
15-2

56(9):217 WGP
3-82.
15-3

63(12):22 WGP
21-9.
16-1

40(2):137 WGP
-40.
16-2

論文タイトル
Impact of low-dose irradiation and in vivo
T-cell depletion on hematopoietic stem
318 cell transplantation for non-malignant
diseases using fludarabine-based
reduced-intensity conditioning.

著者
Umeda K, Yabe H, Kato K, Imai K,
Kobayashi M, Takahashi Y, Yoshida N,
Sato M, Sasahara Y, Kato K, Adachi S,
Koga Y, Okada K, Inoue M, Hashii Y,
Atsuta Y, Morio T; Inherited Disease
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

雑誌名

発行
年

刊・号・
頁

業績
番号

Bone Marrow
2019
Transplant54(8):122 WGP
7-36.
16-3

Iguchi A, Cho Y, Yabe H, Kato S, Kato K,
Long-term outcome and chimerism inHara J, Koh K, Takita J, Ishihara T, Inouepatients with Wiskott-Aldrich syndrome
M, Imai K, Nakayama H, Hashii Y,
319 treated by hematopoietic cell
Morimoto A, Atsuta Y, Morio T;
Int J Hematol 2019transplantation: a retrospective nationwide Hereditary disorder Working Group of thesurvey.
Japan Society for Hematopoietic Cell
Transplantation.

110(3):36 WGP
4-9.
16-4

Impact of Graft-Versus-Host Disease on
the Clinical Outcome of Allogeneic
320
Hematopoietic Stem Cell Transplantation
for Non-Malignant Diseases.

Umeda K, Imai K, Yanagimachi M, Yabe H,
Kobayashi M, Takahashi Y, Kajiwara M,
Yoshida N, Cho Y, Inoue M, Hashii Y,
Int J Hematol 2020
Atsuta Y, Morio T; Inherited Disease
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

111(6):86 WGP
9-76.
16-5

Long-term outcome in patients with
Fanconi anemia who received
321
hematopoietic stem cell transplantation: aretrospective nationwide analysis.

Yabe M, Morio T, Tabuchi K, Tomizawa
D, Hasegawa D, Ishida H, Yoshida N,
Koike T, Takahashi Y, Koh K, Okamoto Y,
Int J Hematol 2021
Sano H, Kato K, Kanda Y, Goto H, Takita
J, Miyamura T, Noguchi M, Kato K, Hashii
Y, Astuta Y, Yabe H.

113(1):13 WGP
4-44.
16-6

Yanagimachi M, Kato K, Iguchi A, Sasaki
K, Kiyotani C, Koh K, Koike T, Sano H,
Hematopoietic Cell Transplantation for
Shigemura T, Muramatsu H, Okada K,
322
Chronic Granulomatous Disease in Japan. Inoue M, Tabuchi K, Nishimura T,
Mizukami T, Nunoi H, Imai K, Kobayashi
M, Morio T.

Front
Immunol

2020

11:1617.

Miyamoto S, Umeda K, Kurata M,
Nishimura A, Yanagimachi M, Ishimura M,
Hematopoietic Cell Transplantation for
Sato M, Shigemura T, Kato M, Sasahara J Clin
323 Severe Combined Immunodeficiency
Y, Iguchi A, Koike T, Takahashi Y,
Immunol
Patients: a Japanese Retrospective Study.
Kajiwara M, Inoue M, Hashii Y, Yabe H,
Kato K, Atsuta Y, Imai K, Morio T.

2021

41(8):186 WGP
5-77.
16-8

Stem cell transplantation for pediatricpatients with adrenoleukodystrophy: A
324
nationwide retrospective analysis inJapan.

2022

26(1):e14 WGP
125.
16-9

2022

42(3):529 WGP
-45.
16-10

Bone Marrow
2023
Transplant58(5):600 WGP
-2.
16-11

Br J
Haematol

161(4):56 WGP
6-77.
17-1

Hematopoietic Cell Transplantation forInborn Errors of Immunity Other than325 Severe Combined Immunodeficiency inJapan: Retrospective Analysis for 19852016.

Graft-versus-host disease-free, relapsefree, second transplant-free survival in
326
allogeneic hematopoietic celltransplantation for genetic disorders.

Kato K, Yabe H, Shimozawa N, Adachi S,
Kurokawa M, Hashii Y, Sato A, Yoshida Pediatr
N, Kaga M, Onodera O, Kato S, Atsuta Y, TransplantMorio T.
Miyamoto S, Umeda K, Kurata M,
Yanagimachi M, Iguchi A, Sasahara Y,
Okada K, Koike T, Tanoshima R, Ishimura
J ClinM, Yamada M, Sato M, Takahashi Y,
Immunol
Kajiwara M, Kawaguchi H, Inoue M, Hashii
Y, Yabe H, Kato K, Atsuta Y, Imai K,
Morio T.
Kawaguchi K, Umeda K, Miyamoto S,
Yoshida N, Yabe H, Koike T, Kajiwara M,
Kawaguchi H, Takahashi Y, Ishimura M,
Sakaguchi H, Hama A, Cho Y, Sato M,
Kato K, Sato A, Kato K, Tabuchi K,
Atsuta Y, Imai K.

Impact of a single human leucocyte
antigen (HLA) allele mismatch on theoutcome of unrelated bone marrow
Kanda Y, Kanda J, Atsuta Y, Maeda Y,
transplantation over two time periods. A Ichinohe T, Ohashi K, Fukuda T,
327
retrospective analysis of 3003 patients
Miyamura K, Iida H, Mori T, Iwato K, Etofrom the HLA Working Group of the Japan T, Kawa K, Morita S, Morishima Y.
Society for Blood and Marrow
Transplantation.

2013

WGP
16-7

論文タイトル

著者

雑誌名

発行
年

Tanaka J, Morishima Y, Takahashi Y,
Yabe T, Oba K, Takahashi S, Taniguchi S,
Blood Cancer
Ogawa H, Onishi Y, Miyamura K,
2013
J
Kanamori H, Aotsuka N, Kato K, Kato S,
Atsuta Y, Kanda Y.
Atsuta Y, Kanda J, Takanashi M,
Morishima Y, Taniguchi S, Takahashi S,
Different effects of HLA disparity on
Ogawa H, Ohashi K, Ohno Y, Onishi Y,
transplant outcomes after single-unit cord
Haematologic
329
Aotsuka N, Nagamura-Inoue T, Kato K,
2013
blood transplantation between pediatricaKanda Y; HLA Working Group of theand adult patients with leukemia.
Japan Society for Hematopoietic Cell
Transplantation.
Effects of KIR ligand incompatibility on
clinical outcomes of umbilical cord blood328
transplantation without ATG for acuteleukemia in complete remission.

Impact of the direction of HLA mismatch
330 on transplantation outcomes in single
unrelated cord blood transplantation.

Kanda J, Atsuta Y, Wake A, Ichinohe T,
Takanashi M, Morishima Y, Taniguchi S,
Takahashi S, Ogawa H, Ohashi K, Ohno
Y, Aotsuka N, Onishi Y, Kato K,
Nagamura-Inoue T, Kanda Y; HLA
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

刊・号・
頁

業績
番号

3:e164.

WGP
17-2

98(5):814 WGP
-22.
17-3

Biol Blood
Marrow
Transplant2013

19(2):247 WGP
-54.
17-4

Kanda Y, Kanda J, Atsuta Y, Fuji S,
Maeda Y, Ichinohe T, Takanashi M,
Changes in the clinical impact of high-risk
Ohashi K, Fukuda T, Miyamura K, Mori T, Biol Blood
human leukocyte antigen allele mismatch
331
Sao H, Kobayashi N, Iwato K, Sawada A, Marrowcombinations on the outcome of unrelatedMori S; HLA working group of the Japan Transplantbone marrow transplantation.
Society for Hematopoietic Cell
Transplantation.

2014

20(4):526 WGP
-35.
17-5

Kanda J, Fuji S, Kato S, Takami A,
Tanaka J, Miyamura K, Ohashi K, Fukuda
T, Ozawa Y, Kanamori H, Eto T,
Decision analysis for donor selection in
Kobayashi N, Iwato K, Morishima Y,
stem cell transplantation-HLA-8/8 alleleBlood Cancer
332
Sakamaki H, Atsuta Y, Kanda Y; HLA
2014
matched unrelated donor vs HLA-1 AG
J
Working Group; Donor/Source Working
mismatched related donor.
Group; Adult AML Working Group; Adult
ALL Working Group of the Japan Societyfor Hematopoietic Cell Transplantation.

Impact of HLA allele mismatch on the
333 clinical outcome in serologically matched
related hematopoietic SCT.

Fuji S, Kanda J, Kato S, Ikegame K,
Morishima S, Miyamoto T, Hidaka M,
Kubo K, Miyamura K, Ohashi K,
Kobayashi H, Maesako Y, Adachi S,
Ichinohe T, Atsuta Y, Kanda Y; HLA
Working Group of Japan Society for
Hematopoietic Cell Transplantation.

Bone Marrow
2014
Transplant

Kanda J, Ichinohe T, Fuji S, Maeda Y,
Impact of HLA mismatch direction on the Ohashi K, Fukuda T, Miyamura K, Iwato
outcome of unrelated bone marrow
K, Eto T, Nakamae H, Kobayashi N, Mori Biol Blood
334 transplantation: a retrospective analysis
T, Mori S, Morishima Y, Atsuta Y, Kanda Marrowfrom the Japan Society for Hematopoietic Y; HLA Working Group of the Japan
Transplant
Cell Transplantation.
Society for Hematopoietic Cell
Transplantation.

4:e263.

WGP
17-6

49(9):118 WGP
7-92.
17-7

2015

21(2):305 WGP
-11.
17-8

A single high-resolution HLA mismatch
has a similar adverse impact on the
335 outcome of related hematopoietic stem
cell transplantation as a single lowresolution HLA mismatch.

Fuji S, Kanda J, Kato S, Ikegame K,
Morishima S, Miyamoto T, Hidaka M,
Kubo K, Miyamura K, Tsudo M, Kobayashi
Am J
H, Maesako Y, Eto T, Adachi S, Ichinohe
HematolT, Atsuta Y, Kanda Y; HLA Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

2015

90(7):618 WGP
-23.
17-9

Unrelated bone marrow transplantation or
immediate umbilical cord blood
336 transplantation for patients with acute
myeloid leukemia in first complete
remission.

Yanada M, Kanda J, Ohtake S, Fukuda T,
Sakamaki H, Miyamura K, Miyawaki S,
Uchida N, Maeda T, Nagamura-Inoue T, Eur J
Asou N, Morishima Y, Atsuta Y, Miyazaki HaematolY, Kimura F, Kobayashi Y, Takami A,
Naoe T, Kanda Y.

2016

97(3):278 WGP
-87.
17-10

雑誌名

発行
年

刊・号・
頁

Influence of Differently Licensed
KIR2DL1-Positive Natural Killer Cells in
337 Transplant Recipients with Acute
Leukemia: A Japanese National Registry
Study.

Arima N, Nakamura F, Yabe T, Tanaka J,
Fuji S, Ohashi K, Fukuda T, Miyamura K, Biol Blood
Iwato K, Eto T, Mori T, Kobayashi N,
Marrow
Hoshino T, Kato C, Kanamori H, Nakamae Transplant
H, Atsuta Y, Morishima Y, Kanda Y.

201622(3):423 WGP
-31.
17-11

Haploidentical and Matched Sibling Donor
Hematopoietic Cell Transplantation for
338
Patients with HLA-Homozygous
Haplotypes.

Kanda J, Ikegame K, Fuji S, Kurokawa M,
Kanamori H, Fukuda T, Ohashi K,
Biol Blood
Ishikawa J, Ogawa H, Inoue M, Ichinohe
Marrow
T, Atsuta Y, Kanda Y; HLA Working
TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.

2016

22(11):20 WGP
31-7.
17-12

Yokoyama H, Kanda J, Fuji S, Kim SW,
Fukuda T, Najima Y, Ohno H, Uchida N,
Impact of Human Leukocyte Antigen Allele
Ueda Y, Eto T, Iwato K, Kobayashi H,
Biol Blood
Mismatch in Unrelated Bone Marrow
339
Ozawa Y, Kondo T, Ichinohe T, Atsuta Y, Marrow
Transplantation with Reduced-Intensity
Kanda Y; HLA Working Group of theTransplant
Conditioning Regimen.
Japan Society for Hematopoietic Cell
Transplantation.

201723(2):300 WGP
-9.
17-13

論文タイトルImpact of the presence of HLA 1-locus
mismatch and the use of low-dose
340
antithymocyte globulin in unrelated bonemarrow transplantation.
Homozygous HLA-C1 is Associated with
Reduced Risk of Relapse after HLA341
Matched Transplantation in Patients with
Myeloid Leukemia.

Comparison of HLA Allele Mismatch andAntigen Mismatch in Unrelated Bone
342
Marrow Transplantation in Patients with
Leukemia.

HLA discrepancy between graft and host343 rather than that graft and first donor
impact the second transplant outcome.

著者

Kawamura K, Kanda J, Fuji S, Murata M,
Ikegame K, Yoshioka K, Fukuda T, Ozawa
Bone Marrow
Y, Uchida N, Iwato K, Sakura T, Hidaka
2017
Transplant
M, Hashimoto H, Ichinohe T, Atsuta Y,
Kanda Y.
Arima N, Kanda J, Tanaka J, Yabe T,
Morishima Y, Kim SW, Najima Y, Ozawa
Biol Blood
Y, Eto T, Kanamori H, Mori T, Kobayashi
Marrow
2018
N, Kondo T, Nakamae H, Uchida N, Inoue
TransplantM, Fukuda T, Ichinohe T, Atsuta Y, Kanda
Y.
Atsuta Y , Kato S , Morishima Y , Ohashi
K , Fukuda T , Ozawa Y , Eto T , Iwato K
Biol Blood, Uchida N , Ota S , Onizuka M , Ichinohe
Marrow
2019
T , Kanda J , Kanda Y ; HLA Working
TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.
Maeda Y , Ugai T , Kondo E , Ikegame K ,Murata M , Uchida N , Miyamoto T ,Takahashi S , Ohashi K , Nakamae H ,Haematologic
2019
Fukuda T , Onizuka M , Eto T , Ota S ,aHirokawa M , Ichinohe T , Atsuta Y ,Kanda Y , Kanda J.

業績
番号52(10):13 WGP
90-8.
17-14

24(4):717 WGP
-25.
17-15

25(3):436 WGP
-42.
17-16

104(5):10 WGP
55-61.
17-17

Yokoyama H, Kanda J, Kato S, Kondo E,
Maeda Y, Saji H, Takahashi S, Onizuka M,
Effects of HLA mismatch on
Onishi Y, Ozawa Y, Kanamori H, Ishikawa
Bone Marrow
344 cytomegalovirus reactivation in cord blood J, Ohno Y, Ichinohe T, Takanashi M, Kato
2019
Transplanttransplantation.
K, Atsuta Y, Kanda Y; HLA Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

54(7):100 WGP
4-12.
17-18

Clinical significance of low-dose total
body irradiation in HLA-mismatched345
reduced-intensity stem celltransplantation.

Fujiwara SI, Kanda J, Tatara R, Ogawa H,
Fukuda T, Okumura H, Ohashi K, Iwato K,
Ueda Y, Ishiyama K, Eto T, Matsuoka KI,
Bone Marrow
Nakamae H, Onizuka M, Atsuta Y, Kanda
2019
Transplant
Y, HLA Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

54(8):132 WGP
7-36.
17-19

Effects of Haplotype Matching on
346 Outcomes after Adult Single-Cord Blood
Transplantation.

Kanda J, Kawase T, Tanaka H, Kojima H,
Morishima Y, Uchida N, Nagafuji K,
Matsuhashi Y, Ohta T, Onizuka M, Sakura
Biol Blood
T, Takahashi S, Miyakoshi S, Kobayashi
Marrow
H, Eto T, Tanaka J, Ichinohe T, Atsuta Y,
Transplant
Morishima S; HLA Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

26(3):509 WGP
-18.
17-20

2020

雑誌名

発行
年

刊・号・
頁

Kawase T, Tanaka H, Kojima H, Uchida N,
Ohashi K, Fukuda T, Ozawa Y, Ikegame
K, Eto T, Mori T, Miyamoto T, Hidaka M, Biol Blood
Shiratori S, Takanashi M, Atsuta Y,
Marrow
Ichinohe T, Kanda Y, Kanda J; HLA
Transplant
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

2019

25(12):24 WGP
82-9.
17-21

Impact of Homozygous Conserved
Morishima Y, Morishima S, Murata M,
Extended HLA Haplotype on Single Cord Arima N, Uchida N, Sugio Y, Takahashi S, Biol Blood
348 Blood Transplantation: Lessons for
Matsuhashi Y, Onizuka M, Eto T, Nagafuji Marrow
Induced Pluripotent Stem Cell Banking
K, Onishi Y, Inoue M, Atsuta Y, Fukuda T, Transplant
and Transplantation in Allogeneic Settings. Ichinohe T, Kato S, Kanda J.

2020

26(1):132 WGP
-8.
17-22

Int J Hematol 2019109(6):68 WGP
4-93.
17-23

論文タイトルImpact of High-Frequency HLA
Haplotypes on Clinical Cytomegalovirus
347
Reactivation in Allogeneic Hematopoietic
Stem Cell Transplantation.

Short-term clinical outcomes after HLA
1-locus mismatched uPBSCT are similar349
to that after HLA-matched uPBSCT and
uBMT.

著者

Fuji S, Miyamura K, Kanda Y, Fukuda T,
Kobayashi T, Ozawa Y, Iwato K, Uchida
N, Eto T, Ashida T, Mori T, Sawa M,
Ichinohe T, Atsuta Y, Kanda J; HLA
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

Yokoyama H, Morishima Y, Fuji S, Uchida
N, Takahashi S, Onizuka M, Tanaka M,
Impact of HLA Allele Mismatch at HLA-A, Yuju O, Eto T, Ozawa Y, Takada S,
Biol Blood
350 -B, -C, and -DRB1 in Single Cord Blood Takanashi M, Kato K, Kanda Y, Ichinohe Marrow
Transplantation.
T, Atsuta Y, Kanda J; HLA Working
TransplantGroup of the Japan Society for
Hematopoietic Cell Transplantation.
Increased Relapse Risk of Acute
Arima N, Kanda J, Yabe T, Morishima Y,
Lymphoid Leukemia in Homozygous HLA- Tanaka J, Kako S, Sakaguchi H, Kato M, Biol Blood
351 C1 Patients after HLA-Matched
Ohashi K, Ozawa Y, Fukuda T, Ota S,
Marrow
Allogeneic Transplantation: A JapaneseTachibana T, Onizuka M, Ichinohe T,
Transplant
National Registry Study.
Atsuta Y, Kanda Y.
Kawamura K, Kanda J, Ohashi K, Fukuda
Influence of HLA 1-3-locus mismatch andT, Iwato K, Eto T, Fujiwara SI, Mori T,
352 antithymocyte globulin administration in
Ann Hematol
Fukushima K, Ozawa Y, Uchida N, Ashidaunrelated bone marrow transplantation.
T, Ichinohe T, Atsuta Y, Kanda Y.
Morishima S, Fukuda T, Doki N, Mori T,
Onizuka M, Kawakita T, Kato C, Ozawa Y,
Individual HLAs influence immunological
Tanaka M, Kurokawa M, Kamimura T,
events in allogeneic stem cell
Bone Marrow
353
Inoue M, Tanaka J, Ichinohe T, Atsuta Y,
transplantation from HLA-identical sibling
Transplant
Morishima Y; HLA Working Group of thedonors.
Japan Society for Hematopoietic Cell
Transplantation.

業績
番号

2020

26(3):519 WGP
-28.
17-24

2020

26(3):431 WGP
-7.
17-25

2020

99(5):109 WGP
9-110.
17-26

2021

56(3):646 WGP
-54.
17-27

Kawajiri A, Kawase T, Tanaka H, Fukuda
T, Mukae J, Ozawa Y, Eto T, Uchida N,
Human leukocyte antigen (HLA) haplotype Mori T, Ashida T, Kondo T, Onizuka M,
Bone Marrow
354 matching in unrelated single HLA allele
Ichinohe T, Atsuta Y, Morishima S, Kanda
2022
Transplantmismatch bone marrow transplantation.
J; HLA Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.

57(3):407 WGP
-15.
17-28

Shiratori S, Sugita J, Fuji S, Aoki J,
Sawa M, Ozawa Y, Hashimoto D,
Matsuoka KI, Imada K, Doki N, Ashida T,
Ueda Y, Tanaka M, Sawayama Y,
Ichinohe T, Terakura S, Morishima S,
Atsuta Y, Fukuda T, Teshima T.
Fuji S, Hakoda A, Kanda J, Murata M,
Impact of HLA disparity on the risk ofTerakura S, Inamoto Y, Uchida N, Toya
overall mortality in patients with grade IIT, Eto T, Nakamae H, Ikegame K, Tanaka
356 IV acute GVHD on behalf of the HLA
M, Kawakita T, Kondo T, Miyamoto T,
Working Group of Japan Society for
Fukuda T, Ichinohe T, Kimura T, Atsuta
Hematopoietic Cell Transplantation.
Y, Shintani A, Morishima S.
Low-dose antithymocyte globulin inhibits
chronic graft-versus-host disease in355
peripheral blood stem cell transplantationfrom unrelated donors.

Bone Marrow
2021
Transplant

56(9):223 WGP
1-40.
17-29

Bone Marrow
2021
Transplant56(12):29 WGP
90-6.
17-30

論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

業績
番号

Yokoyama H, Kanda J, Kawahara Y,
Uchida N, Tanaka M, Takahashi S,
Onizuka M, Noguchi Y, Ozawa Y,
Bone Marrow
2021
Katsuoka Y, Ota S, Ohta T, Kimura T,
Transplant
Kanda Y, Ichinohe T, Atsuta Y, Nakasone
H, Morishima S.

56(6):135 WGP
2-63.
17-31

Yokoyama H, Hirayama M, Takahashi Y,
Altered effect of killer immunoglobulin-like Uchida N, Tanaka M, Onizuka M, Ozawa
receptor-ligand mismatch by graft versus Y, Onai D, Katsuoka Y, Wake A, Sawa M, Bone Marrow358
2021
host disease prophylaxis in cord blood
Kobayashi H, Maruyama Y, Ozeki K,
Transplanttransplantation.
Kimura T, Kanda J, Fukuda T, Atsuta Y,
Terakura S, Morishima S.

56(12):30 WGP
59-67.
17-32

Kanda J, Hirabayashi S, Yokoyama H,
Kawase T, Tanaka H, Uchida N, Taniguchi
Effect of multiple HLA-locus mismatches
S, Takahashi S, Onizuka M, Tanaka M,
Transplant
359 on outcomes after single cord blood
Sugio Y, Eto T, Kanda Y, Kimura T,
Cell Thertransplantation.
Ichinohe T, Atsuta Y, Morishima S;
JSTCT HLA Working Group.

2022

28(7):398 WGP.e1-9.
17-33

Impact of human leukocyte antigen
mismatch on outcomes after unrelated
360 bone marrow transplantation in paediatricpatients: A retrospective analysis by the
JSTCT HLA working group.

2022

199(3):39 WGP
2-400.
17-34

2023

142(11):1 WGP
008-21. 17-35

Fukunaga K, Ikegame K, Nakamae H, DokiN, Fukuda T, Kondo Y, Ara T, Eto T, MoriY, Matsuoka KI, Kanda Y, Onizuka M,
Int J Hematol 2024
Atsuta Y, Ichinohe T, Morishima S, Kanda
J; JSTCT HLA Working Group.

119(2):17 WGP
3-82.
17-36

Fuji S, Hakoda A, Kanda J, Fukuda T,
Impact of HLA disparity on overall
Doki N, Katayama Y, Uchida N, Ozawa Y,
mortality risk in patients with extensive
Kanda Y, Tanaka M, Kataoka K, Ara T,
Bone Marrow
363 chronic GVHD: The HLA Working Group of2023
Sawa M, Onizuka M, Onishi Y, Kimura T, Transplant
Japanese Society for Transplantation and
Ichinohe T, Atsuta Y, Shintani A,
Cellular Therapy.
Morishima S.

58(11):12 WGP
57-9.
17-37

Kanda J, Ichinohe T, Kato S, Uchida N,
Terakura S, Fukuda T, Hidaka M, Ueda Y,
Unrelated cord blood transplantation vsKondo T, Taniguchi S, Takahashi S,
related transplantation with HLA 1Nagamura-Inoue T, Tanaka J, Atsuta Y,
364
Leukemia
antigen mismatch in the graft-versus-host Miyamura K, Kanda Y; Donor/Source
direction.
Working Group and HLA Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.

2013

27(2):286 WGP
-94.
18-1

Kuwatsuka Y, Atsuta Y, Horowitz MM,
Inagaki J, Kanda J, Kato K, Koh K, Zhang
Graft-versus-host disease and survival
MJ, Eapen M; Center for International
Biol Blood
after cord blood transplantation for acute Blood and Marrow Transplant Research
365
Marrow
leukemia: a comparison of Japanese(CIBMTR), and Donor/Source and GVHD
Transplantversus White populations.
Working Group of the Japan Society for
Hematopoietic Cell Transplantation(JSHCT).

2014

20(5):662 WGP
-7.
18-2

Tanaka M, Miyamura K, Terakura S, Imai
Comparison of cord blood transplantation
K, Uchida N, Ago H, Sakura T, Eto T,
Biol Bloodwith unrelated bone marrow
366
Ohashi K, Fukuda T, Taniguchi S, Mori S, Marrowtransplantation in patients older than fifty
Nagamura-Inoue T, Atsuta Y, Okamoto Transplant
years.
S.

2015

21(3):517 WGP
-25.
18-3

Reduced leukemia relapse throughcytomegalovirus reactivation in killer cell357
immunoglobulin-like receptor-ligandmismatched cord blood transplantation.

Kato I, Sakaguchi H, Kato S, Sato M,
Noguchi M, Yoshida N, Koh K, Koike T,
Yanagimachi M, Kato K, Takahashi Y,
Fujita N, Sato A, Hashii Y, Tabuchi K,
Atsuta Y, Morishima S, Kanda J.

Br J
HaematolUmino K, Morita K, Ikeda T, Kawaguchi
SI, Nagayama T, Ito S, Minakata D,
Ashizawa M, Yamamoto C, Hatano K,
Antibody-mediated pathogenesis of
Sato K, Ohmine K, Fujiwara SI, Kimura SI,
361 chronic GVHD through DBY/HLA class II
Blood
Kako S, Doki N, Ozawa Y, Mori Y, Eto T,
complexes and induction of a GVL effect.
Hiramoto N, Nakamae H, Kanda J,
Ichinohe T, Atsuta Y, Nakasone H,
Morishima S, Kanda Y.
HLA haploidentical stem celltransplantation from HLA homozygous
donors to HLA heterozygous donors may
have lower survival rates than362
haploidentical transplantation from HLA
heterozygous donors to HLA
heterozygous donors: a retrospective
nationwide analysis.

雑誌名

発行
年

刊・号・
頁

Terakura S, Atsuta Y, Tsukada N,
Kobayashi T, Tanaka M, Kanda J, Najima
Biol Blood
Y, Fukuda T, Uchida N, Takahashi S,
Marrow
Nagamura-Inoue T, Morishima Y,
Transplant
Miyamura K; Japan Society for
Hematopoietic Cell Transplantation.

201622(2):330 WGP
-8.
18-4

Kumar R, Kimura F, Ahn KW, Hu ZH,
Kuwatsuka Y, Klein JP, Pasquini M,
Comparing Outcomes with Bone Marrow Miyamura K, Kato K, Yoshimi A, Inamotoor Peripheral Blood Stem Cells as Graft
Y, Ichinohe T, Wood WA Jr, Wirk B,
Biol Blood
368 Source for Matched Sibling Transplants in Seftel M, Rowlings P, Marks DI, Schultz Marrow
Severe Aplastic Anemia across Different KR, Gupta V, Dedeken L, George B, Cahn Transplant
Economic Regions.
JY, Szer J, Lee JW, Ho AY, Fasth A,
Hahn T, Khera N, Dalal J, Bonfim C,
Aljurf M, Atsuta Y, Saber W.

201622(5):932 WGP
-40.
18-5

Graft-versus-Host Disease after HLAMatched Sibling Bone Marrow orPeripheral Blood Stem Cell
369
Transplantation: Comparison of North
American Caucasian and Japanese
Populations.

Kanda J, Brazauskas R, Hu ZH,
Kuwatsuka Y, Nagafuji K, Kanamori H,
Kanda Y, Miyamura K, Murata M, Fukuda Biol Blood
T, Sakamaki H, Kimura F, Seo S, Aljurf M, Marrow
Yoshimi A, Milone G, Wood WA, Ustun C, Transplant
Hashimi S, Pasquini M, Bonfim C, Dalal J,
Hahn T, Atsuta Y, Saber W.

201622(4):744 WGP
-51.
18-6

Comparison of Donor Sources in
Hematopoietic Stem Cell Transplantation
370
for Childhood Acute Leukemia: A
Nationwide Retrospective Study.

Sakaguchi H, Watanabe N, Matsumoto K,
Yabe H, Kato S, Ogawa A, Inagaki J,
Goto H, Koh K, Yoshida N, Kato K, Cho Biol Blood
Y, Kosaka Y, Takahashi Y, Inoue M, Kato Marrow
K, Atsuta Y, Miyamura K; Donor/Source Transplant
Working Group of Japan Society of
Hematopoietic Cell Transplantation.

2016

22(12):22 WGP
26-34.
18-7

Kuwatsuka Y, Kanda J, Yamazaki H, Mori
T, Miyamura K, Kako S, Uchida N, Ohashi
A Comparison of Outcomes for Cord
K, Ozawa Y, Takahashi Y, Kato C, Iwato
Biol Blood
Blood Transplantation and Unrelated Bone K, Ishiyama K, Kobayashi H, Eto T,
371
Marrow
Marrow Transplantation in Adult Aplastic Kahata K, Kato J, Miyamoto T, Kato K,
Transplant
Anemia.
Mori S, Atsuta Y, Kimura F, Kanda Y;
Japan Society for Hematopoietic Cell
Transplantation.

2016

22(10):18 WGP
36-43.
18-8

Konuma T, Tsukada N, Kanda J, UchidaN, Ohno Y, Miyakoshi S, Kanamori H,
Comparison of transplant outcomes from Hidaka M, Sakura T, Onizuka M,
matched sibling bone marrow or peripheral Kobayashi N, Sawa M, Eto T, Matsuhashi Am J
372
blood stem cell and unrelated cord blood Y, Kato K, Ichinohe T, Atsuta Y,
Hematolin patients 50 years or older.
Miyamura K; Donor/Source Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

2016

91(5):E28 WGP
4-92.
18-9

Kimura F, Kanda J, Ishiyama K, Yabe T,
Yoshifuji K, Fukuda T, Ozawa Y, Iwato K,
Eto T, Mori T, Uchida N, Ota S, Sakura
Bone Marrow
T, Ichinohe T, Atsuta Y, Kanda Y;
2019
Transplant
donor/source working group of theJapan Society for Hematopoietic Cell
Transplantation.

54(10):16 WGP
76-85.
18-10

論文タイトルComparison of Outcomes of 8/8 and 7/8
Allele-Matched Unrelated Bone Marrow
367 Transplantation and Single-Unit Cord
Blood Transplantation in Adults with
Acute Leukemia.

ABO blood type incompatibility lost the
373 unfavorable impact on outcome inunrelated bone marrow transplantation.

著者

業績
番号

Kanda J, Hayashi H, Ruggeri A, Kimura F,
Volt F, Takahashi S, Labopin M, Kako S,
Prognostic factors for adult single cord
Tozatto-Maio K, Yano S, Sanz G, Uchidablood transplantation among European andN, Van Lint MT, Kato S, Mohty M,
374 Japanese populations: the
Leukemia
Forcade E, Kanamori H, Sierra J, Ohno Y,
Eurocord/ALWP-EBMT and
Saccardi R, Fukuda T, Ichinohe T,
JSHCT/JDCHCT collaborative study.
Takanashi M, Rocha V, Okamoto S,
Nagler A, Atsuta Y, Gluckman E.

202034(1):128 WGP
-37.
18-11

Konuma T, Kanda J, Inamoto Y, Hayashi
H, Kobayashi S, Uchida N, Sugio Y,
Tanaka M, Kobayashi H, Kouzai Y,
Am JTakahashi S, Eto T, Mukae J, Matsuhashi Hematol
Y, Fukuda T, Takanashi M, Kanda Y,
Atsuta Y, Kimura F.

2020

95(4):343 WGP
-53.
18-12

Improvement of early mortality in single375 unit cord blood transplantation forJapanese adults from 1998 to 2017.

論文タイトル

376

Comparison of ReducedIntensity/Toxicity Conditioning Regimens
for Umbilical Cord Blood Transplantation
for Lymphoid Malignancies.

著者

雑誌名

発行
年

Imahashi N, Terakura S, Kondo E, Kako
S, Uchida N, Kobayashi H, Inamoto Y,
Sakai H, Tanaka M, Ishikawa J, Kozai Y,
Bone Marrow
Matsuoka KI, Kimura T, Fukuda T, Atsuta
2020
Transplant
Y, Kanda J; Donor/Source Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

Miyao K, Terakura S, Kimura F, Konuma
T, Miyamura K, Yanada M, Kako S,
Updated Comparison of 7/8 HLA AlleleMorhishima S, Uchida N, Toya T, Ozawa
Matched Unrelated Bone Marrow
Biol Blood
Y, Fukuda T, Tanaka M, Sawa M, Takada
377 Transplantation and Single-Unit Umbilical
Marrow
S, Yoshida S, Kimura T, Ichinohe T,
Cord Blood Transplantation as Alternative
Transplant
Atsuta Y, Kanda J; Donor/Source
Donors in Adults with Acute Leukemia.
Working Group of the Japan Society for
Hematopoietic Cell Transplantation.

刊・号・
頁

業績
番号

55(11):20 WGP
98-108. 18-13

2020

26(11):21 WGP
05-14.
18-14

Kobayashi S, Kanda Y, Konuma T,
Outcomes of third allogeneic
Inamoto Y, Matsumoto K, Uchida N,
hematopoietic stem cell transplantation in Ikegame K, Miyamoto T, Doki N, Nakamae Bone Marrow378
2022
relapsed/refractory acute leukemia after a H, Katayama Y, Takahashi S, Shiratori S, Transplantsecond transplantation.
Saito S, Kawakita T, Kanda J, Fukuda T,
Atsuta Y, Kimura F.

57(1):43- WGP
50.
18-15

Kanda J, Hayashi H, Ruggeri A, Kimura F,
Volt F, Takahashi S, Kako S, TozattoMaio K, Yanada M, Sanz G, Uchida N,
Angelucci E, Kato S, Mohty M, Forcade Bone Marrow
2022
E, Tanaka M, Sierra J, Ohta T, Saccardi Transplant
R, Fukuda T, Ichinohe T, Kimura T,
Rocha V, Okamoto S, Nagler A, Atsuta Y,
Gluckman E.

57(1):57- WGP
64.
18-16

Imahashi N, Terakura S, Kondo E, Kato K,
Kim SW, Shinohara A, Watanabe M,
Impact of donor types on reducedFukuda T, Uchida N, Kobayashi H,
intensity conditioning allogeneic stem cell
Bone Marrow
380
Ishikawa J, Kataoka K, Shiratori S, Ikeda
2022
transplant for mature lymphoidTransplant
T, Matsuoka KI, Yoshida S, Kondo T,
malignancies.
Kimura T, Onizuka M, Ichinohe T, Atsuta
Y, Kanda J.

57(2):243 WGP
-51.
18-17

The impact of GVHD on outcomes after
379 adult single cord blood transplantation in
European and Japanese populations.

Differential Effect of Graft-versus-Host
381 Disease on Survival in Acute Leukemia
according to Donor Type.

Konuma T, Kanda J, Kuwatsuka Y,
Yanada M, Kondo T, Hirabayashi S, Kako
S, Akahoshi Y, Uchida N, Doki N, Ozawa Clin Cancer
Y, Tanaka M, Eto T, Sawa M, Yoshioka S, Res
Kimura T, Kanda Y, Fukuda T, Atsuta Y,
Kimura F.

2021

27(17):48 WGP
25-35.
18-18

Wada F, Watanabe M, Konuma T, Okabe
M, Kobayashi S, Uchida N, Ikegame K,
HLA 1-3 antigen-mismatched related
Tanaka M, Sugio Y, Mukae J, Onizuka M,
peripheral blood stem cells transplantation Kawakita T, Kuriyama T, Takahashi S,
Am J
382 using low-dose antithymocyte globulin
Fukuda T, Nakano N, Sawa M, Kimura T,
Hematolversus unrelated cord blood
Ichinohe T, Atsuta Y, Kanda J;
transplantation.
Donor/Source Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

2022

97(3):311 WGP
-21.
18-19

Ideal Body Weight Is Useful For Predicting Okada Y, Nakasone H, Konuma T, Uchida
Neutrophil Engraftment and Platelet
N, Tanaka M, Sugio Y, Aotsuka N,
Transplant
383 Recovery for Overweight and Obese
Nishijima A, Katsuoka Y, Ara T, Ota S,
Cell Ther
Recipients in Single-Unit Cord Blood
Onizuka M, Sawa M, Kimura T, Fukuda T,
Transplantation.
Atsuta Y, Kanda J, Kimura F.

2022

28(8):504 WGP.e1-7.
18-20

Konuma T, Kanda J, Uchida N, Nishijima
Intensified conditioning regimens improved
A, Tanaka M, Ozawa Y, Sawa M, Onizuka
disease-free survival and engraftment
M, Ota S, Maruyama Y, Kanda Y,
after unrelated single-unit cord blood
Kawakita T, Ara T, Eto T, Nakamae H,
Hematological
384 transplantation but not after matched
2023
Kimura T, Fukuda T, Atsuta Y;
Oncology
sibling or matched unrelated donor
Donor/Source Working Group ofallogeneic hematopoietic cell
theJapanese Society for Transplantationtransplantation.
and Cellular Therapy.

41(1):147 WGP
-58.
18-21

論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

業績
番号

Impact of the combination of donor age
385 and HLA disparity on the outcomes of
unrelated bone marrow transplantation.

Seo S, Usui Y, Matsuo K, Atsuta Y,
Igarashi A, Fukuda T, Ozawa Y, Katayama
Y, Yoshida S, Uchida N, Kondo T, Kako S, Bone Marrow
2021
Tsukada N, Kato S, Onizuka M, Ichinohe TransplantT, Kimura F, Kanda Y, Miyamura K, Kanda
J; JSHCT Donor Source Working Group.

56(10):24 WGP
10-22.
18-22

Impact of stem cell selection betweenbone marrow and peripheral blood stem
cells for unrelated hematopoietic stem
cell transplantation for hematologic
386
malignancies: on behalf of the
Donor/Source Working Group of theJapanese Society for Transplantation andCellular Therapy.

Hayashi H, Iwasaki M, Nakasone H,
Tanoshima R, Shimabukuro M, Takeda W,
Nishida T, Kako S, Fujiwara SI, Katayama
Y, Sawa M, Serizawa K, Matsuoka KI,
Cytotherapy
Uchida N, Ikeda T, Ohigashi H, Fukushima
K, Hino M, Kanda Y, Fukuda T, Atsuta Y,
Kanda J.

2024

26(2):178 WGP
-84.
18-23

2024

99(2):263 WGP
-73.
18-24

Association of individual comorbidities
with outcomes in allogeneic hematopoietic Konuma T, Harada K, Shinohara A,
cell transplantation from unrelated adult Uchida N, Shingai N, Ito A, Ozawa Y,
donors versus unrelated cord blood: A
Tanaka M, Sawa M, Onizuka M, Katayama Am J
387
study on behalf of the Donor/Source and Y, Hiramoto N, Nakano N, Kimura T,
Hematol
Transplant Complications Working Groups Kanda Y, Fukuda T, Atsuta Y, Nakasoneof the Japanese Society for
H, Kanda J.
Transplantation and Cellular Therapy.

Development of an umbilical cord blood
388 transplantation-specific non-relapse
mortality risk assessment score.

Okada Y, Usui Y, Hayashi H, Nishikubo M,
Toubai T, Uchida N, Tanaka M, Onizuka
M, Takahashi S, Doki N, Uehara Y,
Blood
Maruyama Y, Ishiwata K, Kawakita T,
Advances
Sawa M, Eto T, Ishimaru F, Kato K,
Fukuda T, Atsuta Y, Kanda J, Yakushijin
K, Nakasone H.

Comparison of fludarabine-based
conditioning regimens in adult cord blood389
transplantation for myeloid malignancy: A
retrospective, registry-based study.

Kurita N, Imahashi N, Chiba S, Tanaka M,
Kobayashi H, Uchida N, Kuriyama T,
Anzai N, Nawa Y, Nakano N, Ara T,
Onizuka M, Katsuoka Y, Koi S, Kimura T, Am J
Ichinohe T, Atsuta Y, Kanda J;
Hematol
Donor/Source Working Group of theJapanese Society for Transplantation
and Cellular Therapy.

Watanabe M, Konuma T, Imahashi N,
Terakura S, Seo S, Morishima S, Uchida
Scoring system for optimal cord blood
N, Doki N, Tanaka M, Nishida T, Kawakita
390 unit selection for single cord blood
Cytotherapy
T, Eto T, Takahashi S, Sawa M, Ueharatransplantation.
Y, Kim SW, Ishimaru F, Ichinohe T,
Fukuda T, Atsuta Y, Kanda J.
Clinical factors predicting the response of Murata M, Nakasone H, Kanda J, Nakane
acute graft-versus-host disease toT, Furukawa T, Fukuda T, Mori T,
Biol Bloodcorticosteroid therapy: an analysis from
Taniguchi S, Eto T, Ohashi K, Hino M,
391
Marrow
the GVHD Working Group of the Japan
Inoue M, Ogawa H, Atsuta Y, NagamuraTransplantSociety for Hematopoietic Cell
Inoue T, Yabe H, Morishima Y, Sakamaki
Transplantation.
H, Suzuki R.

A case-control study of bronchiolitis
392 obliterans syndrome following allogeneic
hematopoietic stem cell transplantation.

393

Risk factors and organ involvement ofchronic GVHD in Japan.

in press2024

99(2):236 WGP
-44.
18-26

in press

2013

Nakasone H, Kanda J, Yano S, Atsuta Y,
Ago H, Fukuda T, Kakihana K, Adachi T,
Yujiri T, Taniguchi S, Taguchi J,
Morishima Y, Nagamura T, Sakamaki H, Transpl Int
2013
Mori T, Murata M; GVHD Working Groupof the Japan Society for Hematopoietic
Cell Transplantation.
Kanda J, Nakasone H, Atsuta Y, Toubai
T, Yokoyama H, Fukuda T, Taniguchi S,
Bone Marrow
Ohashi K, Ogawa H, Eto T, Miyamura K,
2014
Transplant
Morishima Y, Nagamura-Inoue T,
Sakamaki H, Murata M.

WGP
18-25

WGP
18-27

19(8):118 WGP
3-9.
19-1

26(6):631 WGP
-9.
19-2

49(2):228 WGP
-35.
19-3

論文タイトル

Impact of conditioning intensity and TBI
394 on acute GVHD after hematopoietic celltransplantation.

Age influences post-graft-versus-hostdisease non-relapse mortality in adults
395 with acute graft-versus-host disease ofvarying severity following allogeneic
hematopoietic cell transplant.

著者

雑誌名

発行
年

Nakasone H, Fukuda T, Kanda J, Mori T,
Yano S, Kobayashi T, Miyamura K, Eto T,
Kanamori H, Iwato K, Uchida N, Mori S,
Bone Marrow
Nagamura-Inoue T, Ichinohe T, Atsuta Y,
2015
Transplant
Teshima T, Murata M; GVHD working
group of the Japan Society of
Hematopoietic Cell Transplantation.
Nakane T, Fukuda T, Kanda J, Taniguchi
S, Eto T, Ohashi K, Nakamae H,
Leuk
Kurokawa M, Mori T, Morishima Y,
2015
Lymphoma
Nagamura-Inoue T, Sakamaki H, Atsuta
Y, Murata M.

Umeda K, Adachi S, Tanaka S, Ogawa A,
Hatakeyama N, Kudo K, Sakata N,
Comparison of continuous and twice-daily Igarashi S, Ohshima K, Hyakuna N, Chin
infusions of cyclosporine A for graftM, Goto H, Takahashi Y, Azuma E, Koh K,
Pediatr Blood
396 versus-host-disease prophylaxis in
Sawada A, Kato K, Inoue M, Atsuta Y,
2015
Cancerpediatric hematopoietic stem cell
Takami A, Murata M; on behalf of thetransplantation.
GVHD Working Group of the Japan
Society for Hematopoietic Cell
Transplantation.
Sakai R, Taguri M, Oshima K, Mori T, Ago
A comparison of tacrolimus and
H, Adachi S, Morita S, Taniguchi S,
cyclosporine combined with methotrexate
Fukuda T, Ohashi K, Eto T, Miyamura K,
397 for graft-versus-host disease prophylaxis,
Int J Hematol 2016
Iwato K, Kobayashi N, Kanamori H,
stratified by stem cell source: aMorishima Y, Nagamura-Inoue T,
retrospective nationwide survey.
Sakamaki H, Atsuta Y, Murata M.
Arai Y, Kanda J, Nakasone H, Kondo T,
Risk factors and prognosis of hepatic
Uchida N, Fukuda T, Ohashi K, Kaida K,
Bone Marrow
398 acute GvHD after allogeneic
Iwato K, Eto T, Kanda Y, Nakamae H,
2016
Transplant
hematopoietic cell transplantation.
Nagamura-Inoue T, Morishima Y,
Hirokawa M, Atsuta Y, Murata M.
Kanda J, Morishima Y, Terakura S, Wake
A, Uchida N, Takahashi S, Ono Y, Onishi
Impact of graft-versus-host disease on
Y, Kanamori H, Aotsuka N, Ozawa Y,
399 outcomes after unrelated cord blood
Leukemia
2017
Ogawa H, Sakura T, Ohashi K, Ichinohe
transplantation.
T, Kato K, Atsuta Y, Teshima T, Murata
M.
Murata M, Ikegame K, Morishita Y, Ogawa
H, Kaida K, Nakamae H, Ikeda T, Nishida
Low-dose thymoglobulin as second-line
T, Inoue M, Eto T, Kubo K, Sakura T,
Bone Marrow
400 treatment for steroid-resistant acute2017
Mori T, Uchida N, Ashida T, Matsuhashi Transplant
GvHD: an analysis of the JSHCT.
Y, Miyazaki Y, Ichinohe T, Atsuta Y,
Teshima T.
Terakura S, Wake A, Inamoto Y, Murata
Exploratory research for optimal GvHD
M, Sakai R, Yamaguchi T, Takahashi S,
prophylaxis after single unit CBT in adults:
Uchida N, Onishi Y, Ohashi K, Ozawa Y, Bone Marrow
401 short-term methotrexate reduced the2017
Kanamori H, Yamaguchi H, Fukuda T,
Transplant
incidence of severe GvHD more than
Ichinohe T, Takanashi M, Atsuta Y,
mycophenolate mofetil.
Teshima T.
Inamoto Y, Kimura F, Kanda J, Sugita J,
Comparison of graft-versus-host diseaseIkegame K, Nakasone H, Nannya Y,
free, relapse-free survival according to a
Uchida N, Fukuda T, Yoshioka K, Ozawa Haematologic
402 variety of graft sources: antithymocyte
2016
Y, Kawano I, Atsuta Y, Kato K, Ichinohe aglobulin and single cord blood provide
T, Inoue M, Teshima T; JSHCT GVHD
favorable outcomes in some subgroups.
Working Group.
Allogeneic unrelated bone marrowtransplantation from older donors results403
in worse prognosis in recipients withaplastic anemia.

Arai Y, Kondo T, Yamazaki H, Takenaka
K, Sugita J, Kobayashi T, Ozawa Y,
Uchida N, Iwato K, Kobayashi N,
Haematologic
Takahashi Y, Ishiyama K, Fukuda T,
2016aIchinohe T, Atsuta Y, Mori T, Teshima T;
Japan Society for Hematopoietic Cell
Transplantation.

刊・号・
頁

業績
番号

50(4):559 WGP
-65.
19-4

56(8):239 WGP
2-7.
19-5

62(2):291 WGP
-8.
19-6

103(3):32 WGP
2-33.
19-7

51(1):96- WGP
102.
19-8

31(3):663 WGP
-8.
19-9

52(2):252 WGP
-7.
19-10

52(3):423 WGP
-30.
19-11

101(12):1 WGP
592-602. 19-12

101(5):64 WGP
4-52.
19-13

論文タイトル

著者

雑誌名

発行
年

Terakura S, Kuwatsuka Y, Yamasaki S,
Wake A, Kanda J, Inamoto Y, Mizuta S,
GvHD prophylaxis after single-unit
Yamaguchi T, Uchida N, Kouzai Y,
reduced intensity conditioning cord blood
Bone Marrow
404
Aotsuka N, Ogawa H, Kanamori H,
2017transplantation in adults with acuteTransplant
Nishiwaki K, Miyakoshi S, Onizuka M,
leukemia.
Amano I, Fukuda T, Ichinohe T, Atsuta Y,
Murata M, Teshima T.

刊・号・
頁

業績
番号

52(9):126 WGP
1-7.
19-14

Impacts of thymoglobulin in patients with
405 acute leukemia in remission undergoing
allogeneic HSCT from different donors.

Wakamatsu M, Terakura S, Ohashi K,
Fukuda T, Ozawa Y, Kanamori H, Sawa
M, Uchida N, Ota S, Matsushita A, Kanda
Blood
Y, Nakamae H, Ichinohe T, Kato K,
Advances
Murata M, Atsuta Y, Teshima T; GVHDWorking Group of the Japan Society for
Hematopoietic Cell Transplantation.

2019

3(2):105- WGP
15.
19-15

Effect of Graft-Versus-Host Disease on
406 Outcomes After Pediatric Single Cord
Blood Transplantation.

Kanda J, Umeda K, Kato K, Murata M,
Sugita J, Adachi S, Koh K, Noguchi M,
Goto H, Yoshida N, Sato M, Koga Y, Hori Bone Marrow
2020
T, Cho Y, Ogawa A, Inoue M, Hashii Y,
Transplant
Atsuta Y, Teshima T; JSHCT GVHDWorking Group.

55(7):143 WGP
0-7.
19-16

Effect of methotrexate dose in graftversus-host disease prophylaxis after
407
single-unit cord blood transplantation in
adult acute myeloid leukemia.

Terakura S, Kuwatsuka Y, Sugita J,
Takahashi S, Ozawa Y, Ozeki K, Yoshioka
S, Nakamae H, Kawakita T, Sawa M,
Morishige S, Najima Y, Katsuoka Y,
Int J Hematol 2021
Sakaida E, Kouzai Y, Kimura T, Ichinohe
T, Fukuda T, Atsuta Y, Murata M,
Teshima T.

113(6):84 WGP
0-50.
19-17

Off-the-shelf bone marrow-derived
mesenchymal stem cell treatment for
408
acute graft-versus-host disease: realworld evidence.

Murata M, Terakura S, Wake A, Miyao K,
Ikegame K, Uchida N, Kataoka K,
Miyamoto T, Onizuka M, Eto T, Doki N,
Bone Marrow
2021
Ota S, Sato M, Hashii Y, Ichinohe T,
Transplant
Fukuda T, Atsuta Y, Okamoto S, TeshimaT.

56(10):23 WGP
55-66.
19-18

Antithymocyte Globulin Potentially Could
Overcome an Adverse Effect of Acute409 Graft-versus-Host Disease in MatchedRelated Peripheral Blood Stem Cell
Transplantation.

Miyao K, Kuwatsuka Y, Murata M,
Nagafuji K, Teshima T, Takeuchi Y,
Shiratori S, Najima Y, Uchida N, Tanaka
M, Sawa M, Ota S, Fukuda T, Ozawa Y,
Transplant
Kako S, Kawakita T, Ara T, Tanaka J,
Cell Ther
Kanda Y, Atsuta Y, Kanda J, Terakura S;
GVHD Working Group and Donor/Source
Working Group of the Japanese Society
for Transplantation and Cellular Therapy.

2022

28(3):153 WGP.e1-11.
19-19

Different effects of thymoglobulin on
acute leukemia with pre-transplant
410
residual blasts in HLA mismatch
transplantation.

Wakamatsu M, Murata M, Kanda J,
Fukushima K, Fukuda T, Najima Y,
Katayama Y, Ozawa Y, Tanaka M, Kanda
Y, Eto T, Takada S, Kako S, Uchida N,
Int J Hematol 2023
Kawakita T, Yoshiko H, Ichinohe T,
Atsuta Y, Terakura S; GVHD Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

117(6):88 WGP
9-99.
19-20

Effect of graft-versus-host disease on
outcomes of HLA-haploidentical
411
peripheral blood transplantation using
post-transplant cyclophophamide.
Impact of hepatitis C virus infection onclinical outcome in recipients after
412
allogeneic hematopoietic celltransplantation.
Pre-transplant risk factors forcryptogenic organizing
413 pneumonia/bronchiolitis obliteransorganizing pneumonia after hematopoietic
cell transplantation.

Shimomura Y, Komukai S, Kitamura T,
Sobue T, Akahoshi Y, Kanda J, Ohigashi
H, Nakamae H, Hiramoto N, Nagafuji K,
Tanaka T, Eto T, Ota S, Maruyama Y,
Akasaka T, Matsuoka KI, Mori Y, Fukuda
T, Atsuta Y, Terakura S.
Nakasone H, Kurosawa S, Yakushijin K,
Taniguchi S, Murata M, Ikegame K,
Kobayashi T, Eto T, Miyamura K,
Sakamaki H, Morishima Y, Nagamura T,
Suzuki R, Fukuda T.

Bone Marrow
2024
Transplant59(1):66- WGP
75.
19-21

Am J
Hematol

2013

88(6):477 WGP
-84.
20-1

Nakasone H, Onizuka M, Suzuki N, Fujii
N, Taniguchi S, Kakihana K, Ogawa H,
Bone Marrow
2013
Miyamura K, Eto T, Sakamaki H, Yabe H, Transplant
Morishima Y, Kato K, Suzuki R, Fukuda T.

48(10):13 WGP
17-23.
20-2

論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

業績
番号

Kato M, Matsumoto K, Suzuki R, Yabe H,
Salvage allogeneic hematopoietic SCT for Inoue M, Kigasawa H, Inagaki J, Koh K,
Bone Marrow414
2013
primary graft failure in children.
Hashii Y, Tauchi H, Suminoe A, Kikuta A, Transplant
Sakamaki H, Kawa K, Kato K, Fukuda T.

48(9):117 WGP
3-8.
20-3

Pre-transplant diabetes mellitus is a risk
factor for non-relapse mortality,415
especially infection-related mortality,
after allogeneic hematopoietic SCT.

50(4):553 WGP
-8.
20-6

Takano K, Fuji S, Uchida N, Ogawa H,
Bone Marrow
Ohashi K, Eto T, Sakamaki H, Morishima
2015
Transplant
Y, Kato K, Suzuki R, Fukuda T.

Fuji S, Takano K, Mori T, Eto T,
Taniguchi S, Ohashi K, Sakamaki H,
Bone Marrow
2014
Morishima Y, Kato K, Miyamura K, Suzuki Transplant
R, Fukuda T.
Yakushijin K, Atsuta Y, Doki N, Yokota A,
Sinusoidal obstruction syndrome after
Kanamori H, Miyamoto T, Ohwada C,
allogeneic hematopoietic stem cell
Miyamura K, Nawa Y, Kurokawa M,
Bone Marrow
417
2016
transplantation: Incidence, risk factors and Mizuno I, Mori T, Onizuka M, Taguchi J, Transplant
outcomes.
Ichinohe T, Yabe H, Morishima Y, Kato K,
Suzuki R, Fukuda T.
Impact of pretransplant body mass index
416 on the clinical outcome after allogeneic
hematopoietic SCT.

Cytomegalovirus Reactivation after
Allogeneic Hematopoietic Stem Cell
Transplantation is Associated with a
Reduced Risk of Relapse in Patients with
418 Acute Myeloid Leukemia Who Survived to
Day 100 after Transplantation: The Japan
Society for Hematopoietic Cell
Transplantation Transplantation-related
Complication Working Group.

49(12):15 WGP
05-12.
20-4

51(3):403 WGP
-9.
20-7

Takenaka K, Nishida T, Asano-Mori Y,
Oshima K, Ohashi K, Mori T, Kanamori H, Biol Blood
Miyamura K, Kato C, Kobayashi N, Uchida Marrow
N, Nakamae H, Ichinohe T, Morishima Y, Transplant
Suzuki R, Yamaguchi T, Fukuda T.

2015

21(11):20 WGP
08-16.
20-5

Kato M, Yamashita T, Suzuki R,
Donor cell-derived hematologic
Matsumoto K, Nishimori H, Takahashi S,
419 malignancy: A survey by the Japan society Iwato K, Nakaseko C, Kondo T, Imada K, Leukemia
for hematopoietic cell transplantation.
Kimura F, Ichinohe T, Hashii Y, Kato K,
Atsuta Y, Taniguchi S, Fukuda T.

201630(8):174 WGP
2-5.
20-8

Impact of total body irradiation on
successful neutrophil engraftment in
420
unrelated bone marrow or cord bloodtransplantation.

Nakasone H, Fuji S, Yakushijin K, Onizuka
M, Shinohara A, Ohashi K, Miyamura K,
Uchida N, Takanashi M, Ichinohe T,
Am J
Atsuta Y, Fukuda T, Ogata M;
Hematol
Complication Working Group of JapaneseSociety for Hematopoietic Cell
Transplantation.

2017

92(2):171 WGP
-8.
20-9

Clinical characteristics and outcome ofhuman herpesvirus-6 encephalitis after
421
allogeneic hematopoietic stem celltransplantation.

Ogata M, Oshima K, Ikebe T, Takano K,
Kanamori H, Kondo T, Ueda Y, Mori T,
Hashimoto H, Ogawa H, Eto T, Ueki T,
Miyamoto T, Ichinohe T, Atsuta Y,
Fukuda T.

Bone Marrow
2017
Transplant

52(11):15 WGP
63-70.
20-10

BM is preferred over PBSCs in
422 transplantation from an HLA-matched
related female donor to a male recipient.

Nakasone H, Kawamura K, Yakushijin K,
Shinohara A, Tanaka M, Ohashi K, Ota S,
Blood
Uchida N, Fukuda T, Nakamae H,
Advances
Matsuoka KI, Kanda J, Ichinohe T, Atsuta
Y, Inamoto Y, Seo S, Kimura F, Ogata M.

20193(11):175 WGP
0-60.
20-11

Clinical course of autologous recovery
with chromosomal abnormalities after
423
allogeneic hematopoietic stem celltransplantation.

Kato M, Nakasone H, Nakano N, Fuji S,
Shinohara A, Yokoyama H, Sakashita K,
Hori T, Takahashi S, Nara M, Kanda Y,
Mori T, Takita J, Kawaguchi H, Kawakita Bone Marrow
2020
T, Ichinohe T, Fukuda T, Atsuta Y, Ogata Transplant
M; Transplantation Complication Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

55(6):102 WGP
3-8.
20-12

Risk Factors and Predictive Scoring
System For Post-Transplant
424
Lymphoproliferative Disorder after
Hematopoietic Stem Cell Transplantation.

Fujimoto A, Hiramoto N, Yamasaki S,
Inamoto Y, Uchida N, Maeda T, Mori T,
Biol Blood
Kanda Y, Kondo T, Shiratori S, Miyakoshi
Marrow
S, Ishiyama K, Ikegame K, Matsuhashi Y,
Transplant
Tanaka J, Ichinohe T, Atsuta Y, Ogata M,
Suzuki R.

25(7):144 WGP
1-9.
20-13

2019

論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

業績
番号

Low incidence of post-transplant
lymphoproliferative disorder after
425 allogeneic stem cell transplantation inpatients with lymphoma treated withrituximab.

Fujimoto A, Hiramoto N, Yamasaki S,
Inamoto Y, Ogata M, Sugio Y, Fukuda T,
Uchida N, Ikegame K, Matsuoka KI,
Shiratori S, Kondo T, Miyamoto T, Eto T, Hematological
2020
Ichinohe T, Kanda Y, Atsuta Y, Suzuki R; Oncology
Complication Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

38(2):146 WGP
-52.
20-14

Impact of pretransplant donor-specificanti-HLA antibodies on cord bloodtransplantation on behalf of the426Transplant Complications Working Groupof Japan Society for Hematopoietic Cell
Transplantation.

Fuji S, Oshima K, Ohashi K, Sawa M,
Saito T, Eto T, Tanaka M, Onizuka M,
Bone Marrow
Nakamae H, Shiratori S, Ozawa Y, Hidaka
2020
Transplant
M, Nagamura-Inoue T, Tanaka H, Fukuda
T, Ichinohe T, Atsuta Y, Ogata M.

55(4):722 WGP
-8.
20-15

Comparison of the outcomes after
haploidentical and cord blood salvage
427 transplantations for graft failure following
allogeneic hematopoietic stem celltransplantation.

Harada K, Fuji S, Seo S, Kanda J, Ueki T,
Kimura F, Kato K, Uchida N, Ikegame K,
Onizuka M, Matsuoka KI, Doki N,
Kawakita T, Onishi Y, Yano S, Fukuda T, Bone Marrow
2020
Takanashi M, Kanda Y, Atsuta Y, Ogata Transplant
M; transplant complications working
group of the Japan Society for
Hematopoietic Cell Transplantation.

55(9):178 WGP
4-95.
20-16

Comparison of immunosuppressantregimens in salvage cord blood
428 transplantation for graft failure after
allogeneic hematopoietic stem celltransplantation.

Harada K, Fuji S, Seo S, Uchida N,
Kawakita T, Yano S, Ozawa Y, Yoshioka
S, Onishi Y, Noguchi Y, Onizuka M,
Matsuhashi Y, Kimura T, Ichinohe T,
Atsuta Y; Transplant Complications
Bone Marrow
2021
Working Group of the Japan Society for Transplant
Hematopoietic Cell Transplantation;
GVHD Working Group of the Japan
Society for Hematopoietic Cell
Transplantation, Terakura S, Nakasone H.

56(2):400 WGP
-10.
20-17

Severe acute graft-versus-host disease
increases the incidence of blood stream
429 infection and mortality after allogeneic
hematopoietic cell transplantation:
Japanese transplant registry study.

Inoue Y, Okinaka K, Fuji S, Inamoto Y,
Uchida N, Toya T, Ikegame K, Eto T,
Ozawa Y, Iwato K, Kanda Y, Atsuta Y,
Ogata M, Fukuda T; Transplant
Complications Working Group of The
Japan Society for Hematopoietic Cell
Transplantation.

56(9):212 WGP
5-36.
20-18

Effect of cytomegalovirus reactivation
with or without acute graft-versus-host430
disease on the risk of nonrelapse
mortality.

Akahoshi Y, Kimura SI, Inamoto Y, Seo S,
Muranushi H, Shimizu H, Ozawa Y,
Tanaka M, Uchida N, Kanda Y, Katayama Clin InfectY, Shiratori S, Ota S, Matsuoka KI,
Dis
Onizuka M, Fukuda T, Atsuta Y, Murata
M, Terakura S, Nakasone H.

2021

73(3):e62 WGP
0-8.
20-19

Cytomegalovirus reactivation isassociated with an increased risk of lateonset invasive aspergillosis independently
431 of grade II-IV acute graft-versus-hostdisease in allogeneic hematopoietic stem
cell transplantation: JSTCT Transplant
Complications Working Group.

Kimura SI, Tamaki M, Okinaka K, Seo S,
Uchida N, Igarashi A, Ozawa Y, Ikegame
K, Eto T, Tanaka M, Shiratori S, Nakamae
Ann Hematol 2021
H, Sawa M, Kawakita T, Onizuka M,
Fukuda T, Atsuta Y, Kanda Y, Nakasone
H.

100(12):3 WGP
029-38. 20-20

Prognostic factors in salvagetransplantation for graft failure following
432
allogeneic hematopoietic stem celltransplantation.

Cytomegalovirus gastroenteritis in
433 patients with acute graft-versus-hostdisease.

Bone Marrow
2021
Transplant

Harada K, Kimura SI, Fuji S, Najima Y,
Yakushijin K, Uchida N, Onizuka M,
Ikegame K, Yano S, Shingai N, Matsuoka Bone Marrow
2021
KI, Onishi Y, Sawa M, Takada S, Kawakita TransplantT, Fukuda T, Kanda J, Atsuta Y,
Nakasone H.
Akahoshi Y, Kimura SI, Tada Y,
Matsukawa T, Tamaki M, Doki N, Uchida
N, Tanaka M, Nakamae H, Kuriyama T,
Blood
2022
Matsuoka KI, Ikeda T, Kimura T, Fukuda Advances
T, Kanda Y, Atsuta Y, Murata M,
Terakura S, Nakasone H.

56(9):218 WGP
3-93.
20-21

6(2):574- WGP
84.
20-22

論文タイトル

著者

雑誌名

発行
年

刊・号・
頁

Transplant
Cell Ther

業績
番号

Risk and Predictive Factors for
Candidemia After Allogeneic
434 Hematopoietic Cell Transplantation:
JSTCT Transplant Complications Working
Group.

Kimura SI, Kameda K, Harada K, Saburi
M, Okinaka K, Shinohara A, Uchida N,
Nishijima A, Ozawa Y, Tanaka M,
Kuriyama T, Katayama Y, Sawa M,
Ikegame K, Kawakita T, Kanda Y,
Nakamae H, Ara T, Kimura T, Sato A,
Fukuda T, Atsuta Y, Nakasone H.

2022

28(4):209 WGP.e1-9.
20-23

Risk factors and prognosis of noninfectious pulmonary complications after
435
allogeneic hematopoietic stem celltransplantation.

Onizuka M, Fujii N, Nakasone H, Ogata M,
Atsuta Y, Suzuki R, Uchida N, Ohashi K,
Ozawa Y, Eto T, Ikegame K, Nakamae H,
Inoue M, Fukuda T; Transplant
Int J Hematol 2022
Complications Working Group of theJapan Society for Hematopoietic Cell
Transplantation.

115(4):53 WGP
4-44.
20-24

Risk factors for fatal cardiac
complications after allogeneic
hematopoietic cell transplantation:
436
Japanese Society for Transplantation andCellular Therapy transplant complications
working group.

Yanagisawa R, Tamaki M, Tanoshima R,
Misaki Y, Uchida N, Koi S, Tanaka T,
Ozawa Y, Matsuo Y, Tanaka M, Ikegame Hematological2023
K, Katayama Y, Matsuoka KI, Ara T,
Oncology
Kanda Y, Matsumoto K, Fukuda T, Atsuta
Y, Kato M, Nakasone H.

41(3):535 WGP
-45.
20-25

Deletion of Y chromosome before
allogeneic hematopoietic stem cell437
transplantation in male recipients withfemale donors.

Tamaki M, Kameda K, Kimura SI, HaradaN, Uchida N, Doki N, Tanaka M, Ikegame
Blood
K, Sawa M, Katayama Y, Miyakoshi S, Ara
Advances
T, Kanda J, Onizuka M, Fukuda T, Atsuta
Y, Kanda Y, Yakushijin K, Nakasone H.

2022

6(6):1895 WGP
-903.
20-26

Harada K, Najima Y, Kato M, Fuji S,
Shinohara A, Nakamae H, Toyosaki M,
Int J Hematol 2022
Ashiarai M, Onizuka M, Hashii Y, Ichinohe
T, Atsuta Y, Nakasone H.

116(5):74 WGP
4-53.
20-27

Okinaka K, Inoue Y, Uchida N, Toya T,
J Infect
Ogawa H, Ozawa Y, Eto T, Mori T, Sugita
ChemotherJ, Kondo T, Kato K, Suzuki R, Fukuda T.

2023

29(7):726 WGP
-30.
20-28

Impact of anti-thymocyte globulin on
survival outcomes in female-to-male440
allogeneic hematopoietic stem celltransplantation.

Tamaki M, Akahoshi Y, Ashizawa M,
Misaki Y, Koi S, Kim SW, Ozawa Y,
Fujiwara SI, Kako S, Matsuoka KI, Sawa
M, Katayama Y, Onizuka M, Kanda Y,
Fukuda T, Atsuta Y, Yakushijin K,
Nakasone H.

2023

13(1):716 WGP
6.
20-29

Clinical characteristics of late-onset
441 interstitial pneumonia after allogeneic
hematopoietic stem cell transplantation.

Fujii N, Onizuka M, Fukuda T, Ikegame K,
Kawakita T, Nakamae H, Kobayashi T,
Kataoka K, Tanaka M, Kondo T, Kato K,
Int J Hematol 2023
Sato A, Ichinohe T, Atsuta Y, Ogata M,
Suzuki R, Nakasone H; JSTCTTransplant Complications Working Group.

118(2):24 WGP
2-51.
20-30

Hematopoietic Stem Cell Transplantation
in Solid Organ Recipients with Emphasis
on Transplant Complications: A
442 Nationwide Retrospective Survey on
Behalf of the Japan Society for
Hematopoietic Stem Cell Transplantation
Transplant Complications Working Group.

Shinohara A, Oshima K, Fuji S, Umeda K,
Kako S, Kurokawa M, Tsukada N, Kasai
Biol Blood
M, Kondo T, Hashii Y, Nakamae H,
Marrow
Ikegame K, Kosaka Y, Shimada A, Nawa
TransplantY, Makoto Y, Yoshiko A, Fukuda T,
Tanaka J, Ogata M.

2020

26(1):66- WGP
75.
20-31

Risk factors and outcome of
Stenotrophomonas maltophilia infection
443 after allogeneic hematopoietic stem celltransplantation: JSTCT, Transplant
Complications Working Group.

Saburi M, Oshima K, Takano K, Inoue Y,
Harada K, Uchida N, Fukuda T, Doki N,
Ikegame K, Matsuo Y, Katayama Y,
Ozawa Y, Matsuoka KI, Kawakita T, MoriY, Ara T, Nakamae H, Kimura T, Kanda Y, Ann Hematol 2023
Atsuta Y, Ogata M; Transplant
Complications Working Group of theJapanese Society for Transplantation
and Cellular Therapy.

102(9):25 WGP
07-16.
20-32

Outcomes of salvage haploidenticaltransplantation using posttransplant
438 cyclophosphamide for graft failure
following allogeneic hematopoietic stem
cell transplantation.
Clinical characteristics and risk factors ofpneumococcal diseases in recipients of
439 allogeneic hematopoietic stem celltransplants in the late phase: A
retrospective registry study.

Sci Rep

雑誌名

発行
年

刊・号・
頁

Yokoyama H, Takenaka K, Nishida T, Seo
S, Shinohara A, Uchida N, Tanaka M,
Takahashi S, Onizuka M, Kozai Y,
Yasuhiro S, Ozawa Y, Katsuoka Y, Doki Biol Blood
N, Sawa M, Kimura T, Kanda J, Fukuda T, Marrow
Atsuta Y, Nakasone H; Japan Society for Transplant
Hematopoietic Cell Transplantation
Transplantation-Related Complication
Working Group.

2020

26(7):136 WGP
3-70.
20-33

Blood
Advances2023

7(17):473 WGP
8-47.
20-34

Cytotherapy

2023

25(11):12 WGP
12-9.
20-35

Outcomes in human T-cell leukemia virus
type I carriers after hematopoietic stem
447 cell transplantation for diseases otherthan adult T cell leukemia/lymphoma: aJapanese national survey.

Nakano N, Nakasone H, Fuji S, Shinohara
A, Suzuki R, Utsunomiya A, Eto T,
Lancet Reg
Morishima S, Ikegame K, Kakinoki Y,
Health West
Matsuoka K, Mori Y, Suehiro Y, Uchida N,
Pac
Ito A, Doki N, Ozawa Y, Kanda J, Kanda
Y, Fukuda T, Atsuta Y, Ogata M.

2023

40:10090 WGP
2.
20-36

Analysis of risk factors for fatal renal
448 complications after allogeneic
hematopoietic cell transplantation.

Yanagisawa R, Koyama H, Yakushijin K,
Uchida N, Jinguji A, Takeda W, Nishida T,
Tanaka M, Eto T, Ohigashi H, Ikegame K, Bone Marrow
Matsuoka KI, Katayama Y, Kanda Y, Sawa Transplant
M, Kawakita T, Onizuka M, Fukuda T,
Atsuta Y, Shinohara A, Nakasone H.

論文タイトルFavorable Effect of Cytomegalovirus
Reactivation on Outcomes in Cord Blood
444
Transplant and Its Differences Among
Disease Risk or Type.

著者

Akahoshi Y, Tada Y, Sakaida E, Kusuda
M, Doki N, Uchida N, Fukuda T, Tanaka
Novel risk assessment for the intensity of445
M, Sawa M, Katayama Y, Matsuoka KI,
conditioning regimen in older patients.
Ozawa Y, Onizuka M, Kanda J, Kanda Y,
Atsuta Y, Nakasone H.
Okada Y, Kimura F, Kurita N, Takahashi
H, Shimazu Y, Mizuno S, Uchida N,
Adverse impact of delay of platelet
Kataoka K, Hiramoto N, Ota S, Kako S,
recovery after autologous hematopoietic
446
Tsukada N, Kanda Y, Kurahashi S, Dokicell transplantation for aggressive nonN, Nishikawa A, Kim SW, Hangaishi A,
Hodgkin lymphoma and multiple myeloma.
Kanda J, Fukuda T, Atsuta Y, Kondo E,
Kawamura K, Nakasone H.

Takenaka K, Fuji S, Matsukawa T, Uchida
N, Kobayashi T, Tanaka M, Ara T,
Outcomes of allogeneic hematopoietic cell
Ikegame K, Ozawa Y, Kanda Y, Sawa M,
449 transplantation under letermovir
Ann Hematol
Maruyama Y, Fukuda T, Nakamae H,
prophylaxis for cytomegalovirus infection.
Kimura T, Ogata M, Seo S, Atsuta Y,
Matsuo K, Nakasone H.
Tamaki M, Akahoshi Y, Okada Y, Uchida
Unrelated female-to-male bone marrow
N, Tanaka M, Doki N, Sawa M, Maruyamatransplantation would be preferred overY, Ueda Y, Miyakoshi S, Katayama Y,
450
Cytotherapy
cord blood transplantation in male
Kawakita T, Kimura T, Onizuka M, Fukuda
patients.
T, Atsuta Y, Yanagisawa R, Yakushijin K,
Kanda J, Nakasone H.
Kimura SI, Akahoshi Y, Shiratori S,
Association Between Candidemia andOkinaka K, Harada K, Uchida N, Doki N,
Noninfectious Interstitial Pneumonia After
Ikegame K, Nakamae H, Tanaka M,
Open Forum
451 Allogeneic Hematopoietic Cell
Takada S, Kawakita T, Matsuoka KI, Ara Infect Dis
Transplantation: JSTCT Transplant
T, Ota S, Sawa M, Onizuka M, Fukuda T,
Complications Working Group.
Atsuta Y, Kanda Y, Nakasone H.
Disease-specific impact of antiFuji S, Hirakawa T, Takano K, Doki N,
thymocyte globulin in allogeneic
Sawa M, Kanda Y, Uchida N, Ara T,
hematopoietic cell transplantation: aMiyamoto T, Eto T, Matsuoka KI,
Bone Marrow452
nationwide retrospective study on behalf Kawakita T, Ozawa Y, Katayama Y,
Transplantof the JSTCT, transplant complications
Onizuka M, Fukuda T, Atsuta Y,
working group.
Nakasone H.

Late Mortality and Causes of Death
453 among Long-Term Survivors after
Allogeneic Stem Cell Transplantation.

Atsuta Y, Hirakawa A, Nakasone H,
Kurosawa S, Oshima K, Sakai R, Ohashi
K, Takahashi S, Mori T, Ozawa Y, Fukuda
Biol Blood
T, Kanamori H, Morishima Y, Kato K,
Marrow
Yabe H, Sakamaki H, Taniguchi S,
Transplant
Yamashita T; Late Effect and Quality ofLife Working Group of the Japan Societyfor Hematopoietic Cell Transplantation.

in press

業績
番号

WGP
20-37

2024

103(1):28 WGP
5-96.
20-38

2023

25(11):12 WGP
20-8.
20-39

2023

10(4):ofa WGP
d163.
20-40

2022

57(3):479 WGP
-86.
20-41

2016

22(9):170 WGP
2-9.
21-1

論文タイトル

Outcomes of patients who developed
454 subsequent solid cancer after
hematopoietic cell transplantation.

Characterization of myeloid neoplasms
455 following allogeneic hematopoietic celltransplantation.

著者

雑誌名

Inamoto Y, Matsuda T, Tabuchi K,
Kurosawa S, Nakasone H, Nishimori H,
Yamasaki S, Doki N, Iwato K, Mori T,
Takahashi S, Yabe H, Kohno A, Nakamae
H, Sakura T, Hashimoto H, Sugita J, Ago
Blood
H, Fukuda T, Ichinohe T, Atsuta Y,
Advances
Yamashita T; Japan Society for
Hematopoietic Cell Transplantation Late
Effects and Quality of Life Working
Group.
Kuno M, Yamasaki S, Fujii N, Ishida Y,
Fukuda T, Kataoka K, Uchida N,
Katayama Y, Sato M, Onai D, Miyamoto
T, Ota S, Yoshioka S, Ara T, Hangaishi A,
Am J
Hashii Y, Onizuka M, Ichinohe T, Atsuta
Hematol
Y, Inamoto Y; on behalf of the Japan
Society for Hematopoietic Cell
Transplantation Late Effects and Qualityof Life Working Group.

Iida M, Nakasone H, Yamashita T, Inoue
M, Ishida Y, Uchiyama H, Katayama Y,
Miyamoto T, Yoshioka S, Shiratori S,
Late mortality and causes of death among
Mori T, Sawa M, Sugio Y, Fukuda T,
Blood Cell
456 long-term survivors after autologous
Ichinohe T, Atsuta Y, Inamoto Y, for the Therapy
hematopoietic stem cell transplantation.
Late Effect and Quality of Life Working
Group of the Japan Society for
Hematopoietic Cell Transplantation.

発行
年

刊・号・
頁

業績
番号

2018

2(15):190 WGP
1-13.
21-2

2022

97(2):185 WGP
-93.
21-3

2020

3:11-7.

WGP
21-4

Severe short-term adverse events in
457 related bone marrow or peripheral blood
stem cell donors.

Yanagisawa R, Hirakawa T, Doki N,
Ikegame K, Matsuoka KI, Fukuda T,
Nakamae H, Ota S, Hiramoto N, Ishikawa
Int J Hematol 2023
J, Ara T, Tanaka M, Koga Y, Kawakita T,
Maruyama Y, Kanda Y, Hino M, Atsuta Y,
Yabe H, Tsukada N.

117(3):42 WGP
1-7.
22-1

Comparative Analysis of Allogeneic Bone
Marrow Transplantation Outcomes
458
Between Japanese and Non-Japanese
Populations.

Yanagisawa R, Shindo M, Shinohara A,
Kuwatsuka Y, Nakase K, Kimura F,
Shingai N, Nishida T, Fukuda T, Sakurai
M, Kurokawa M, Koike T, Ota S, Takada Transplant
S, Onizuka M, Uchida N, Tanaka M,
Proc
Noguchi M, Maruyama Y, Hagihara M,
Ichinohe T, Atsuta Y, Kanda J, Nakasone
H, Toubai T.

in press

WGP
23-1